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Abstract 
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a fatal 
monogenic motoneuron disease in children with unknown etiology caused by mutations in 
the immunoglobulin μ-binding protein 2 (IGHMBP2) gene coding for DNA/RNA 
ATPase/helicase. Despite detailed knowledge of the underlying genetic changes, the cellular 
mechanisms leading to this disease are not well understood. In the Nmd2J ("neuromuscular 
disorder") mouse, the mouse model for the juvenile form of SMARD1 patients, in which 
similar pathological features as diaphragmatic paralysis and skeletal muscle atrophy are 
observed. Ex vivo studies in Nmd2J mice showed that loss of the motor axon precedes 
atrophy of the gastrocnemius muscle and does not correlate with neurotransmission defects 
in the motor endplate. The already described independent myogenic anomalies in the 
diaphragm and heart of the Nmd2J mouse raised the question whether spinal motoneuron 
degeneration develops cell autonomously. Ighmbp2 is predominantly localized in the 
cytoplasm and seems to bind to ribosomes and polysomes, suggesting a role in mRNA 
metabolism. 
In this Ph.D. thesis, morphological and functional analyses of isolated Ighmbp2-
deficient (Ighmbp2-def.) motoneurons were performed to answer the question whether the 
SMARD1 phenotype results from dysregulation of protein biosynthesis. Ighmbp2-deficient 
motoneurons show only negligible morphological alterations with respect to a slight increase 
in axonal branches. This observation is consistent with only minor changes of transcriptome 
based on RNA sequencing data from Ighmbp2-deficient motoneurons. Only the mRNA of 
fibroblast growth factor receptor 1 (Fgfr1) showed significant up-regulation in Ighmbp2-
deficient motoneurons. Furthermore, no global aberrations at the translational level could be 
detected using pulsed SILAC (Stable Isotope Labeling by Amino acids in cell culture), AHA 
(L-azidohomoalanine) labeling and SUnSET (SUrface SEnsing of Translation) methods. 
However, a reduced β-actin protein level was observed at the growth cones of Ighmbp2-
deficient motoneurons, which was accompanied with a reduced level of Imp1 protein, a 
known β-actin mRNA interactor. Live-cell imaging studies using fluorescence recovery after 
photobleaching (FRAP) showed translational down-regulation of eGFPmyr-β-actin 3'UTR 
mRNA in the growth cones and the cell bodies, although the amount of β-actin mRNA and 
the total protein amount in Ighmbp2-deficient motoneurons showed no aberrations. This 
compartment-specific reduction of β-actin protein occurred independently of a non-existent 
direct IGHMBPF2 binding to β-actin mRNA. Fgfr1, which was upregulated on the RNA level, 
did not show an increased protein amount in Ighmbp2-deficient motoneurons, whereas a 
reduced amount could be detected. Interestingly, a correlation could be found between the 
reduced amount of the Imp1 protein and the increased Fgfr1 mRNA, since the IMP1 protein 
binds the FGFR1 mRNA and thus could influence the transport and translation of FGFR1 
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mRNA. In summary, all data suggest that Ighmbp2 deficiency leads to a local but modest 
disturbance of protein biosynthesis, which might contribute to the motoneuron defects of 
SMARD1. 
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Zusammenfassung 
Die spinale Muskelatrophie mit Atemnot Typ 1 (SMARD1) ist eine tödliche, monogene 
Motoneuron-Erkrankung bei Kindern mit unbekannter Ätiologie. SMARD1 wird durch 
Mutationen im Immunoglobulin µ-bindenden Protein 2 (IGHMBP2)-Gen verursacht, welches 
für eine DNA/RNA ATPase/Helikase kodiert. Trotz detaillierter Kenntnisse über die zugrunde 
liegenden genetischen Veränderungen sind die zellulären Mechanismen, die zu dieser 
Krankheit führen, nicht gut verstanden. In der Nmd2J („neuromuscular disorder“) Maus, dem 
Mausmodell für die juvenile Form von SMARD1-Patienten, werden ähnliche pathologische 
Merkmale wie Diaphragma-Lähmung und Skelettmuskelatrophie beobachtet. Ex vivo-Studien 
an Nmd2J-Mäusen zeigten, dass der Verlust des motorischen Axons einer Atrophie des 
Gastrocnemius-Muskels vorausgeht und nicht mit Neurotransmissionsfehlern an der 
motorischen Endplatte korreliert. Die bereits beschriebenen, unabhängig auftretenden 
myogenen Anomalien in Zwerchfell und Herz der Nmd2J-Maus führten zu der Frage, ob sich 
die spinale Motoneuron-Degeneration zellautonom entwickelt. Ighmbp2 ist prädominant im 
Zytoplasma lokalisiert und scheint an Ribosomen und Polysomen zu binden, was auf eine 
Rolle im mRNA-Stoffwechsel hindeutet. 
In dieser Doktorarbeit wurden morphologische und funktionelle Analysen von 
isolierten Ighmbp2-defizienten (Ighmbp2-def.) Motoneuronen durchgeführt, um die Frage zu 
beantworten, ob der SMARD1-Phänotyp aus der Deregulierung der Proteinbiosynthese 
resultiert. Ighmbp2-defiziente Motoneuronen weisen nur geringfügige morphologische 
Unterschiede hinsichtlich einer leichten Zunahme der axonalen Verzweigungen auf. Diese 
Beobachtung steht im Einklang mit nur geringen Veränderungen im Transkriptom basierend 
auf den RNA-Sequenzierungs-Daten in Ighmbp2-defizienten Motoneuronen. Ausschließlich 
die mRNA des Fibroblasten-Wachstumsfaktor-Rezeptor 1 (Fgfr1) zeigte eine signifikante 
Hoch-Regulation in Ighmbp2-defizienten Motoneuronen. Des Weiteren konnten keine 
globalen Aberrationen auf der translationalen Ebene mit Hilfe der gepulsten SILAC (Stable 
Isotope Labeling by Amino acids in der Zellkultur), AHA (L-Azidohomoalanin)-Markierung und 
der SUnSET (SUrface SEnsing of Translation) Methoden ermittelt werden. Jedoch konnte 
eine verringerte β-actin Proteinmenge an den Wachstumskegeln von Ighmbp2-defizienten 
Motoneuronen beobachtet werden, die von einer Reduktion an Imp1 Protein, einem 
bekannten β-actin mRNA Interaktor, begleitet wurde. Lebendzell-Bildgebungsstudien mittels 
Fluoreszenz-Recovery after Photobleaching (FRAP) Untersuchung zeigten eine 
translatorische Herunter-Regulation der eGFPmyr-β-actin 3‘UTR mRNA in Wachstumskegeln 
und Zellkörpern, obwohl die Menge an β-actin mRNA und die Gesamt-Proteinmenge in 
Ighmbp2-defizienten Motoneuronen im Vergleich zu wildtypischen Motoneuronen 
unverändert war. Diese Kompartiment-spezifische Reduktion von β-actin Protein trat 
unabhängig von einer nicht vorhandenen direkten IGHMBP2-Bindung an die β-actin mRNA 
VIII 
 
auf. Der auf RNA Ebene hochregulierte Fgfr1 zeigte hingegen keine erhöhte, aber eine 
verringerte Proteinmenge in Ighmbp2-defizienten Motoneuronen. Interessanterweise konnte 
ein Zusammenhang zwischen der reduzierten Menge des Imp1 Proteins und der erhöhten 
FGFR1 mRNA gezogen werden. Da das IMP1 Protein neben der β-actin mRNA ebenfalls die 
FGFR1 mRNA bindet, könnte es so den Transport und die Translation beeinflussen. 
Alle Daten deuten zusammenfassend daraufhin, dass Ighmbp2-Mangel zu einer 
lokalen und geringen Störung der Proteinbiosynthese führt, die aber durchaus zu den 
beobachteten Motoneuron-Defekten in SMARD1 beitragen könnte. 
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1. Introduction 
Science has been driven for years by the fascination of neurobiology to focus 
extensively on the development and complex organization of the central nervous system 
(CNS). Due to the evolutionary progress of this organ, higher organisms can adapt to various 
environmental influences by developing flexible regulatory mechanisms. These diverse 
mechanisms are present in embryonic development as well as in the adult organism and are 
mediated by hormones, neurotrophic factors and extracellular matrix proteins (Kanning et al., 
2010; Klausmeyer et al., 2011; Sendtner et al., 2000). In the case of dysfunction of these 
mechanisms, the crucial role can be recognized, as a result of a neurodegenerative disease. 
Motoneuron research offers promising ways for possible treatments and thus represents a 
great motivation for research. 
 
1.1 The Development of the Spinal Cord 
Development of the spinal cord is under the control of various developmental control 
genes and homeodomain (HD) transcription factors. The sonic hedgehog (Shh) 
concentration gradient decreasing from ventral to dorsal influences the expression of HD 
transcription factors (Fig. 1A). If the Shh concentration is increased, it suppresses the 
expression of Class I HD transcription factors such as Pax6, Pax7, Dbx1, Dbx2, and Irx3, 
whereas the same concentration induces the expression of Class II HD transcription factors 
such as Nkx6 and Nkx2.2 (Fig. 1B). Five specialized neuroepithelial domains (p0, p1, p2, p3, 
and pMN) are formed due to the different expression patterns of the different homeodomain 
proteins along the proliferative ventricular zone. Within these domains, the differentiation of 
different neuron types and glial cells takes place (Fig. 1B). 
During neurogenesis, motoneurons develop from the pMN precursor domain, 
whereas interneurons emerge from the other four precursor domains (Dessaud et al., 2008). 
With the delayed onset of gliogenesis, the oligodendrocyte precursors differentiate from the 
pMN precursor domain and the other four precursor domains take over the formation of 
astrocytes (Briscoe et al., 2000; Ericson et al., 1996; Lee et al., 2000). 
 
2 
 
 
Figure 1 - Dorsal-ventral patterns of progenitor domains in the neural tube are influenced by secreted 
signals by regulating the spatial expression of transcription factors. (A) Schematic transverse section of an 
amniotic embryo. Different neurons are produced by the signals in the neural tube and the surrounding tissue 
within the spinal cord. One of the most important signals is the Shh concentration gradient (purple). Retinoic acid 
(RA, light blue) is produced from the surrounding Somites and flanking the neural tube. From the roof plate, BMP 
and Wnt signals (orange) are secreted. (B) Schematic representation of the ventral half of the neural tube. 
Depending on the Shh concentration gradient, different HD transcription factors are expressed. The same 
concentration of Shh suppresses the expression of Class I HD transcription factors such as Pax6, Pax7, Dbx1, 
Dbx2 and Irx3 and induces the expression of Class II HD transcription factors such as Nkx6 and Nkx2. These 
different expression patterns of the different homeodomain proteins form five specialized neuroepithelial domains 
(p0, p1, p2, p3, and pMN) along the proliferative ventricular zone. Modified according to (Dessaud et al., 2008). 
 
1.2 Neurotrophic Factors 
Neurotrophic factors are small survival factors that play a crucial role in the 
development of the nervous system (Levi-Montalcini, 1987). At the beginning of the 
embryogenesis, numerous types of neurons are produced in abundance and in the following 
developmental process these immature neurons compete for the limiting neurotrophic factors 
secreted by the target tissue (Oppenheim, 1991). Neurons which were able to form functional 
connections survive while the other neurons die. The neuronal target tissue releases only 
minimal amounts of neurotrophic factors, and the excess unlinked neurons are eliminated by 
apoptosis. This process is called the "neurotrophin hypothesis" (Barde, 1989; Korsching, 
1993; Levi-Montalcini, 1987; Thoenen and Barde, 1980; Thoenen, 1995). This observation 
was the basis for the identification of neurotrophic factors in the twentieth century (Sendtner, 
2014). The group of neurotrophic factors can be divided into five different families (Sendtner 
et al., 2000): the leukemia inhibitory factor (LIF) / Ciliarly neurotrophic factor (CNTF) family, 
the hepatocyte growth factor (HGF)/ scatter factor (SF) family, the insulin-like growth-factor 
family, the glia-derived neurotrophic factor (GDNF) family and the neurotrophin family 
(Sendtner et al., 2000). The family of neurotrophins is particularly interesting for the 
development and function of the nervous system. The members of this family interact 
predominantly with cells of the nervous system (Lewin and Barde, 1996). In addition to their 
survival-promoting properties, neurotrophic factors provide additional functions that have 
already been described. They support the survival, differentiation, synaptogenesis and 
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synaptic plasticity of developing neurons (Chao, 2003; Huang and Reichardt, 2001; Kaplan 
and Miller, 2000; Segal and Greenberg, 1996; Thoenen, 1995). 
It has been suspected for a long time that dysregulated neurotrophic signals may 
contribute to the degeneration of motoneurons, for example in amyotrophic lateral sclerosis 
and spinal muscular atrophy. 
 
1.3 The Motor System 
The locomotor system of all higher organisms is a part of the CNS to control arbitrary 
movements and thus adapt to environmental conditions. The primary motor cortex is the 
highest level in the hierarchy of this very complex structured system. From layer V the axons 
pass the corticospinal tract through the capsula interna and thus form the connection 
between the cortex cerebri and the thalamus (Fig. 2) (Kandel et al., 2012). They cross the 
midbrain beyond the pons and pass at the base of the medulla oblongata to form a tract. This 
tract is called the pyramidal tract (Fig. 2) (Kandel et al., 2012). At the edge between medulla 
and spinal cord, the two pyramidal tracts cross and form the lateral corticospinal tract of the 
spinal cord, which ends in the dorsolateral region of the anterior horn (Fig. 2) (Kandel et al., 
2012). Here, they transmit their information to the motoneurons or interneurons, which in turn 
innervate and control the distal muscles (Kandel et al., 2012).  
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Figure 2 - The corticospinal tract mediates voluntary movement and forms the connection between the 
cortex cerebri and the spinal cord. This image illustrates the coordination of all involved components of the 
motor system. The corticospinal tract is shown in orange and ends in the dorsolateral region of the anterior horn 
of the spinal cord. Here the axons transmit their information to the motoneurons or interneurons that control 
contraction of the muscles. Modified according to (Kandel et al., 2012) (Figure 16-9, page 367). 
 
1.3.1 The Motoneuron 
In general, motoneurons are known as afferent cells that stimulate muscle fibers and 
thereby exercise direct or indirect muscle control (Buller et al., 1960). Like all neurons, 
motoneurons have a soma (cell body), an axon and dendrites (Kandel et al., 2012). The 
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dendrites serve mainly as perception or transmission of stimuli from adjacent nerve cells. On 
the axon hill, these nerve impulses are transmitted from the soma via the axon through the 
synapse to the periphery, for example to the muscle fibers (Kandel et al., 2012). 
Furthermore, a distinction can be made between myelinated and non-myelinated axons, 
which are responsible for the saltatory transmission of the nerve impulses and thus for the 
speed of transmission (Kandel et al., 2012). The myelin layer is basically formed by glial 
cells, whereas the oligodendrocytes in the CNS and the Schwann cells in the peripheral 
nervous system (PNS) perform this task (Kandel et al., 2012). By covering the axon with 
myelin, the transmission of nerve impulses is considerably faster, and saves energy and 
space compared to signal transmission by non-myelinated axons (Huxley and Stampfli, 
1949). In addition, motoneurons can be classified as either somatic (innervate skeletal 
muscles) and visceral motoneurons (innervate smooth muscles) as well as lower (2nd 
motoneuron) and upper (1st motoneuron) motoneurons (Schmidt, 2001). The lower 
motoneurons, in turn, can also be divided into three subtypes: α-, β- and γ-motoneurons. β- 
and γ-motoneurons innervate the intrafusal muscle fibers or the intrafusal fibers within the 
muscle spindle (Burke et al., 1977), whereas the α-motoneurons represent the largest group 
and are responsible for the direct generation of muscle contractions and thus stimulate the 
extra-fusal skeletal muscle fibers. α-Motoneurons are highly differentiated, postmitotic and 
non-dividing cells. Neurotrophic factors are essential for development, maintenance and 
restoration after injury (Sendtner et al., 2000). α-Motoneurons and muscle fibers form the 
basic component of motor control - the motor unit (Kandel et al., 2012). The distal end of 
each motor axon, the presynaptic terminal, together with the postsynaptic muscle fiber forms 
a synaptic cleft. Such a synapse is called neuromuscular junction (NMJ). 
1.3.2 Neuromuscular Junction (NMJ) 
Neuromuscular junctions (NMJ) are the connections of motoneuron and the skeletal 
muscle fiber through a chemical synapse (Kandel et al., 2012; Tintignac et al., 2015). Its 
function is to transfer action potentials from the presynaptic membrane of the motoneuron to 
the postsynaptic muscle fibers to produce muscle contraction (Kandel et al., 2012; Tintignac 
et al., 2015). The dendrites and soma of the motoneurons are located in the spinal cord, 
while their axons are sent to the periphery to form a neuromuscular junction with skeletal 
muscle fibers (Kandel et al., 2012; Tintignac et al., 2015). The axons are surrounded by 
myelin sheaths formed by the Schwann cells (Kandel et al., 2012; Tintignac et al., 2015). The 
end of the axon is branched and forms the presynaptic nerve terminals, which are covered 
by terminal Schwann cells and kranocytes (Tintignac et al., 2015). The motor axon and the 
postsynaptic skeletal muscle fiber are highly specialized at the NMJ. In the active zone of 
presynaptic nerve terminals, a high number of mitochondria and acetylcholine (ACh)-filled 
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vesicles can be observed (Tintignac et al., 2015). The postsynapse is strongly folded and 
contains aggregates of acetylcholine receptors (AChRs) at the crest and a high concentration 
of voltage-gated sodium channels NaV1.4 in the troughs of the folds (Tintignac et al., 2015). 
The specialized distribution of the receptors and the high concentration are necessary for 
efficient neuromuscular transmission. The pre- and postsynapse is separated by a narrow, 
50- to 80-nm-wide gap called the synaptic cleft (Tintignac et al., 2015). 
If the action potential reaches the presynapse, voltage-dependent calcium channels 
(P/Q type) open (Robitaille et al., 1993), calcium enters the presynapse and 
Ca2+ / calmodulin-dependent protein kinase II (CaM kinase) is activated by the increased 
intracellular calcium concentration (Mayford et al., 1996). The CaM kinase, in turn, 
phosphorylates synapsin I and thus removes the synaptic vesicles containing the 
neurotransmitter ACh from the actin cytoskeleton (Evergren et al., 2007). These vesicles are 
guided by Rap proteins under guanosine triphosphate (GTP) hydrolysis to the active zone of 
the presynapse (Leenders et al., 2001), where they fuse with the terminal membrane and 
release ACh into the synaptic cleft (Kandel et al., 2012). ACh binds to its AChRs of the 
postsynaptic muscle fiber, which is mainly permeable to sodium and potassium and to a 
lesser extent to calcium ions (Kandel et al., 2012; Tintignac et al., 2015). The net inward 
current of ACh per vesicle causes 3-4nA in the muscle fiber, the so-called quantal current or 
miniature endplate current (mEPC) (Tintignac et al., 2015). The simultaneous fusion of 
several vesicles causes an action potential and generates a current of several hundred nA at 
the NMJ (Tintignac et al., 2015). This event leads to a local depolarization of the muscle fiber 
by ~30-40mV, the so-called endplate potential (EPP) (Tintignac et al., 2015). This EPP is 
much higher than a postsynaptic action potential would require. This buffer is called the 
"safety factor" of neuromuscular transmission (Wood and Slater, 2001). In case of NMJ 
dysfunction, this can lead to severe limitations in mobility and breathing. Here, different 
components of the motor unit can be affected. 
1.3.3 Disorders of the Motor Unit 
The essential importance of the motor system becomes apparent when drastic and 
life-threatening diseases occur. Depending on the components of the motor unit, there are 
various diseases that can be distinguished. 
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Figure 3 – Motor unit disorder. Graphical illustration of a motoneuron and its neuromuscular junctions 
(NMJ) at the innervated muscle fiber. Various diseases (highlighted in red) can be distinguished depending on 
the affected components of the motor unit. Designed with Servier Medical Art by Verena Surrey. 
 
These distinguishing features vary depending on which functional component is 
affected. The following diseases can be distinguished (Fig. 3): (1) If motor neuron disease is 
present, the cell body of the motoneuron is usually affected, or death occurs through a dying 
back mechanism of axons, as can be observed in spinal muscular atrophy (SMA) (Cifuentes-
Diaz et al., 2002). (2) If the corresponding axon or myelin sheath is affected, it is referred to 
as peripheral neuropathy. (3) A disease of the neuromuscular junctions (NMJs) is defined by 
disturbances of neuromuscular transmission between the motor axon and the muscle. (4) 
Furthermore, diseases can occur in the muscle fiber innervated by the motor neuron. Such a 
disease is called myopathy (Kandel et al., 2012). 
Neuropathies and myopathies can also be distinguished differential-diagnostically. In 
a healthy and resting muscle with intact innervation, no activity outside the end-plate can 
normally be observed (Kandel et al., 2012). In the case of a neurogenic disease with a 
partially denervated and resting muscle, it is possible to measure spontaneous activities. In a 
chronic disease, the muscle innervated by a dying motoneuron atrophied, so that some 
muscle fibers disappear (Kandel et al., 2012). However, it can be observed that the axons of 
surviving motoneurons develop additional sprouts and re-innervate remaining muscle fibers 
in the environment. As a result, the muscle fibers are bundled according to their type and the 
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motor unit becomes larger. This process is called fiber-type grouping. In a myopathic disease 
with an atrophied and resting muscle with intact innervation, there is no activity or a changed 
number of motor units (Kandel et al., 2012). 
Motoneuron diseases are classified according to the symptoms and the type of 
affected motoneurons (Donaghy, 1999). Various factors can cause this motoneuron disease 
such as genetic factors, excitotoxicity, chronic inflammation, aggregated proteins, oxidative 
stress, dysregulated RNA processing and signaling, impaired axonal transport and abnormal 
neurofilament accumulation (Bossy-Wetzel et al., 2004; Bruijn et al., 2004; Ferraiuolo et al., 
2011). Amyotrophic lateral sclerosis (ALS) is the most common form of motoneuron disease. 
The variable phenotype is determined by the decline of the upper and lower motoneurons 
(Christensen et al., 1990; Ekestern, 2004; Kiernan et al., 2011) and depends on how 
severely the individual motoneuron types are affected. In general, involuntary fasciculations, 
muscle atrophies, and severe muscle spasms can lead to spastic contractions and obstacles 
to chewing, speaking, breathing and swallowing (Gubbay et al., 1985; Shaw, 2001). 
The difference between ALS, in which both upper and lower motoneurons are 
affected and the autosomal recessive neurodegenerative disorder of spinal muscular atrophy 
(SMA) is that in the latter case only the lower motoneurons degenerate. Here, the symptoms 
and the course of the disease are also variable and varied, and lead to muscle atrophy which 
results in impaired mobility and, in the end-stage, respiratory failure (Crawford and Pardo, 
1996; Korinthenberg et al., 1997; Lunn and Wang, 2008). This variable appearance of 
classical SMA makes it even more difficult to distinguish SMA from spinal muscular atrophy 
with respiratory distress type 1 (SMARD1). 
 
1.4 Spinal Muscular Atrophy with Respiratory Distress Type I (SMARD1) 
Spinal muscular atrophy with respiratory distress type 1 (SMARD1 or DSMA1) was 
first described in 1974. Two infants showed symptoms of a classic, proximal pronounced 
spinal muscular atrophy (SMA) in combination with a very early, severe respiratory distress 
(Mellins et al., 1974). By additional examinations of the children, the symptoms of the 
disease could be further distinguished from the more classic SMA symptoms. The respiratory 
distress occurring in the early stage of the disease could not be attributed to paralysis of the 
intercostal muscles, but to paralysis of the diaphragm (Bertini et al., 1989; Bove and 
Lannaccone, 1988; Gilmartin et al., 1977; Grohmann et al., 2003; McWilliam et al., 1985; 
Murphy et al., 1985; Novelli et al., 1995; Poets et al., 1990; Rudnik-Schoneborn et al., 1996; 
Schapira and Swash, 1985; Sivan and Galvis, 1990). Muscular atrophy also extends 
predominantly to the distal muscle regions (Rudnik-Schoneborn et al., 1996). This is an 
additional alteration to the proximal pronounced muscle weakness of the SMA disease. 
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Nevertheless, an accurate diagnosis is problematic because SMARD1 symptoms are very 
similar to SMA. A genetic comparison of these two diseases showed further differences. 
SMA patients suffer from mutations or deletions of the survival motor neuron gene 1 (SMN1), 
whereas SMARD1 patients have recessive inherited mutations of the immunoglobulin μ-
binding protein 2 gene (IGHMBP2) (Grohmann et al., 2001). 
1.4.1 Clinical Phenotype of SMARD1 
In 1974, Mellins et al. first described a variation of infantile SMA characterized by a 
pronounced diaphragmatic paresis with respiratory distress (Mellins et al., 1974). Several 
years later, in 1989, Bertini et al. also described this special form of proximal SMA (Bertini et 
al., 1989). 
First phenotypical symptoms of SMARD1 are characterized by a sudden onset of 
respiratory distress within the first 13 months of life of the children due to the paralysis of the 
diaphragm in combination with the onset of distal muscle weakness. Due to the early onset 
of severe respiratory weakness, the children are usually artificially ventilated in the early 
stages of the disease. In the course of the disease, this distal muscle weakness spreads to 
the entire body and results in complete paralysis. Furthermore, intrauterine growth disorders, 
seizures and dysfunction of the autonomic nervous system (e.g. excessive sweating, cardiac 
arrhythmia, arterial hypertension, or bladder dysfunction) can also occur (Eckart et al., 2012; 
Giannini et al., 2006; Grohmann et al., 2001; Grohmann et al., 2003; Guenther et al., 2007; 
Kaindl et al., 2008; Mohan et al., 2001; Pitt et al., 2003; Rudnik-Schoneborn et al., 2004). 
Basically, two different SMARD1 types can be distinguished: (1) the infantile and rapidly 
appearing form, in which the paralysis of the diaphragm is diagnosed within the first 6 weeks 
to 6 months after birth and (2) the juvenile or slowly progressive form, in which the 
respiratory distress becomes apparent after several years (Guenther et al., 2007; Guenther 
et al., 2009b). This symptomatology clearly distinguishes the infantile form of SMARD1 from 
the classical SMA, since the phenotype occurs in the opposite order. Diaphragm palsy can 
be observed using differential-diagnostic x-rays by the passive displacement of the 
diaphragm into the thorax. 
In addition, other classic symptoms can be described: paresis of the facial muscles 
and atrophy of the hand and foot muscles. As previously mentioned, muscle weakness starts 
in the distal parts of the body. Therefore, the infants show contractures on the fingers, 
deformed feet and bumps and are no longer able to move them against gravity (Grohmann et 
al., 2003). 
Studies have already shown that muscle innervation is impaired by the death of 
myelinated axons of motor and sensory nerves. This leads to a high number of de-
myelinated axons (Grohmann et al., 2003; Mohan et al., 2001; Wilmshurst et al., 2001). 
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A similarity to SMA was described by ultrastructural studies on mixed motor and 
sensory nerves, skeletal muscles, and NMJ since Wallerian degeneration and axonal atrophy 
were shown (Diers et al., 2005). In the later course of the disease, the sensory nervous 
system is also affected (Diers et al., 2005; Wilmshurst et al., 2001). The longest lifespan of a 
juvenile SMARD1 infant that is documented was 11 years (Giannini et al., 2006), in contrast, 
children with the infantile form of SMARD1 do not survive the first year of their life 
(Grohmann et al., 2003).  
1.4.2 Genetic Background of SMARD1 
The encoding Ighmbp2 gene is located on the medium-sized human chromosome 11 
(11q13) (Grohmann et al., 2001), which carries a very high number of genes. Mutations in 
these coding genes are the origin of many diseases (Taylor et al., 2006). In 1996, 200 
patients with an early onset SMA could be analyzed, of which 2 had diaphragm involvement 
and no mutations in survival motor neuron 1 (SMN1) gene on chromosome 5q (Porro et al., 
2014; Rudnik-Schoneborn et al., 1996). Three years later, 9 additional cases of SMARD1 
were described in three families with different geographical origins (Grohmann et al., 1999; 
Porro et al., 2014) showing the classical SMARD1 phenotype. Likewise, in these families no 
reference to the SMA locus on 5q or mutations within 1q- and 7p-loci could be found. 1q and 
7p loci are the orthological regions corresponding to the murine Pmn gene region, which is 
also an established model of hereditary motor neuropathies. The genetic analysis of 
Lebanese and German families regarding diaphragmatic SMA revealed a participation of the 
region 11q13-q21. The first descriptions of IGHMBP2 gene mutations in connection with 
SMARD1 disease were published in 2001 (Grohmann et al., 2001). Here, mutations in six 
different SMARD1 families were described and in the following years further mutations in the 
IGHMBP2 gene were identified (AlSaman and Tomoum, 2010; Grohmann et al., 2003; 
Guenther et al., 2004; Wong et al., 2006). Various mutations of the gene are known, 
including frameshift deletions, missense, and nonsense mutations and splice donor 
mutations (Giannini et al., 2006; Grohmann et al., 2001; Guenther et al., 2009b; Maystadt et 
al., 2004).  
The IGHMBP2 gene consists of 15 exons and mutations could be described over all 
15 exons of the gene. The most frequent regions are exon 10 and 12 (Grohmann et al., 
2001; Jedrzejowska et al., 2014; Nomura et al., 2013; Novelli et al., 1995; Pitt et al., 2003). In 
general, the SMARD1 disease can be distinguished between an infantile and a juvenile form, 
depending on the temporal occurrence of respiratory weakness (Guenther et al., 2009b). 
The functionality of the ATPase/helicase domain seems to play a crucial biochemical 
role, as the most mutations were found in this area of SMARD1 patients (Guenther et al., 
2009b). If helicase activity is impaired, this could lead to disturbances in cellular processes 
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such as translation, splicing or mRNA processing. Further evidence of a key role in helicase 
activity is provided by mutations in the senataxin gene. The Ighmbp2 and senataxin proteins 
show a high homology and are structurally very similar. Missense mutations in the helicase 
domain of senataxin have been described, which leads to a motoneuron disorder such as the 
juvenile form of ALS (ALS4) (Chen et al., 2004). 
1.4.3 The Helicase Immunoglobulin µ-Binding Protein 2 (Ighmbp2) 
In principle, helicases are ubiquitous and highly conserved enzymes that remodel 
nucleic acids or nucleic acid-protein complexes by ATP hydrolysis and are classified into six 
superfamilies (SFs) according to their sequence, structure, and functionality. They have 
many functions in various areas of DNA and RNA metabolism. SF1 and SF2 consist of non-
ring-forming helicases and contain all eukaryotic RNA and DNA helicases (Fairman-Williams 
et al., 2010; Jankowsky, 2011). These families use a highly conserved helicase core 
consisting of two tandem RecA-like domains. All SF1 and SF2 helicases are characterized 
by seven sequence motifs and all other motifs define the subfamilies (Gorbalenya et al., 
1989; Jankowsky, 2011). The helicase Ighmbp2 belongs to SF1, which is divided into three 
subgroups - UvrD/Rep, the PIF1 and the UPF1-like helicases (Fairman-Williams et al., 2010). 
Due to its sequence, Ighmbp2 is classified into the group of UPF1-like helicases, which work 
on DNA and RNA (Guenther et al., 2009a; Jankowsky, 2011). 
 
Figure 4 - Domain structure of the human IGHMBP2 protein. Shown are the motifs of the helicase domain, an 
R3H-type nucleic acid binding domain, and an AN1-type zinc finger motif. Helicase domain of UPF1 is very similar 
to IGHMBP2 containing two RecA-like helicase domains (1A and 2A) and two subdomains (1B and 1C). In the 
helicase core, all seven highly conserved sequence motifs of superfamily (SF) 1 and SF2 helicases (I, Ia, II, III, IV, 
V and VI) can be found. Modified according to (Lim et al., 2012). 
IGHMBP2 is a multidomain protein consisting of 993 amino acids (Mizuta et al., 1993) 
and is composed of a DExxQ type helicase/ATPase domain, a R3H domain and a zinc finger 
domain (Fig. 4) (Guenther et al., 2009a; Lim et al., 2012). The helicase core of IGHMBP2 
includes four domains: two RecA-like domains and two subdomains (Lim et al., 2012). 
IGHMBP2 as ATP-dependent 5'3' helicase unwinds RNA and DNA duplices and is co-
localized with ribosomal subunits such as the 40S, 60S, and 80S (Guenther et al., 2009a) 
and with tRNA or factors that are important for tRNA transcription and ribosome maturation 
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(de Planell-Saguer et al., 2009). Furthermore, Ighmbp2 is predominantly localized in the 
cytoplasm and axons of isolated motoneurons (Grohmann et al., 2004). It is therefore 
obvious that Ighmbp2 plays an important role in mRNA translation. Other members of SF1 
helicases are described to be involved in different processes of RNA metabolism including 
transcription, splicing, translation and RNA decay (Jankowsky, 2011). Ighmbp2 has a very 
high structural similarity to UPF1 and 42% of its helicase domain is similar to Senataxin 
(Chen et al., 2004). However, the exact function of Ighmbp2 is unknown and its pathogenic 
role in SMARD1 is unclear. 
1.4.4 Nmd2J Mouse: Mouse Model for SMARD1 
The neuromuscular disorder (Nmd2J) mouse line with a spontaneous autosomal-
recessive mutation in the Ighmbp2 gene represents the mouse model for human SMARD1 
disease and was first discovered and described in the Jackson Laboratories in 1995 (Cook et 
al., 1995). It has a point mutation in the fourth intron of the nmd gene on chromosome 19, 
which encodes Ighmbp2. A new splice donor site is induced at an AG-transition leading to 
a truncated protein by alternatively spliced mRNA, a frameshift and a premature stop codon 
(Cox et al., 1998). As a result, the remaining level of functional Ighmbp2 in all tissues is 
reduced to 20%. The motoneuron disease of the Nmd2J mice manifests itself through atrophy 
of the skeletal muscle and progressive paralysis and thus corresponds to the human 
phenotype of SMARD1 patients. The first symptoms are the muscle weakness in the hind 
limbs and the overall decrease in mobility, which can be observed at the age of two to three 
weeks (Cox et al., 1998). The body size of Nmd2J mice is significantly smaller compared to 
heterozygous littermates. Nevertheless, the survival rate of these mice is very variable 
ranging from six to ten weeks up to eleven months (Cox et al., 1998; Shababi et al., 2016) 
and thus resembles SMARD1 patients with a milder course of the disease, which 
corresponds to the juvenile form of SMARD1 (Grohmann et al., 2004). 
The α-motoneurons in the lumbar spinal cord of Nmd2J (Ighmbp2-deficient) mice show 
a massive degeneration, which can already be measured before the first clinical symptoms 
occur (Grohmann et al., 2004). Postnatal day (P) 10 Nmd2J mice already show a significant 
reduction of 63% of α-motoneurons compared to control mice. In the late stage of the 
disease, the number of motoneurons drops to 28% (Grohmann et al., 2004). In the early 
stages between P16 and P21 of the disease, morphologically intact NMJs and undisturbed 
innervation can be observed (Krieger et al., 2013), which speaks against a “dying back” 
pathomechanism. This is a clear alteration from classic spinal muscular atrophy (SMA), 
where the death of the motoneurons originates from the end plates. Furthermore, an 
increased sprouting of the nerve endings of the Nmd2J motoneurons can be detected 
compared to wildtype controls (Krieger et al., 2013). Further studies have shown that 
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transgenic expression of wildtype Ighmbp2 cDNA in neurons can stop motoneuron 
degeneration, but these mice developed severe congestive heart failure due to dilated 
cardiomyopathy. Besides the motoneurons, this observation points to an important influence 
of Ighmbp2 on myocytes (Maddatu et al., 2004). When Ighmbp2 was expressed in both 
myocytes and motoneurons, these double-transgenic Nmd2J mice showed a wildtype-like 
phenotype (Maddatu et al., 2005). However, if the Ighmbp2 level is ubiquitously upregulated 
using adenoviral gene transfer, this, in turn, leads to a more effective phenotypic rescue 
(Shababi et al., 2016). 
Primary Ighmbp2-deficient motoneurons in vitro show a reduced growth cone size 
with a reduced amount of β-actin protein in combination with an enhanced axonal outgrowth 
cultured on a synapse-specific laminin-211/221 (Krieger et al., 2014b). However, the survival 
of Ighmbp2-deficient motoneurons shows no deficits, which in turn indicates other non-
cellular autonomous mechanisms. In the blood serum of Nmd2J mice a reduction of insulin 
growth factor 1 (Igf1) can be observed, which can be rescued by external application of 
polyethylene glycol-coupled (PEG)-IGF1. Thus, motoneuron death cannot be prevented, but 
the Nmd2J mice show increased survival through increased muscles strength (Krieger et al., 
2014a; Krieger et al., 2014b). 
 
1.5 Actin Cytoskeleton 
Actins in combination with the microtubules and intermediate filaments form the 
eukaryotic cytoskeleton and have an essential effect on cellular processes and functions. 
They are distributed throughout the neuron and are found especially in the neurites. The 
actins form polymers in the shape of a strand and two thin strands wound around each other 
forming the microfilaments. These microfilaments are constantly built up and disassembled in 
order to react to extrinsic and intrinsic signals in a dynamic way. This process is controlled by 
the neuron itself (Kandel et al., 2012). The monomeric, globular G-actins spontaneously 
polymerize to filamentous F-actins, which are highly dynamic structures (Pollard and Cooper, 
2009). Six different actin isoforms can be observed in mammals, encoded by different genes. 
αcardiac-, αskeletal-, αsmooth- and γsmooth-actin are predominantly found in striated and smooth 
muscles, while βcyto- and γcyto-actin are expressed ubiquitously in all cell types. Actin isoforms 
are 93% similar in identity (Perrin and Ervasti, 2010). 
The actin cytoskeleton plays a crucial role in the morphological development of 
neurons and in the maintenance and structural alteration of adult neurons (Luo, 2002) 
including axon initiation, growth, guidance, branching, synapse formation as well as stability 
and is part of the axon initial segment (AIS) (Xu et al., 2013). Impairment of F-actin interferes 
with the diffusion barrier at AIS, leading to mislocalization of somatodendritic proteins in the 
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axonal compartment (Song et al., 2009). Actin-microtubule interaction contributes to growth 
cone extension and axonal growth (Suter and Miller, 2011). Actins are abundantly 
represented in membrane protrusions, whereby two types of protrusions have to be 
distinguished: First the filopodia, which have unbranched bundled actin filaments, and 
second lamellipodia, which have a network of branched actin filaments (Kalil and Dent, 
2014). 
 
1.6 Fibroblast Growth Factor Receptor 1 (FGFR1) 
The fibroblast growth factor receptors (FGFRs) belong to a superfamily of tyrosine 
kinase receptors and persist about 800 amino acids (Ornitz and Itoh, 2015). Four different 
FGFRs are known consisting of an extracellular ligand binding domain, three 
immunoglobulin-like domains (I-III), a transmembrane domain and a split intracellular 
tyrosine kinase domain. The latter domains are functionally dimerized upon activation (Chen 
et al., 2008; Furdui et al., 2006). With the help of 18 different fibroblast growth factors 
(FGFs), FGFRs can be activated by binding to the extracellular domain of FGFR (Ornitz and 
Itoh, 2015). FGF-2, also known as bFGF, is a paracrine growth factor that binds to and 
activates FGFR1 (Ibrahimi et al., 2004). Originally, bFGF was isolated from the brain and 
pituitary gland as a mitogen for cultured fibroblasts (Gospodarowicz et al., 1975; 
Gospodarowicz et al., 1978). 
The activation of FGFRs by FGF binding depends on cofactors such as heparin, 
heparan sulfate and klotho (Schlessinger et al., 2000; Suzuki et al., 2008) and results in 
dimerization, which activates tyrosine kinase and starts several signaling pathways. The 
following signaling pathways are activated: STAT signaling PI3K/AKT and 
RAS/RAF/MEK/MAPK signaling (Ornitz and Itoh, 2015). 
In general, the FGFRs activated signaling pathways control growth, survival, and 
differentiation of precursor cells in organogenesis (Borello et al., 2008; Kong et al., 2014; 
Potthoff et al., 2012; Vincentz et al., 2005). In addition, the specific expression of FGFs is 
crucial for neurogenesis, as they influence neuronal differentiation (Borello et al., 2008). 
It should be noted that FGFRs are involved in many diseases such as Kallmann 
syndrome (Albuisson et al., 2005; Gill et al., 2004) and several cancers (Acevedo et al., 
2007; Ugolini et al., 1999; Wang et al., 2018).  
 
1.7 Insulin-like Growth Factor-2 mRNA Binding Protein 1 (IMP1) 
Insulin-like growth factor-2 mRNA binding protein 1 (IMP1) is an RNA binding protein 
consisting of six RNA binding sites, two RNA recognition motifs and four hnRNP-K homology 
(KH) domains (Nielsen et al., 1999; Ross et al., 1997; Yisraeli, 2005). RNA binding to the 
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domains described above influences the stability of RNA, its transport and the translational 
control of the transcript (Huttelmaier et al., 2005; Leeds et al., 1997; Leung et al., 2006). 
High expression of Imp1 during embryonic stages plays a crucial role in the 
development of the nervous system (Hansen et al., 2004; Nishino et al., 2013). Imp1-
deficient mice develop a small cerebral cortex and show a general impairment of embryonic 
development (Nishino et al., 2013). Previous studies have shown that the interaction of Imp1 
with β-actin mRNA regulates growth cone guidance, axonal remodeling and dendritic 
morphology (Eom et al., 2003; Medioni et al., 2014; Sasaki et al., 2010). RNA looping 
mediates protein-mRNA interaction, which in turn is predominantly regulated by IMP1 
concentration (Nicastro et al., 2017) and β-actin mRNA is released after phosphorylation of 
IMP1 protein (Ceci et al., 2012; Huttelmaier et al., 2005; Urbanska et al., 2017).  
 
1.8 Objective 
This Ph.D. thesis addresses a morphological and functional analysis of primary 
Ighmbp2-deficient (Ighmbp2-def.) Nmd2J motoneurons compared to wildtype (Ighmbp2+/+) 
motoneurons. The investigation can be divided into five main parts. The first part focuses on 
the production and validation of the self-made polyclonal rabbit anti Ighmbp2 antibody. The 
second part is concerned with a morphological and functional analysis of Ighmbp2-deficient 
and Ighmbp2+/+ motoneurons regarding axonal outgrowth, branching behavior, spontaneous 
Calcium (Ca2+) transients at the distal axon, growth cone size and signal intensity of β-actin 
in the growth cones, compartment-specific local translation of β-actin protein, general 
translational effects, and analyses of distribution and amount of actin isoform mRNAs and 
proteins. The third part comprises of the analysis whether Ighmbp2 influences translation 
caused by RNA binding. Furthermore, the fourth part deals with Insulin-like growth factor-2 
mRNA- binding protein 1 (Imp1) and fibroblast growth factor receptor 1 (Fgfr1) as affected 
targets in primary Ighmbp2-deficient motoneurons. Finally, the fifth part is targeted at 
possible protein interaction partners of Ighmbp2 using immunocytochemical staining (ICC) 
and Co-immunoprecipitation (Co-IP). 
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2. Materials 
2.1 Manufacturers 
Table 1 - List of Manufacturers 
Manufacturer Location 
Adobe San José, CA, USA 
AGFA Mortsel, Belgium 
Ambion Waltham, MA, USA 
Amersham Bioscience Freiburg, Germany 
Antikörper-Online Aachen, Germany 
AppliChem Darmstadt, Germany 
BD Bioscience Heidelberg, Germany 
Bemis Neenah, WI, USA 
Binder Tuttlingen, Germany 
Biometra Göttingen, Germany 
Bio-Rad München, Germany 
Biozym Scientific Ohlendorf, Germany 
Brand Wertheim, Germany 
Carl Roth GmbH Karlsruhe, Germany 
Carl Zeiss AG Oberkochen, Germany 
cp-Pharma Burgdorf, Germany 
Dianova Hamburg, Germany 
Dumont Montignez, Switzerland 
Elma Singen, Germany 
Endnote Philadelphia, PA, USA 
Eppendorf AG Hamburg, Germany 
Eurofins Scientific Luxembourg, Luxemburg 
Exiquon Vedbaek, Denmark 
Fresenius Kabi Bad Homburg vor der Höhe, Germany 
GE Health Care Life Sciences Freiburg, Germany 
GeneOn Ludwigshafen, Germany 
Gibco Karlsruhe, Germany 
Gilson Middleton, WI, USA 
GLW Würzburg, Germany 
GraphPad Software, Inc. La Jolla, CA, USA 
Greiner Bio One Frickenhausen, Germany 
Hartenstein Würzburg, Germany 
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Hartmann Heidenheim 
Hartmann Analytic GmbH Braunschweig, Germany 
Heraeus Instruments Langenselbold, Germany 
Hettich Tuttlingen, Germany 
Hoffmann La-Roche Basel, Switzerland 
Holten Allerød, Dänemark 
Ibidi Martinsried, Germany 
Intas Science Imaging Göttingen, Germany 
Invitrogen Karlsruhe, Germany 
Kern PCB Balingen, Germany 
Keyence Osaka, Japan 
KNF Neuberger Freiburg im Breisgau, Germany 
Leica Microsystems Wetzlar, Germany 
Lexogen Vienna, Austria 
LG electronics Seoul, South Korea 
LI-COR Bioscience Lincoln, NE, USA 
Linaris Mannheim, Germany 
Macherey und Nagel Düren, Germany 
Memmert Schwabach, Germany 
Merck Millipore Billerica, MA, USA 
Microsoft Redmond, WA, USA  
Mirus Köln, Germany 
Neolab Heidelberg, Germany 
Nikon Tokio, Japan 
Olympus Tokyo, Japan 
Peprotech Rocky Hill, NJ, USA 
Peqlab Biotech. Gmbh Erlangen, Germany 
Pfizer Berlin, Germany 
Philips Amsterdam, Nederland 
Polysciences Warrington, PA, USA 
Promega Maddison, WI, USA 
Qiagen Hilden, Germany 
Qimaging Surrey, BC, Canada 
R. Langenbrinck Emmendingen, Germany 
Roche Diagnostics Rotkreuz, Switzerland 
Sarstedt AG and Co. Nümbrecht, Germany 
SchuettPhoenix Dublin, Irland 
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Schülke Zürich, Switzerland 
Scotsman Berlin, Germany 
SensiCare Ice Kleve, Germany 
Sigma-Aldrich GmbH München, Germany 
StarLab Hamburg, Germany 
System Bioscience Palo Alto, CA, USA 
Th. Geyer Renningen, Germany 
Thermo Fisher Scientific Waltham, MA, USA 
VWR Int. Darmstadt, Germany 
Wayne Rasband (NIH) Bethesda, MD, USA 
Worthington Lakewood, NJ, USA 
ZVG Troisdorf, Germany 
 
2.2 Appliances 
Table 2 - List of Appliances 
Appliance Manufacturer 
Accujet pro 
Centrifuge 
5417R 
5415D 
5804R 
Mini Spin 
Mini Centrifuge MC-6400 
Rotofix 32A 
Brand 
 
Eppendorf AG 
Eppendorf AG 
Eppendorf AG 
Eppendorf AG 
Hartenstein 
Hettich 
Clean Bench 
Hera Safe (HS 18/2) 
LaminAir (HV PCR) 
 
Heraeus Instruments 
Holten 
Confocal Laser Scanning Microscope 
Olympus Fluo View FV1000 (IX81) 
Olympus BX51WI with 
40x Objective LUMPlanFI/IR and 
Rolera-XR 
 
Olympus 
Olympus 
Olympus 
Qimaging 
Cunx60 developer AGFA 
Fluorescence microscope  
Biozero (BZ8000K) 
Leitz DMRBE 
 
Keyence 
Leica Microsystems 
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Gel chamber (Mini Protean Tetra Cell) 
Gas jet 
Bio-Rad 
SchuettPhoenix 
Heating block 
Thermomixer comfort (1.5 ml/2 ml) 
 
Eppendorf AG 
Ice machine Scotsman 
Incubator 
BD23 E2 
CB210 E3 
 
Binder 
Binder 
Light Cycler  
Light Cycler 1.5 Roche Diagnostics 
Light Cycler 96 Roche Diagnostics 
Light optical microscope 
Nikon Eclipse TS100 with  
Philips Projection lamp (5761) 
 
Nikon 
Philips 
Microwave LG electronics 
Nanodrop 1000 Spectrophotometer Peqlab Biotech. GmbH 
Neubauer Cell Counter Chamber Brand, Wertheim 
PCR Cycler Mastercycler Nexus X2 flexlid Eppendorf AG 
Photometer Eppendorf AG 
Pipettes 
Pipetman (20 µl, 200 µl, 1000 µl) 
ErgoOne (2.5 µl, 10 µl, 20 µl, 200 µl, 1000 µl) 
 
Gilson 
StarLab 
Power Supply  
Power Pack HC Bio-Rad 
Power Pack P25 T Biometra 
Scale Kern PCB 
Stereo Microscope 
Leica S8AP0 with Leica L2 
Zeiss Stemi 2000 with KL200LED 
Suction pump 
 
Leica Microsystems 
Carl Zeiss AG 
Neolab 
UV transluminator Peqlab Biotech. GmbH 
Ultrasonic bath Elma 
Vacuum pump 
ECOM-P 4153 
N010 KN-18 
 
Eppendorf AG 
KNF Neuberger 
Vortex Mixer GLW L46 GLW 
Water Bath Memmert 
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2.3 Consumables 
Table 3 - List of Consumables 
Consumable Manufacturer 
µ-dish35mm, high glass bottom Ibidi 
4-12% NuPAGE Bis-Tris gel Bio-Rag 
Capillaries Roche 
Cell Culture Well Plates (12 Well, 24 Well) Sarstedt 
Cellstar 4-Wells Greiner BioOne 
Centricon Millipore 
Centrifugation tube (15 ml, 50 ml) Greiner BioOne 
Cuvettes Hartenstein 
Filter Paper (Mini Trans-Blot) Bio-Rad 
Filter Tips Sarstedt 
Forceps, Dumoxel n°5 Dumont 
Glass Capillaries Roche Diagnostics 
Glass Pasteur Pipettes Hartenstein 
Glasspipetts 5ml, 10ml, 25ml, 50ml Hartenstein 
Gloves SensiCare Ice 
Glutathione sepharose transferase beads Amersham Bioscience 
LightCycler 8-Tubes Stripes (white) Roche 
Microscope cover glasses (Ø 10 mm) Hartenstein 
Microscope slides (ca. 76x26 mm) R. Langenbrinck 
Mini Trans Blot Cell Bio-Rad 
Ni-NTA agarose beads Qiagen 
Nunc Cryotubes Thermo Scientific 
Parafilm Bemis 
PCR tubes Sarstedt 
Peha Soft nitrile gloves Hartmann 
Petri dishes (6 cm, 8 cm, 15 cm) Greiner BioOne 
Pipette Tips Sarstedt 
Precast Protein Gel (4-20% gradient Mini-Protean 
polyacrylamide gel) 
Bio-Rad 
 
PVDF membrane (Immun Blot) Bio-Rad 
Reaction tubes (1.5 ml, 2 ml) Sarstedt 
T75 cell culture flask Sarstedt 
Terralin Schülke 
X-ray films (Fujifilm Super RX) Hartenstein 
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ZetMedica Laboratory and hygiene tissue ZVG, Troisdorf 
 
2.4 Chemicals 
Table 4 - List of Chemicals 
Chemical Manufacturer 
16% formaldehyde solution Sigma -Aldrich 
20xSSC Ambion 
Agarose 
Acrylamid 40% 
Ampuwa 
Biozym Scientific 
Biorad 
Fresenius Kabi 
Aqua Poly/Mount Polysciences 
Bacto-tryptone BD Bioscience 
Bacto-yeast extract BD Bioscience 
Betaine monohydrate Sigma -Aldrich 
Boric acid Sigma -Aldrich 
Bromophenol blue Sigma -Aldrich 
Chelex Bio-Rad 
Chloramphenicol Sigma -Aldrich 
CuSO4 Sigma -Aldrich 
Dimethyl-Pimelimidate (DMP) Sigma -Aldrich 
Disodium phosphate (Na2HPO4) Sigma -Aldrich 
Disodium tetraborate Sigma -Aldrich 
DNA ladder (GeneRuler) Thermo Fisher Scientific 
Dynabeads Protein A Thermo Fisher Scientific 
EDTA (Ethylenediaminetetraacetic acid) Sigma -Aldrich 
Ethanol Sigma -Aldrich 
Ethanolamine Sigma -Aldrich 
Formaldehyde solution (16%) Thermo Fisher Scientific 
Glucose Sigma -Aldrich 
Glycerol Sigma -Aldrich 
HEPES Sigma -Aldrich 
Hybridisation solution Sigma -Aldrich 
Igepal CA-630 Sigma 
Immersion Oil (Immoil F30CC) Olympus 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Sigma -Aldrich 
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K2HPO4 Sigma -Aldrich 
Ketavet Pfizer 
KH2PO4 Sigma -Aldrich 
Methanol Th. Geyer 
Midori Green Intas Science Imaging 
Monopotassium phosphate (KH2PO4) Sigma -Aldrich 
Monosodium diphosphate (NaH2PO4) Sigma -Aldrich 
Paraformaldehyde (pH 7.6) Merck Millipore 
Poly-DL-ornithine-hydrobromide (PORN-H 100x) Sigma -Aldrich 
Potassium chloride Sigma -Aldrich 
Powdered Milk Carl Roth 
Protein Ladder Thermo Fisher Scientific 
RIPA buffer Sigma -Aldrich 
Saline sodium citrate Thermo Fisher Scientific 
Salmon Sperm DNA Sodium Salt AppliChem 
Sarkosyl (N-Lauroylsarcosine) Sigma -Aldrich 
Sodium acetate Sigma -Aldrich 
Sodium chloride Sigma -Aldrich 
Sodium dodecyl sulfate AppliChem 
Sodium metaperiodate Sigma -Aldrich 
Tango Buffer (10x) Thermo Fisher Scientific 
TBTA Sigma 
TCEP Sigma 
Terralin Schülke 
Tris base Sigma -Aldrich 
Triton X100 Sigma -Aldrich 
Tween 20 Sigma -Aldrich 
Xylavet cp-Pharma 
β-Mercaptoethanol Carl Roth 
γ-32P-ATP Hartmann Analytic GmbH 
 
23 
 
2.5 Media, Supplements and Enzymes 
Table 5 – List of Media, Supplements and Enzymes 
Media, Supplements and Enzymes Manufacturer 
Ampicillin Sigma -Aldrich 
Anisomycin Sigma -Aldrich 
Arginine Sigma 
B27 Supplement Thermo Fisher Scientific 
BamII Thermo Fisher Scientific 
bFGF (murine) Peprotech 
Bovine Serum Albumin/BSA Sigma 
Brain-derived neurotrophic factor (BDNF) Affinity Purification 
Ciliary neurotrophic factor (CNTF) Affinity Purification 
Dulbecco´s Modified Eagle Medium (DMEM) Gibco 
DMEM, methionine-free Gibco 
DMSO Sigma 
EcoRI Thermo Fisher Scientific 
Fetal Calf Serum/FCS Linaris 
Geneticin Thermo Fisher Scientific 
GlutaMAX Supplement (100x) Thermo Fisher Scientific 
GoTaq G2 Hot Start Green Master Mix Promega 
Hank’s Balanced Salt Solution (HBSS) Gibco 
Horse Serum Gibco 
Horse Serum, dialyzed Gibco 
HpyF3I Ddel (10 U/µl) Thermo Fisher Scientific 
Laminin-111 Invitrogen 
Laminin-211/221 Millipore 
L-azidohomoalanine (AHA) Thermo Fisher Scientific 
Lipofectamine 2000 Invitrogen 
Lysin Sigma 
Neurobasal Gibco 
Neurobasal, amino acid-free Gibco 
NuPAGE MOPS SDS Running Buffer Invitrogen 
Opti-MEM Gibco 
Oregon Green 488 BAPTA-1, AM-Ester (OGB) Thermo Fisher Scientific 
Penicillin/Streptomycin (P/S) Thermo Scientific 
Phosphatase Inhibitor „PhosSTOP“ Roche 
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Pluronic F-27 Thermo Fisher Scientific 
Proline Sigma 
Protease Inhibitor cOmplete mini Roche 
Proteinase K Roche 
RIPA buffer Sigma 
RNasin RNase Inhibitor Promega 
T4 ligase Thermo Fisher Scientific 
Trans-IT Mirus 
Trypsin Worthington 
Trypsin-Inhibitor Sigma -Aldrich 
T-DNAse Invitrogen 
 
2.6 Kits and Detection Systems 
Table 6 – List of Kits and Detection Systems 
Kit or Detection System Manufacturer 
Amersham ECL Normal/ Prime/ Select Western Blotting 
Detection Reagent 
GE Health Care Life Sciences 
C2 Mouse Growth Factor Antibody Array Antikörper-Online 
Luminaris HiGreen qPCR Master Mix Thermo Fisher Scientific 
mRNA-Seq Library Prep Kit V2 Lexogen 
NucleoBond Xtra Midi/Maxi EF Machery und Nagel 
NucleoSpin RNA Kit Machery und Nagel 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
Plasmid mini-prep kit Machery und Nagel 
QIAEX II – Gel Extraction Kit Qiagen 
SuperScript III Kit Invitrogen 
TOPO TA cloning kit Invitrogen 
TRIzol Reagent Ambion 
TURBO DNA-free Kit Invitrogen 
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2.7 Primary Antibodies 
Table 7 – List of Primary Antibodies 
Antigen Host Clonality Manufacturer Dilution Experiment 
Ago2 rat polyclonal Self-made, Lab 
Gunter Meister 
1:10 WB 
Calnexin goat polyclonal Acris 1:1000 WB 
CPSF73 rabbit polyclonal Bethyl 1:1000 WB 
Digoxigenin mouse (IgG1) monoclonal Abcam 1:1000 ISH 
FGFR-1 mouse monoclonal Novus 
Biologicals 
1:200 
1:500 
ICC 
WB 
GFP chicken polyclonal Abcam 1:2000 ICC 
GluTub mouse (IgG) monoclonal Synaptic system 1:1000 ICC 
Histone H3 rabbit polyclonal Abcam 1:3000 WB 
hnRNPR rabbit polyclonal Abcam 1:2000 WB 
Ighmbp2 rabbit polyclonal Affinity 
Purification 
1:2000 ICC 
IMP1 rabbit polyclonal Cell Signaling 1:1000 WB 
LSM4 chicken polyclonal Sigma 1:10000 WB 
Map-2 mouse monoclonal Sigma-Aldrich 1:1000 ICC 
Mov10 rabbit polyclonal Bethyl 1:1000 WB 
p75 mouse monoclonal Biosensis 1:10000 Cell culture 
(panning-plate) 
Puromycin mouse monoclonal Millipore 1:5000 WB 
Sars2 rabbit polyclonal GeneTex 1:1000 WB 
SMN mouse monoclonal BD Biosciences 1:1000 WB 
Tau rabbit polyclonal Sigma-Aldrich 1:800 ICC 
TDP43 rabbit polyclonal Proteintech 1:1500 WB 
Top1 rabbit polyclonal GeneTex 1:500 WB 
UPF1 rabbit polyclonal Abcam 1:10000 WB 
α-actin mouse (IgM) monoclonal Invitrogen 1:500 ICC 
α-Tubulin mouse monoclonal Sigma 1:3000 WB 
β-actin mouse (IgG) monoclonal GeneTex 1:1000 ICC 
βIII Tubulin mouse monoclonal Sigma-Aldrich 1:500 
1:4000 
ICC 
WB 
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2.8 Secondary Antibodies 
Table 8 – List of Secondary Antibodies 
Antigen Host Clonality Manufacturer Dilution Experiment 
Alexa488 α mouse IgM goat polyclonal Invitrogen 1:1000 ICC 
Alexa488 α mouse IgG goat polyclonal Invitrogen 1:800 
1:1000 
ICC 
ISH 
Alexa488 α chicken goat polyclonal Invitrogen 1:800 ICC 
Cy3 α mouse IgG goat polyclonal Jackson 1:300 ICC 
Cy3 α rabbit donkey polyclonal Jackson 1:600 ICC 
Cy5 α rabbit donkey polyclonal Jackson 1:800 ICC 
HRP α mouse goat polyclonal Jackson 1:10000 WB 
HRP α rabbit goat polyclonal Jackson 1:10000 WB 
HRP α goat donkey polyclonal Jackson 1:10000 WB 
HRP α rat goat polyclonal Jackson 1:10000 WB 
HRP α chicken rabbit polyclonal Jackson 1:10000 WB 
 
2.9 LNA mRNA Detection-probes for FISH 
Table 9 – List of LNA mRNA Detection-probes for FISH 
Target mRNA Sequence 5’-3’ Manufacturer 
Actα1 /5DigN/AGTCAATCTATGTACACGTCAA/3Dig_N/ Exiquon 
Actβ /5DigN/ACGCGACCATCCTCCTCTTA/3Dig_N/ Exiquon 
Actγ1 /5DigN/AGTGACCGAGCCACATGAACT/3Dig_N/ Exiquon 
 
2.10 Primer Sequences and Program settings for genotyping 
Table 10 – List of Primer Sequences for genotyping 
Target  Primer Sequence Manufacturer 
Nmd2J forward 5’ TCA CAG AGC ACT GAT GAC AC 3’ Eurofins Scientific 
reverse 5’ TCT CTC TCT CAC ACA CAC ACA 3’ Eurofins Scientific 
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2.11 Bacterial Cell Lines 
Table 11 - List of Bacterial Cell Lines 
Bacterial Cell Lines Manufacturer/Source 
E. coli Top10 Thermo Fisher Scientific 
E. coli Rosetta DE3 pLys Thermo Fisher Scientific 
 
2.12 Plasmid vectors 
Table 12 – List of Plasmid Vectors 
Plasmid vectors Inserts with N/C terminal Manufacturer/Source 
pGex6p1 GST-IGHMBP2-6xHis Amersham Bioscience 
pSIH1-H1-Puro shRNA sh RNA targeting Ighmbp2 System Bioscience 
FU-Valentine ubiquitin promotor LCK-Myr-eGFP+3’UTR β-actin (Rathod et al., 2012) 
pCMV-VSVG Lentiviral packaging helper 
plasmids 
(Dull et al., 1998; 
Zufferey et al., 1998) pCMVΔR8.91 
 
2.13 Primer Sequences and Program settings for quantitative RT-PCR 
Table 13 – List of Primer Sequences for qRT-PCR 
Target mRNA  Primer Sequence 
Gapdh, murine forward 5’ AAC TCC CAC TCT TCC ACC TTC 3’ 
reverse 5’ GGT CCA GGG TTT CTT ACT CCT T 3’ 
α-actin, murine forward 5’ TAG ACA CCA TGT GCG ACG AAG A 3’ 
reverse 5’ ACC TAC CAT GAC ACC CTG GTG A 3’ 
β-actin, murine forward 5’ GAT GAC CCA GAT CAT GTT T 3’ 
 reverse 5’ CGT GAG GGA GAG CAT AG 3’ 
Ighmbp2, murine forward 5’ AGC ACT GAT GAC ACT GAA GAA G 3’ 
 reverse 5’ GCC TTG CTT CAC AGC TTG AAG G 3’ 
Imp1, murine forward 5’ CTC CAT CAA GAT TGC ACC AC 3’ 
 reverse 5’ CTT TAC TTC CTC CTT GGG AC 3’ 
Fgfr1, murine forward 5’ GAG CGA TGT GTG GTC TTT TG 3’ 
 reverse 5’ CTG GGC TTG TCC ATT CGA TG 3’ 
GAPDH, human forward 5’ GCA AAT TCC ATG GCA CC 3’ 
 reverse 5’ CGC CAG TGG ACT CCA CGA C 3’ 
β-Actin, human forward 5’ CGA AAC TAC CTT CAA CTC CAT CAT G 3’ 
 reverse 5’ GCA ATG ATC TTG ATC TTC ATT GTG 3’ 
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IMP1, human forward 5’ CAT CAC TCT GGT GGG TGT AGA TC 3’ 
 reverse 5’ CAG CTG CCG TCA AAT TCT GC 3’ 
FGFR1, human forward 5’ CTC CAA GAA GTG CAT ACA CCG AG 3’ 
reverse 5’ CAT CAC TCT GGT GGG TGT AGA TC 3’ 
 
Table 14 – qRT-PCR Cycle Program for mouse Gapdh mRNA 
Gapdh, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 40 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 59 72 78 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
Table 15 – qRT-PCR Cycle Program for mouse α-actin mRNA 
α-actin, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 63 72 84 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
Table 16 – qRT-PCR Cycle Program for mouse β-actin mRNA 
β-actin, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 59 72 83 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
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Table 17 – qRT-PCR Cycle Program for mouse Ighmbp2 mRNA 
Ighmbp2, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 57 72 75 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous  
Table 18 – qRT-PCR Cycle Program for mouse Imp1 mRNA 
Imp1, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 58 72 78 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
Table 19 – qRT-PCR Cycle Program for mouse Fgfr1 mRNA 
Fgfr1, murine Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 58 72 80 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
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Table 20 – qRT-PCR Cycle Program for human GAPDH mRNA 
GAPDH, human Denaturation Amplification Melting Curve Cooling 
 1 Cycle 40 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 60 72 80 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
Table 21 – qRT-PCR Cycle Program for human β-Actin mRNA 
β-Actin, human Denaturation Amplification Melting Curve Cooling 
 1 Cycle 40 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 59 72 83 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
Table 22 – qRT-PCR Cycle Program for human IMP1 mRNA 
IMP1, human Denaturation Amplification Melting Curve Cooling 
 1 Cycle 40 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 59 72 79 95 65 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
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Table 23 – qRT-PCR Cycle Program for human FGFR1 mRNA 
FGFR1, human Denaturation Amplification Melting Curve Cooling 
 1 Cycle 50 Cycles 1 Cycle 1 Cycle 
Target Temperature 50 95 95 60 72 80 95 78 95 40 
Incubation Time 2 10 15 30 30 5 0 15 0 40 
Temp. Trans. Rate 20 20 20 20 20 20 20 20 0.1 20 
2nd Target Temp. 0 0 0 0 0 0 0 0 0 0 
Step Size 0 0 0 0 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 0 0 0 0 
Acquisition Mode None None None None None None None None Cont. None 
Analysis Mode Quantification Quantification Melting Curve None 
Temp. = Temperature; Trans. = Transition; Cont. = continuous 
 
2.14 Bioinformatics Software 
Table 24 – List of Bioinformatics Software 
Software Manufacturer 
FIJI (Fiji is just ImageJ) Wayne Rasband (NIH) 
GraphPad Prism 5 GraphPad Software, Inc. 
MS Office / Excel Microsoft 
Adobe Illustrator CC 2017 
Endnote X8.2 
Image Studio lite 
Adobe 
Endnote 
LI-COR Bioscience 
 
2.15 Solutions, Buffers, and Cell Culture Media 
Table 25 – List of Solutions, Buffers and Cell Culture Media 
Solutions, Buffers and Cell Culture Media Ingredients 
0.15M boric acid buffer, pH 8.3 9.27g boric acid 
Ad 1l H2O (sterile) 
1% Trypsin 1% Trypsin in HEPES (pH 7.4) 
10% separating gel 10% Acrylamide/Bis Solution 
1x separating gel buffer 
10% APS1 
1% TEMED 
in H2O 
100x PORN-H 500mg Poly-DL-ornithine hydrobromide in 
10ml 0.15M boric acid buffer, pH 8.3 
10mM TRIS, pH 9.5 121.14g TRIS 
Ad 1l H2O (sterile) 
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10x ELPHO 60.6g Tris-Base (250mM) 
288g glycine (2M) 
20g SDS (1%) 
Ad 2l ddH2O 
10x Tris-borate-EDTA-buffer (TBE buffer) 890mM TRIS 
890mM boric acid 
20mM Na2EDTA 
10x Towbin Buffer 60.6g Tris-Base (250mM) 
288g Glycine (2M) 
Ad 2l H2O 
1xPBS (Phosphate buffered saline) 8g NaCl 
0.2g KCl 
1.44g Na2HPO4 
0.24g KH2PO4 
Ad 1l H2O 
1x PORN-H 500µl PORN-H (100x) in 50 ml boric acid 
buffer, pH 8.3 
1x TBS-T (Tris-buffered saline with 
TWEEN20), pH 7.6 
2.24g Tris Base 
8g NaCl 
1ml TWEEN 20 
Ad 1l H2O 
2% Agarose gel 100ml 1x TAE buffer 
2g Agarose 
5µl Midori Green 
4% PFA RNase-free (for FISH) 7.5ml Lysine-phosphate buffer 
2.5ml 16% formaldehyde solution 
+ 0.135g glucose 
+ 0.021g sodium metaperiodate 
4% PFA, pH 7.4 40g PFA 
Ad 500ml H2O 
410ml Na2HPO4 x 2 H2O 
90ml NaH2PO4 x 2 H2O 
4x separating gel buffer 1.5M TRIS, pH 8.8 
0.4% SDS 
4x stacking gel buffer 0.5M TRIS, pH 6.8 
0.4% SDS 
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5% stacking gel 5% Acrylamide/Bis Solution 
1x stacking gel buffer 
10% APS1 
1% TEMED 
in H2O 
50x Tris-acetate-EDTA-buffer (TAE buffer) 2M Tris Base 
25mM Sodium acetate 
50mM EDTA 
AdH2O 
5M Betaine 20.28g Betaine monohydrate 
Ad 30ml H2O 
5x Laemmli Buffer 250mM Tris-HCl (pH 6.8) 
25% β-Mercaptoethanol 
10% SDS 
50% glycerol 
0.2% bromophenol blue 
6x loading buffer 30% glycerin solution in TAE  
0.15% bromophenol blue  
0.15% xylene cyanol  
Add 1× TAE to 50 ml  
ACSF medium (for FRAP) 127mM NaCl 
3mM KCl 
1.25mM NaH2PO4H20 
23mM NaHCO3 
25mM Glucose 
Agar plates 7.5g selective Agar 
10g LB 
Ad 500ml H2O 
Buffer I (for immunoaffinity chromatography) 20mM HEPES, pH 7.5 
500mM NaCl 
5mM MgCl2 
10mM imidazole 
10% glycerin 
5mM ß-mercaptoethanol 
1:1000 protease inhibitors AP, L/P, AEBSF 
and PMSF 
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Buffer II (for immunoaffinity chromatography) 20mM HEPES, pH 7.5 
100mM NaCl 
5mM MgCl2 
10% glycerine 
50mM arginine 
5mM ß-mercaptoethanol 
1:1000 protease inhibitors AP, L/P, AEBSF 
and PMSF 
Culture medium (for HEK293) DMEM 
10% FCS 
1% Geneticin 
DAPI 0.4µg/ml in 1xPBS 
Depolarization solution 4g NaCl 
1.1184g KCl 
Ad 500ml H2O (sterile) 
Digitonin-Lysis Buffer 150mM NaCl 
50mM HEPES, pH7.4 
25µg/ml digitonin 
Elution-buffer (for immunoaffinity 
chromatography) 
20mM HEPES, pH 7.5 
100mM NaCl 
5mM MgCl2 
10% glycerine 
50mM arginine 
5mM ß-mercaptoethanol 
1:1000 protease inhibitors AP, L/P, AEBSF 
and PMSF 
High-salt Wash Buffer 50 mM Tris-HCl, pH 7.4 
1 M NaCl 
1 mM EDTA 
1% Igepal CA-630 
0.1% SDS 
0.5% sodium deoxycholate 
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immunoaffinity chromatography-Lysis buffer 20mM HEPES, pH 7.5 
500mM NaCl 
5mM MgCl2 
10mM imidazole 
10% glycerin 
0.01% NP40 
5mM ß-mercaptoethanol 
1:1000 protease inhibitors AP, L/P, AEBSF 
and PMSF 
IP-Lysis Buffer 50 mM Tris-HCl, pH 7.4 
100 mM NaCl 
1% Igepal CA-630 
0.1% SDS 
0.5% sodium deoxycholate 
Laminin-111 2.5µg/ml Laminin in HBSS 
Laminin-221/211 2.5µg/ml Laminin in HBSS 
LB medium 20g LB in 1l H2O 
Lysis buffer (Quick and Dirty) for DNA 
extraction 
2.5ml 10% Sarcosyl 
1ml 5M NaCl 
2.5g Chelex 
Ad 50ml H2O 
Motoneuron medium (MN medium) Neurobasal 
2% B27 
2% Horse serum (heat-inactivated, 56°C, 
45min) 
Neurobasal medium Neurobasal 
1% Glutamax (100x) 
p75 solution 0.5µg/ml p75 in 10mM TRIS, pH 9.5 
PNK Buffer 20 mM Tris-HCl, pH 7.4 
10 mM MgCl2 
0.2% Tween-20 
RIP-Lysis buffer 50mM TRIS, pH 7.4 
150mM NaCl 
1mM MgCl2 
0.1% NP-40 
100U/ml RNasin RNase Inhibitor 
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Terrific Broth (TB) Medium 12g Bacto-tryptone 
24g Bacto-yeast extract 
4ml glycerol 
2.31g KH2PO4 
12.54g K2HPO4 
Ad 1l H2O 
Transfer Buffer 200ml Methanol 
100ml 10x Towbin Buffer 
Ad 1l H2O 
Trypsin inhibitor 500mg Trypsin inhibitor 
49ml HBSS 
1ml 1M HEPES (pH 7.4) 
 
2.16 Experimental Animals and Animal Facility 
For the following experiments controlled bred mice of the wild typical C57BL/6 or CD1 
strain and the B6.BKS-Ighmbp2nmd-2J/+ (Nmd2J) strain of the institute's own animal facility were 
used. The animals were killed by cervical dislocation. After opening the abdominal cavity, the 
embryos were removed and transferred to HBSS. Subsequently, the age of the embryos was 
determined using a binocular according to Theiler's criteria (Bleyl, 1975). All following 
experiments took place in accordance with the German Animal Protection Act (§ 1, 4, 17 
TierSchG). 
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3. Methods 
3.1 Cell Culture 
The following cell culture methods were performed at a sterile bench under sterile 
conditions. All required media, buffers or solutions were sterile filtered or autoclaved before 
use in order to create a clean experimental condition. This also included the decontamination 
of all equipment, materials and the workplace for disinfection with terralin or 70% technical 
ethanol. 
The horse serum contained in the culture medium was inactivated at 56°C for 45min 
and sterile filtered before use. 
To ensure a gentle cultivation of the cells without stress factors by too cool medium, 
all used media and solutions were heated to 37°C in a water bath.  
In general, all cells were cultivated at 37°C with a humidity of 100% and 5% CO2 
concentration. 
3.1.1 Isolation and Enrichment of Primary Embryonic Motoneurons 
Isolation and enrichment of primary mouse motoneurons (MNs) were performed as 
previously described (Wiese et al., 2010). For the preparation of MNs, head and tail were 
separated from the embryo with the help of tweezers and the embryo was placed in a ventral 
position. Then, the skin was carefully detached, and the central canal of the spinal cord on 
the dorsal side was opened. The spinal cord was removed from the embryo and meninges 
including dorsal root ganglia were removed. The lumbar part of the prepared spinal cord was 
transferred to a 1.5ml reaction tube filled with HBSS. All further steps were carried out at the 
sterile bench. All spinal cords were separately incubated with 0.025% trypsin for 10min at 
37°C. Next, the tissues were transferred separately into new reaction tubes with neurobasal 
and 0.1% Trypsin inhibitor to stop the digestion. To get single cell suspensions of each, 
digested spinal cords were dissociated by carefully pipetting up and down. All single cell 
suspensions were added to a 24-well cell culture plate coated with p75-antibody for 45min at 
RT, which had previously been washed three times with warm NB medium. The plate was 
kept vibration-free to select p75-receptor positive MNs. Additionally, the plate was carefully 
washed three times with warm NB medium and depolarization solution was added for 2min 
at room temperature (RT). Detached MNs were separately collected into 15ml centrifugation 
tubes with motoneuron medium (MN medium).  
For single cell cultures, MNs were plated at a density of 2000 cells/cm2 on glass 
coverslips pre-coated with poly-D/L-ornithine hydrobromide (PORN-H) along with either 
laminin-111 or laminin-211/221 and cultured for three (DIV3), five (DIV5) or seven days 
(DIV7) in vitro. Cells were cultured in neurobasal medium supplied with 2% B27 (Invitrogen), 
2% heat-inactivated horse serum (Linaris), 500µM Glutamax (Invitrogen), 10ng/ml BDNF 
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(brain-derived neurotrophic factor) and 10ng/ml CNTF (ciliary neurotrophic factor). The 
medium was exchanged 24h after plating as well as at DIV3 and DIV5. 
3.1.2 HEK293 Cell Cultivation 
HEK293 cells were used from stocks frozen and stored in liquid nitrogen. This cell line 
was frozen with culture medium and 10% DMSO in cryotubes. After removing the cryotubes 
from the nitrogen tank, the cell suspension was gently thawed in a water bath at 37°C and 
was then transferred into a 15ml centrifugation tube provided with culture medium. The 
resulting cell suspension was centrifuged for 5min at 800rpm and 24°C in the centrifuge, the 
cell pellet was resuspended in culture medium and transferred to a culture flask with 
preheated culture medium. The cell medium was exchanged every three days.  
To split the cells, the culture medium was aspirated, and the cells were washed twice 
with 1xPBS. Then the cells were removed from the bottom of the tissue culture flask by 
incubating with 0.25% trypsin/EDTA for 5min. Afterward, the enzyme reaction was stopped 
with culture medium and the resulting cell suspension was transferred into a 15ml 
centrifugation tube following by centrifugation for 5min at 800rpm at RT. The resulting 
supernatant was removed from the cell pellet, resuspended in culture medium and 
transferred to a new tissue culture flask with culture medium in the desired dilution. The cells 
were split approximately every 5-7 days. 
3.1.2.1 Transient Plasmid Transfection using Lipofectamine 2000 Reagent 
DNA plasmid and lipofectamine 2000 were separately added into two 1.5ml reaction 
tubes containing Opti-MEM medium and incubated for 10min at RT. Then, both solutions 
were mixed, incubated for 20min at RT and added dropwise to the HEK293 cells. Afterward, 
DNA lipid complex was supplied to seeded 106 cells per 6-Well plates cultured in DMEM 
medium without Penicillin/Streptomycin (P/S) for 6 hours (h) at 37°C. Next, the medium was 
aspirated and DMEM medium supplied with P/S was added. Cells were harvest after 36h of 
transfection. 
3.1.2.2 Lentivirus Production 
Lentiviral particles were packaged in HEK293 cells with pCMV-VSVG and 
pCMVΔR8.91 helper plasmids as described by (Rehberg et al., 2008). 
Cells were transfected with lipofectamine 2000 containing Opti-MEM medium with 
10% fetal calf serum for 12-14h and the virus was harvested after 72h of transfection by 
ultracentrifugation. This technique was carried out by my colleague Hilde Troll. 
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3.2 Immunoaffinity chromatography 
3.2.1 Overexpression of Recombinant Full Length Human IGHMBP2 Protein 
1µg pGex6p1 expression vector containing the full-length IGHMBP2 flanked by an N-
terminal GST tag and a C-terminal 6xhis tag (wt) was added in 100µl heat shock competent 
Rosetta DE3 pLys Escherichia coli (E. coli) and incubated on ice for 20min. This was 
followed by a heat shock phase at 42°C for 45sec and cooling on ice for 2min. The cell 
suspension was put on a shaker for 1h at 37°C and 1400rpm and then centrifuged for 3min 
at 5000rpm. The supernatant was discarded up to a volume of 100µl so that the remaining 
cell suspension could be plated completely onto an LB plate mixed with chloramphenicol and 
ampicillin and cultured overnight at 37°C in an incubator. 
The colonies grown on the LB plate were completely washed off and transferred to 
800ml TB medium including 2g glucose and all antibiotics and then cultivated at 180rpm and 
37°C to an optical density (OD) 600 is equal to 1. 
Afterward, the culture was split into 6 cultures and used up to an OD600=0.8. At this 
time, the temperature was reduced to 25°C and the cultures were mixed with 2% EtOH, 
absolute (gel sample before induction). At OD600=1, the expression of recombinant full 
length human IGHMBP2 protein could be induced with 1M Isopropyl-β-D-
thiogalactopyranoside (IPTG) at 14°C overnight (gel sample after induction). 
3.2.2 Purification of 6xHis-IGHMBP2 with the help of Ni-NTA (nitrilotriacetic acid 
agarose) Beads 
Next, the bacteria cultures were centrifuged for 15min at 4000rpm and 4°C. The 
supernatants were discarded, and all pellets were lysed with 25ml 4°C cold Lysis buffer and 
then sonicated on ice (output 5, duty cycle 50, 4x3min with 3min break). 
Subsequently, the lysates were centrifuged for 1h at 25000rpm and 4°C (gel sample 
from supernatant and pellet). The supernatant was incubated with 3ml equilibrated Ni-NTA 
beads for 2h at 4°C on a head-over-tail rotator (gel sample of the supernatant after binding to 
Ni-NTA beads). For equilibration of Ni-NTA beads, beads were washed three times with lysis 
buffer. 
Then, the 6xHis-IGHMBP2-loaded beads were treated with 150ml lysis buffer and 
then with 200ml buffer I. The elution was carried out in 10 fractions with 1ml elution buffer 
each fraction (gel sample of beads before the elution and after the elution). Protein 
concentrations were quantified with the Bradford protein assay. 
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3.2.3 Purification of GST-IGHMBP2 with the help of Glutathione Sepharose 
Transferase Beads 
Next, all fractions were pooled depending on the protein concentration (gel sample of 
pooled fractions). The pooled fractions were incubated with 4 ml equilibrated glutathione-
sepharose transferase (GST) beads for 2h at 4°C on an head-over-tail rotator (gel sample of 
the supernatant after binding to GST beads). For equilibration of GST beads, beads were 
washed three times with buffer I. Subsequently, GST-IGHMBP2-loaded-beads were treated 
with 200ml buffer I and then with 100ml buffer II. 
3.2.4 Cross-linking of GST-IGHMBP2 to Glutathione Sepharose Transferase Beads 
Cross-linking of GST-IGHMBP2 to GST beads was performed with Dimethyl-
pimelimidate (DMP) to create a specific matrix for the Ighmbp2 antibody purification. For this 
purpose, GST beads were washed twice with 10ml 1xPBS + 0,01% NP40 and three times 
with 10ml disodium tetraborate (gel sample of beads before binding). Afterward, the 
IGHMBP2 proteins were covalently cross-linked to GST beads by incubating them with 10ml 
disodium tetraborate + 0.04g DMP for 30min at RT on a head-over-tail rotator (gel sample of 
beads after binding). Then, beads were washed three times with 10ml 0.2M ethanolamine 
(pH 8.0). 
To saturate the still coupling active groups of the crosslinker, the beads were 
incubated with 10ml 0.2M ethanolamine (pH 8.0) overnight at 4°C on a head-over-tail rotator 
(gel sample of beads after saturation). Finally, beads were washed three times with 1xPBS. 
3.2.5 Purification of the Ighmbp2 Antibody using an IGHMBP2-crosslinked 
Glutathione Sepharose Transferase Matrix 
The polyclonal Ighmbp2 antibody of rabbit antiserum was purified with the help of 
IGHMBP2-cross-linked GST matrix. For this purpose, the IGHMBP2- crosslinked GST matrix 
was washed twice with 10ml 1xPBS+0,01% NP40. Previously, a poly prep column was 
incubated once with 10ml 1xPBS+0.01% NP40. Then, the matrix was washed once with 
10ml 0.1M glycine (pH 2.7) and then neutralized with 10ml 1.5M Tris (pH 8.8) and washed 
twice again with 10ml 1xPBS+0.01% NP40. 
Next, the filtered rabbit antiserum (0.4 µm filter) was incubated with the matrix for 
90min at 4°C on the head-over-tail rotator (gel sample of beads). The matrix was washed 
twice again with 10ml 1xPBS + 0.01% NP40 and the elution was carried out in ten fractions 
with the help of a pH drop by 1ml 0.1M glycine (pH 2.7). All collected fractions were 
immediately neutralized with 200µl 1.5M Tris (pH 8.8) (gel samples of the respective 
fractions). 
For long-term storage of IGHMBP2-cross-linked GST matrix, beads were neutralized 
with 10ml 1.5M Tris (pH 8.8) and then washed twice with 1xPBS + 0.01% NP40. It can be 
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stored in 1xPBS with 0.02% sodium azide (w/v) at 4°C for several weeks. The schematic 
diagram is depicted in Fig. 5. 
 
Figure 5 – Schematic diagram of immunoaffinity chromatography: the first step of recombinant GST-
IGHMBP2-6xHis IGHMBP2 protein purification using Ni-NTA beads. The second step of recombinant GST-
IGHMBP2-6xHis IGHMBP2 protein purification using GST beads. GST=glutathione sepharose transferase; Ni-
NTA=nickel nitrilotriacetic acid; DMP=Dimethyl-Pimelimidate; recomb.=recombinant. 
3.2.6 Enhancement of Eluted Ighmbp2 Antibody Solution using a Centricon 
The gel samples and elution fractions were evaluated using SDS page and 
Coomassie staining. The pooled elution fractions were completely transferred into Centricon 
tubes and centrifuged at 5000rpm and 4°C for 1h to 1ml reservoir, refilled with 1xPBS and 
centrifuged to 1ml reservoir. This process was repeated once, and the filtrate was always 
discarded. Thereby a 5fold concentration of the antibody solution was achieved. 
The antibody solution was mixed with 25% glycerin and 0.01% sodium azide, 
aliquoted into 100µl samples and stored at -20°C. 
 
3.3 Immunocytochemistry 
All steps were carried out at RT if not otherwise mentioned. At DIV5 or DIV7 MNs 
were fixed with 4% paraformaldehyde (PFA) for 10min, then washed three times with 1xPBS 
and permeabilized with 0.3% Triton in 1xPBS for 15min. After blocking with 10% BSA in 
1xTBS-T for 1h the cells were incubated overnight at 4°C with primary antibodies diluted in 
1% BSA in 1xTBS-T. Afterward, cells were washed three times with 1xTBS-T for 2min and 
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incubated for 1h with secondary antibodies diluted in 1% BSA in 1xTBS-T and nuclei were 
counterstained with DAPI. Subsequently, cells were washed three times with 1xTBS-T and 
mounted with Polymount. 
For staining against α-, β- and γ-actin the staining protocol varied from the protocol 
described above. For staining of α-actin, the cells were incubated with 0.1% Triton-X in 
1xPBS for 15min and the primary antibody was added on day two of staining and incubated 
for 3h before washing and incubating with secondary antibody. Cells stained with antibodies 
against β- and γ-actin were incubated with ice-cold methanol for 5min before 
permeabilization with 0.3% Triton in 1xPBS for 10min at RT. 
The quantification of dendrite length, soma size, axon length and branching of 
Ighmbp2-deficient and control / wildtype MNs was performed on laminin-111 at DIV7. The 
longest axon per motoneuron was included into the statistical analysis and each primary 
branch of the longest axon was counted. The quantification of growth cone size and signal 
intensity of target proteins of Ighmbp2-deficient and control / wildtype MNs was performed on 
laminin-111 or laminin-211/221 at DIV5. 
 
3.4 Fluorescence in situ Hybridization (FISH) 
Fluorescence in situ hybridization (FISH) was performed according to the 
manufacturer’s instructions (Panomics) with brief variances. All steps were carried out at RT 
if not otherwise mentioned and were performed under RNase-free conditions. MNs cultured 
on 10mm glass coverslips were fixed at DIV5 with 4% RNAse-free PFA for 15min. Next, cells 
were washed three times with newly prepared RNase-free 1xPBS for 5min. Thereafter, cells 
were incubated with hybridization solution supplied with 100µg/ml tRNA (salmon salt DNA) 
for 3min at 63°C and put on ice. The cells were incubated with hybridization solution supplied 
with 100µg/ml tRNA for 45min at 40°C. Next, 40nM Digoxigenin (DIG)-labelled LNA (locked 
nucleic acid) probes were added overnight at 40°C. Then, cells were washed five times with 
2xSSC / 0.1% TWEEN20 for 1min at 45°C and three times with 1xSSC for 1min. Hybridized 
probes were detected by primary mouse anti-DIG antibody in 1% bovine serum albumin 
(BSA) in 1xPBS for 3h. Next, cells were washed five times with 2xSSC / 0.1% TWEEN20 for 
1min and three times with 1xSSC for 1min. Fluorescent-labeled secondary antibody in 1% 
BSA in 1xPBS was added for 1h and the cells were washed again five times with 
2xSSC / 0.1% TWEEN20 for 1min and three times with 1xSSC for 1min. Finally, MNs were 
mounted with Polymount. 
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3.5 Biochemical Methods 
3.5.1 Extraction of Tissue and Cell Lysates 
Ighmbp2-deficient and control / wildtype mice were killed by cervical dislocation. The 
target tissues were removed and immediately frozen in liquid nitrogen. The tissues were 
stored at -80°C until use. The frozen tissues were dispersed with 300μl RIPA buffer in glass 
ground homogenizers. After a centrifugation step of 5min at 4°C, the supernatant was 
removed and transferred to a new reaction tube. 2μl of the lysate was used to determine the 
protein concentration (Bradford test), the residues were stored at -20°C until use. 
All acquired MNs from Ighmbp2-deficient and control / wildtype mouse embryos were 
cultured on PORN-H- and laminin-111-coated 24-well cell culture dishes for DIV7. Cells were 
directly lysed in 5x Laemmli buffer. Protein lysates were heated for 5min at 99°C and then 
centrifuged at 4°C and stored at -20°C until use. 
3.5.2 Determination of Protein Concentration 
In order to determine the protein concentration in tissue lysates, the BioRad protein 
assay was performed. This assay is based on the Bradford method, in which the color 
change of Coomassie Brilliant Blue G-250 dye from brown to blue after protein binding in 
acid solution is used. After an incubation time of 5min at RT, the optical density with the help 
of a photometer at 600nm was determined, a calibration line was calculated, and the 
concentration of the individual lysates was calculated. 
Cell lysates were quantified by a BCA assay. Bivalent copper ions bind to the peptide 
bond and are reduced to monovalent copper ions at alkaline pH. In the presence of BCA, the 
copper ions build a blue-violet dye complex with BCA. The optical density with the help of a 
photometer at 562nm was determined, a calibration line was measured, and the 
concentration of the individual cell lysates was calculated. 
3.5.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The protein samples were separated by polyacrylamide gel electrophoresis under 
denaturing conditions. First, the protein tissue samples were mixed with Laemmli buffer, 
heated to 99°C for 5min and then centrifuged at 4°C. SDS and mercaptoethanol contained in 
the Laemmli buffer denature the proteins and reduce all disulfide bridges. The tissue and cell 
protein samples were loaded into the pockets of a 1mm thick polyacrylamide gel consisting 
of a 5% stacking gel and a 10% separating gel. The negatively charged proteins migrate in 
the gel towards the positive pole and the rate of migration depends on their molecular weight. 
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3.5.4 Western Blot 
A Polyvinylidene fluoride (PVDF) membrane was activated in methanol, then stored 
together with the blotting paper in transfer buffer. A layer of blotting paper, the PVDF 
membrane, the SDS gel and again a blotting paper were placed one after the other on the 
anode of the blotting apparatus. Protein samples separated on SDS-Page gels were 
transferred onto a PVDF membrane using the wet/tank blotting system for 1h at constant 
150V and 4°C.  
3.5.5 Immunodetection of Proteins on PVDF Membranes 
The PVDF membrane was blocked with 5% milk powder in 1xTBS-T for at least 2h at 
RT to reduce unspecific binding of the antibody. The membrane was probed with the primary 
antibodies in 1xTBS-T at 4°C overnight. The membrane was then washed three times for 
10min with 1xTBS-T and a corresponding HRP-coupled secondary antibody was applied for 
2h in 5% milk powder in 1xTBS-T at RT. Afterward, the membrane was washed four times 
for 10min with 1xTBS-T and the immunodetection was performed using ECL Western 
Blotting systems according to the manufacturer´s instructions. 
The light emitted by the oxidation of the Luminol substrate was detected using X-ray 
films with different exposure times. The development was done in a Curix 60 developer of 
AGFA. 
3.5.6 Fractionation-Assay 
Fractionation-assay was performed according to the EMC Research Notes 
instructions (Holden and Horton, 2009) with brief variances. HEK293 cells were cultured in 
10cm dishes to 100% confluency. Cells were lysed with Digitonin-lysis buffer containing 
protease inhibitors (taking out sample / whole lysate). The lysates were centrifuged at 4°C for 
5min at 3.000rcf and the supernatants were obtained. Pellet and supernatant were used to 
produce the nuclear and cytosol fraction. 
Cytosolic fraction 
The supernatant was centrifuged again at 4°C for 10min at 10.000rcf and its 
supernatant was collected and then sonicated on ice (0.5 amplitude and 100% cycles 
2x10sec with 10sec break). The supernatant was centrifuged again at 4°C for 5min at 
20.000rcf and its supernatant was collected as cytosolic fraction. The cytosolic fraction was 
directly diluted in Laemmli buffer and was heated to 99°C for 5min and then centrifuged at 
4°C and stored at -20°C until use. 
Nuclear fraction 
The pellet was washed with Digitonin-lysis buffer and centrifuged at 4°C for 1min at 
3.000rcf. The supernatant was discarded, RIPA buffer was added and the lysate was 
sonicated on ice (0.5 amplitude and 100% cycles 2x10sec with 10sec break). 4µl T-DNAse 
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and 2µl RNase were added to the lysate and incubated for 5min at 37°C. Next, the lysate 
was centrifuged again at 4°C for 5min at 20.000rcf and the supernatant was discarded. The 
pellet/nuclear fraction was diluted in Laemmli buffer and was heated to 99°C for 5min and 
then centrifuged at 4°C and stored at -20°C until use. 
3.5.7 Co-Immunoprecipitation (Co-IP) 
All steps were carried out at RT if not indicated otherwise. Dynabeads Protein A was 
equilibrated and washed two times with IP-Lysis buffer. Next, beads were loaded with 5µg 
target antibody by rotating for at least 1h and then antibody-bound beads were washed three 
times with IP-Lysis buffer. 
HEK293 cells were cultured in 10cm dishes to 100% confluency and UV-crosslinked 
with 254nm with 0.15 Joules/cm2 to covalently bind proteins and RNA molecules. Next, cells 
were incubated with IP-Lysis buffer on ice for 10min and then sonicated on ice (0.5 amplitude 
and 80% cycles 10x10sec with 2min break). Afterward, lysates were cooled down on ice for 
3min and centrifuged for 10min at 10.000rpm and 4°C. The supernatant was collected into a 
new reaction tube (taking out sample / input). IP-Lysis buffer was removed from the beads, 
lysates were added to the beads and were incubated by rotating overnight at 4°C. The 
supernatant was discarded (taking out sample / flow-through). The beads were washed two 
times with high-salt wash buffer and then two times with PNK buffer. Beads were directly 
lysed in Laemmli buffer and subjected to Western Blot assay or stored at -20°C until use. 
3.5.8 Radioactive Labeling of Crosslinked Protein-RNA Complexes 
All steps were carried out at RT if not indicated otherwise. Dynabeads Protein A was 
equilibrated and washed two times with IP-Lysis buffer. Next, beads were loaded with the 
target antibody by rotating for at least 1h and then antibody-bound beads were washed three 
times with IP-Lysis buffer. HEK293 cells were cultured in 10cm dishes to 100% confluency 
and UV-crosslinked with 254nm with 0.15 Joules/cm2 to covalently bind proteins and RNA 
molecules. Next, cells were incubated with IP-Lysis buffer on ice for 10min, followed by mild 
water bath sonication at 4°C (7x15sec with 15sec break). Then, lysates were treated in two 
conditions with a low and high concentration of RNase I for 3min at 1100rpm and 37°C in a 
heating block. Afterward, lysates were cooled down on ice for 3min and centrifuged for 10min 
at 10.000rpm and 4°C. The supernatant was collected into a new reaction tube (taking out of 
sample probe / input). IP-Lysis buffer was removed from the beads, lysates were added to 
the beads and were incubated on a 3D-shaker overnight at 4°C. 
The supernatant was discarded (taking out of sample probe / flow-through). Beads 
were washed two times with high-salt wash buffer and then two times with PNK buffer. PNK 
buffer was removed and 4µl PNK mix was added to the beads for 5min at 1100rpm and 37°C 
in a heating block. Then, the beads were washed once with PNK buffer, absorbed with 
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NuPAGE loading buffer and incubated for 5min at 70°C. Samples were separated on a  
4-12% NuPAGE Bis-Tris gel using MOPS running buffer. Novex wet transfer apparatus was 
used to transfer protein-RNA complexes onto a Nitrocellulose membrane. Protein-RNA 
complexes were detected using X-ray films at -80°C. 
3.5.9 Immunoprecipitation of mRNA-Protein Complexes (RIP) 
Immunoprecipitation of mRNA-protein complexes (RIP) was performed according to 
the Nature protocol instructions (Peritz et al., 2006) with brief variances. All steps were 
carried out at RT if not indicated otherwise. HEK293 cells were cultured in T75 flasks to 
100% confluency and incubated with RIP-Lysis buffer on ice for 15min, followed by mild 
water bath sonication at 4°C (7x15sec with 15sec break). Then, the lysates were centrifuged 
for 15min at 208217rcf and 4°C. Dynabeads Protein A was equilibrated and washed two 
times with RIP-Lysis buffer. Afterward, supernatants of all lysates were precleared twice with 
equilibrated beads by shaking for 1h at 4°C (taking out sample / input) and in parallel beads 
were loaded with 2µg target antibody, control antibody and without antibody by rotating for at 
least 1h. Then, antibody-bound beads were washed three times with RIP-Lysis buffer and 
added to precleared lysates to incubate overnight at 4°C. Next, beads were washed five 
times with RIP-Lysis buffer (taking out sample / flow-through) and incubated with RIP-Lysis 
buffer supplied with 0.1% SDS and 0.3µg/µl proteinase K for 30min at 56°C in a heating 
block. 
RNA isolation, DNase digestion, RNA isolation, and cDNA synthesis were performed 
with TRIzol Reagent, TURBO DNA-free Kit, TRIzol Reagent and the High-Capacity cDNA 
Reverse Transcription Kit according to the manufacturer’s instructions.  
For quantitative RT-PCR, absolute copy numbers of target mRNA from IGHMBP2- 
and IMP1-IP samples were normalized to absolute copy numbers of target mRNA from Input 
and IgG control condition. 
3.5.10 Protein Synthesis Efficiency (SUnSET experiments) 
All acquired MNs from Ighmbp2-deficient and control / wildtype mouse embryos were 
cultured on PORN-H- and laminin-111-coated 24-well cell culture dishes for DIV7. Cells were 
incubated with MN medium supplied with 10µg/ml puromycin and all neurotrophic growth 
factors for 1h at 37°C (Schmidt et al., 2009). Then, MNs were lysed directly in Laemmli buffer 
and were heated for 5min at 99°C, centrifuged at 4°C and subjected to Western Blot assay or 
stored at -20°C until use. 
3.5.11 Label Newly Synthesized Proteins with L-Azidohomoalanine (AHA) 
MNs from Ighmbp2-deficient and control / wildtype mouse embryos were cultured on 
PORN-H- and laminin-111-coated 10mm glass coverslips for DIV5. L-Azidohomoalanine 
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(AHA) labeling was performed according to Tom Dieck et al. 2012, with brief variances (Tom 
Dieck et al., 2012) at DIV5. The medium was aspirated and methionine-free DMEM supplied 
with 2% B27 and 10ng/ml BDNF/CNTF was added for 30min at 37°C. Next, cells were 
incubated for 1h with methionine-free DMEM supplied with 4mM AHA, 2% B27 and 10ng/ml 
BDNF/CNTF, which started the labeling process. As a control experiment, cells were 
incubated with 50ng/µl anisomycin in methionine-free DMEM supplied with 2% B27 and 
10ng/ml BDNF/CNTF for 3h to inhibit protein synthesis before and during AHA-labeling. 
Then, cells were washed two times with pre-warmed PBS-MC and fixed with PFA-Sucrose 
for 20min. All following steps were carried out at RT if not indicated otherwise. Subsequently, 
cells were washed three times with 1xPBS, pH 7.4 for 2min and permeabilized with PBS-Tx 
for 15min. After blocking with B-Block for 1.5h, the cells were washed three times with 
1xPBS for 10min and incubated overnight with FUNCAT reaction mix. Next, cells were 
washed three times with FUNCAT wash buffer for 10min and two times with 1xPBS for 
10min. Finally, MNs were mounted with Polymount. 
 
3.6 Molecular Biological Methods 
3.6.1 Extraction of Genomic DNA 
Tissue samples, e.g. tails from an E12.5 embryo, were digested in Quick and Dirty 
Lysis buffer with 2mg/ml Proteinase K for at least 30min at 55°C and 850rpm in a heating 
block. The samples were then heated to 99°C for 8min and centrifuged at 14000rpm. The 
isolated DNA was stored at 4°C. 
3.6.2 Polymerase Chain Reaction (PCR) 
3.6.2.1 Standard-PCR 
This method was used to amplify specific DNA sequences. The DNA between the two 
primers is multiplied exponentially within several cycles (20-40) of denaturation, annealing, 
and elongation. The used primers were oligonucleotide primers with a length of about 20 
nucleotides and a GC content of about 50%. In addition, the primer pair should not have any 
longer complementary sections. In the initial denaturation step, the double-stranded DNA is 
separated into single strands at high temperature to enable primer hybridization. The 
optimum annealing temperature (50-65°C) depends on the GC content and thus on the 
melting temperature of the primers. The next step is elongation at 72°C. Using a Taq 
polymerase, a new DNA strand is synthesized by attaching complementary 
deoxyribonucleotides (200μM) to the template in the 5'-3' direction. A buffer is added to keep 
the magnesium chloride concentration at approx. 1.5mM so that the Taq polymerase can 
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work correctly. In order to optimize the PCR reaction, betaine was also added to the sample. 
Betaine prevents the formation of secondary structures in GC-rich regions and thus improves 
DNA amplification. 
3.6.2.2 Quantitative Reverse Transcriptase PCR (qRT-PCR) 
Quantitative reverse transcriptase PCR (qRT-PCR) was performed to analyze the 
mRNA expression level of primary mouse MNs or human HEK293 cells. cDNA was 
quantified with LightCycler 96. Used primers and all program settings are shown in chapter 
2.13. For qRT-PCR, absolute copy numbers of target mRNA were normalized to absolute 
copy numbers of Gapdh. 
3.6.3 Genotyping 
Genotyping was performed to determine the genotype of a mouse. This method is 
based on the purification of tissue DNA and its amplification by PCR followed by agarose gel 
electrophoresis. All gel electrophoreses were performed with 2% agarose gels at 120V for 
45min. 
3.6.3.1 Nmd2J Mouse Line 
The Nmd2J mouse strain was obtained from the Jackson Laboratory and backcrossed 
to the genetic C57BL/6 background. The Nmd2J (Ighmbp2-deficient) mouse line and the 
wildtype mouse line on the CD1 background were sheltered in the central animal facility of 
the University Hospital Wuerzburg. The animal care and ethics committees endorsed all 
described procedures and experiments. Genotyping of the Ighmbp2-deficient mouse line was 
performed as previously described (Cox et al., 1998). 
The isolated DNA was amplified using the following PCR Reaction Mix (Table 26) and 
the cycle program is depicted in table 27. 
Table 26 - PCR Reaction Mix 
PCR Reaction Mix Final Concentration 
GoTaq MM (2x) 1x 
DNA template 100-250ng 
Forward Primer F15 0.6µM 
Reverse Primer R14 0.6µM 
Betaine 1M 
Nuclease-Free Water to 25µl 
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Table 27 - PCR Cycle Program 
PCR Cycle Program 
 Temperature [°C] Duration [min:sec] Number of cycles 
Initial Denaturation 94 03:00 1 
Denaturation 94 00:30 
35 Primer Annealing 60 00:30 
Elongation 72 01:00 
Terminal Elongation 72 05:00 1 
Hold 4 ∞ 1 
 
The point mutation in Intron 4 in Nmd2J mice causes a new DdeI restriction interface, 
which is missing in wildtype animals. For this reason, a DdeI digestion was performed after 
PCR. The enzymatic restriction digestion of DNA was performed using DdeI and Tango 
Buffer (10x) according to the manufacturer's instructions. The complete PCR batch was 
incubated together with Tango Buffer and DdeI enzyme for 2.5h at 37°C. The DNA fragments 
were finally separated and analyzed by horizontal gel electrophoresis. In wildtypes, a band 
can be detected at 180bp and in mutants at 120bp. In heterozygous animals, both bands 
appear. 
3.6.4 Horizontal Gel Electrophoresis 
Horizontal gel electrophoresis was used to investigate the size of DNA fragments. 
The DNA samples were mixed with a 6x sample buffer and then pipetted into the pockets of 
a 2% agarose gel. Depending on their size, the negatively charged DNA fragments migrated 
towards the anode according to the applied voltage, whereby the small fragments ran fastest, 
and the highest bands represented the largest DNA fragments. The agarose gels were mixed 
with ethidiumbromide, which intercalates with DNA and was detected with a UV 
transilluminator. A 100bp DNA ladder was used as the size standard. 
3.6.5 RNA Isolation and cDNA Synthesis 
RNA isolation and cDNA synthesis were performed using the Nucleo Spin RNA Kit 
and SuperScript III First-Strand Synthesis Kit or High-Capacity cDNA Reverse Transcription 
Kit according to the manufacturer´s instructions. cDNA was diluted 1:5 with nuclease-free 
water. 
3.6.6 RNA Sequencing 
MNs from Ighmbp2-deficient and control / wildtype mouse embryos were cultured on 
PORN-H- and laminin 111-coated 24-well plate for DIV7. RNA isolation was performed using 
the Nucleo Spin RNA Kit according to the manufacturer´s instructions. RNA was pre-
machined for RNA-Seq library generation using the mRNA-Seq Library Prep Kit V2. Pooled 
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libraries were sequenced on the Illumina NextSeq 500 with the High Output Kit v2 (75 
cycles). Adapters and low-quality reads were designed with TrimGalore, v0.4.0 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) powered by Cutadapt, v1.8 
(https://cutadapt.readthedocs.io/en/stable/) (Martin, 2011). As described in the Lexogen user 
manual, the first nine nucleotides from the 5' end of reading 1 were removed. Next, all reads 
were mapped with the help of STAR v2.5.0a (Dobin et al., 2013) and differentially expressed 
transcripts were defined using the Cufflinks package v2.2.1 (Trapnell et al., 2012) as 
previously described (Briese et al., 2016). The sequencing files have been recorded in 
NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are available through GEO 
Series accession number GSE111224. 
3.6.7 Molecular Cloning 
1µg pSIH-H1 vector was incubated with 0.1U/μl EcoR1 and 0.1U/μl of the BamH1 
enzyme in Tango Yellow Buffer for 1h at 37°C. Then, the cut vector was purified using 
QIAEX II – Gel Extraction Kit according to the manufacturer’s manual. 20µM sense and 
antisense oligonucleotides in Tango Yellow Buffer were incubated for 5min at 95°C and 
annealed for 1h at 37°C. Next, 1µM annealed oligonucleotides and the 25ng linear pSIH-H1 
vector was ligated with the help of 40 U/μl T4 ligase in ligase buffer for 1h at RT. The ligation 
product was used for plasmid transformation in competent Top10 E. coli. For this purpose, 
cells were incubated on ice for 15min following by a heat shock of 50sec in a 42°C water 
bath. Then, LB medium was added and incubated for 1h at 800rpm at 37°C in a heating 
block. The cell suspension was centrifuged for 5min at 1400rpm, 80% of the supernatant was 
discarded. Last 20% of the supernatant including the pellet was plated on an agar plate 
supplied with 1.5mg/ml ampicillin and incubated overnight at 37°C. Picked colonies were 
transferred into LB medium supplied with 4.5µg ampicillin and incubated for 8h at 800rpm 
and 37°C. The cell suspension was used for plasmid purification using the NucleoBond Xtra 
Mini/Midi/Maxi EF kit. Plasmid sequencing was done by LGC Genomics GmbH. 
3.7 Life Cell Imaging 
3.7.1 Calcium Imaging 
MNs from Ighmbp2-deficient and control / wildtype mouse embryos were cultured on 
PORN-H- and laminin-111-coated 10mm glass coverslips for DIV5. Calcium indicator Oregon 
Green 488 BAPTA-1 AM was mixed with Pluronic F-27 / DMSO in an ultrasound sonifier for 
2min. 
For labeling intracellular calcium, MNs were treated with calcium imaging buffer 
supplied with the calcium indicator for 13min at 37°C. Next, recordings were performed in a 
heated chamber with calcium imaging buffer using a confocal microscope with a 40x 
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objective. Time-lapse images with a frequency of 2.5Hz and an exposure time of 400ms 
were acquired. Real-time images were displayed by StreamPix (Norpix) software and MNs 
were irradiated with a LED light source (Visitron Systems) using the following filter settings: 
excitation 482±35nm, dichroitic filter 506nm, emission filter 536±40nm. The analysis was 
performed with ImageJ software with the help of two plugins Intensity vs Time Monitor and 
Time Series Analyzer V2.0, which allowed the determination of activity events by measuring 
calcium influx in defined regions of interest (ROIs). 
3.7.2 Fluorescence Recovery after Photobleaching (FRAP) 
Manufacturing of the lentiviral eGFPmyr reporter construct was described previously 
(Rathod et al., 2012). Stop codon of myristoylated-eGFP in a FUValentin lentivirus vector 
under control of the ubiquitin promoter was directly linked to the complete 3’UTR of β-actin. 
MNs from Ighmbp2-deficient and control / wildtype mouse embryos were cultured on PORN-
H- and laminin-111-coated µ-dishes for DIV5 in presence of 10ng/µl BDNF and 10ng/µl 
CNTF and transduced with eGFPmyr-β-actin 3’UTR lentivirus. Recordings were performed 
with an inverted SP5 confocal microscope using a 60x1.35-NA oil objective as previously 
described (Moradi et al., 2017). First, the axon terminal with an area of approximately 100µm 
was recorded every 30sec for 4min at 19% laser power followed by bleaching using 80% 
laser power. Fluorescence recovery was observed for 1h every 30sec. Post-bleach time-
lapse images were analyzed as the mean intensity grey values per pixel in ROIs of growth 
cone and soma. Upcoming recovery was calculated using Leica LAS lite software. Starting 
signal intensity F0 was defined as the mean intensity average of 8 pre-bleach images. Post-
bleach signal intensity was defined as the average of signal intensities of 10 immediate post-
bleach images. This was done to eliminate the initial postbleach signal. Post-bleach signal 
intensity was then normalized to starting signal intensity to calculate the percentage 
recovery. 
As a control experiment, cells were incubated with 50ng/µl anisomycin for 2h to inhibit 
protein synthesis before recording. 
 
3.8 Mouse Growth Factor Array 
Blood from P28 Ighmbp2-deficient and control/wildtype mice was collected after 
intraperitoneal injection with Ketamin (120mg/kg in 0.9% NaCl) and Xylazine (16mg/kg in 
0.9% NaCl). It was kept for 20min at RT and centrifuged for 30min at 12000rpm. Blood 
serum was diluted with blocking buffer 1:10 supplied with protease inhibitors. Meanwhile, the 
membrane was blocked with blocking buffer for at least 30min at RT. C2 Growth Factor Array 
was carried out according to manufacturer’s manual with the following incubation times: 
sample incubation 5h at RT, biotinylated antibody solution overnight at 4°C and streptavidin 
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antibody solution 2h at RT. Signal intensity quantifications were determined according to the 
manual using Image Studio Lite software. 
 
3.9 Proteomics 
3.9.1 Pulsed SILAC 
The complete acquired Ighmbp2-deficient and control / wildtype MNs per E12.5 
embryo were seeded on PORN-H/laminin-111-coated on 24-well plates with MN medium and 
neurotrophic growth factors for 24h. Then, the medium was exchanged to light media 
condition for the next 24h. Cells were washed twice with pre-warm amino acid-free 
Neurobasal supplied with 500µm Glutamax to wash out the light media and then heavy (H, 
for control MNs) or medium heavy (M, for Ighmbp2-deficient MNs) media condition was 
added to the cells for 20h. Next, cells were washed twice with 1xPBS and RIPA lysis buffer 
was added on ice for 10min. Lysates were centrifuged for 30sec at 208217rcf and 4°C 
followed by mild water bath sonication at 4°C (7x15sec with 15sec break). Then, lysates 
were centrifuged again for 2min at 208217rcf and 4°C and quantified by BCA assay. 
Incorporated heavy or medium-heavy amino acids in newly synthesized proteins of control 
and Ighmbp2-deficient MNs were analyzed by mass spectrometry of resulting mass 
differences. The schematic diagram is depicted in Fig. 6. 
 
Figure 6 - Schematic diagram of pSILAC analysis: motoneuron preparation and labeling of de novo translated 
proteins in control and Nmd2J (Ighmbp2-deficient) motoneurons. Ctrl=control, MN=motoneuron, H=heavy amino 
acids; M/H=medium heavy amino acids. Modified according to (Surrey et al., 2018). 
 
3.10 Statistics 
The depicted results were obtained from at least three independent experiments and 
were shown as mean±standard error of the mean (SEM) or mean±standard deviation (SD). 
Biological and technical replicates were indicated with "n" and the total number of evaluated 
test cases (e.g. axons, growth cones, cell bodies) represents "N". The statistical analyses 
were performed with GraphPad Prism 5 software. In datasets of two groups, the statistical 
analysis was quantified using the Mann-Whitney U-test (no Gaussian distribution; Ca2+ 
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imaging, Western blot, qRT-PCR, axon length, cell body size, dendrite number, mean 
dendrite length, total dendrite length, growth cone size, signal intensities, FPKM RNA-Seq). 
For datasets with more than two groups, two-way ANOVA with Bonferroni post-hoc test 
(Gaussian distribution, FRAP analysis) or a one-way ANOVA with Tukey's multiple 
comparison test (Gaussian distribution, axonal branching and RIP analysis) and a one-way 
ANOVA/Kruskal-Wallis test with Dunn's multiple comparison test (no Gaussian distribution, 
Western blot of Ighmbp2 KD or bFGF long-term treatment FGFR and AHA-labeling) or 
repeated measures test with Dunnett's Multiple Comparison Test (C2 Mouse Growth Factor 
Array) was used. 
Significance levels are consistently reported as n.s. not significant and p*<0.05, 
p**<0.01 and p***<0.001. The images were generated and quantified using the confocal 
microscope SP2 (Leica) / Leica LAS LITE and the confocal laser scanning microscope 
Olympus Fluo View FV1000 (IX81) / FIJI software. The signal intensity was measured as 
arbitrary unit per area based on quantum levels (QL) per pixel. All images were processed 
with FIJI and Adobe Illustrator CS5 and the linear contrast enhancement was applied, and all 
individual images were treated equally. 
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4. Results 
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a motoneuron 
disease in children with fatal outcome and unknown pathomechanism. The mutant IGHMBP2 
gene encoding a superfamily 1 (SF1) RNA/DNA helicase causes the onset of this disorder. 
The neuromuscular disorder (Nmd2J) mouse model is indispensable for the investigation of 
the disease mechanism under SMARD1. Nevertheless, the function and the affected cellular 
processes are almost unknown. With the help of primary motoneuron cultures, a detailed 
knowledge of the spinal muscular atrophy (SMA) disease mechanism has already been 
obtained. Therefore, the present Ph.D. thesis aims to gain a broader understanding of the 
SMARD1 disease mechanism using primary cultured Ighmbp2-deficient motoneurons to 
elucidate the function of the ribosomal RNA/DNA helicase Ighmbp2. 
4.1 Ighmbp2 Antibody Validation 
Most of the results from section 4.1 are published in (Surrey and Jablonka, 2018; 
Surrey et al., 2018). 
Numerous assays and approaches can be used to analyze the function of a protein or 
molecule. However, independent from the chosen experiment, it is essential to tag or mark 
the protein of interest. Since there is no anti-Ighmbp2 antibody available for purchase, it was 
necessary to produce an antibody against the helicase for the following experiments. 
Antibodies against the Ighmbp2 protein were obtained by immunizing rabbits with an antigen 
against the full-length recombinant human IGHMBP2, a polyclonal antibody was formed, 
which differ in their epitope specificities. All antibodies have the same antigen specificity - but 
they are directed at different epitopes of this antigen (Luttmann et al., 2009). Immunoaffinity 
chromatography was performed to purify the rabbit antiserum. 
 
Figure 7 - Overexpression of recombinant human IGHMBP2 in E. coli. The protein with an N-terminal GST- 
and a C-terminal 6xHis-fusion tag was overexpressed in E. coli Rosetta cells (Guenther et al., 2009a). 
For this purpose, a derivative of the pGex-6P-1 expression plasmid vector containing 
the full length of human IGHMBP2 was used, which enables overexpression of the IGHMBP2 
protein in E. coli Rosetta cells (Fig. 7). The construct of recombinant IGHMBP2 was 
described in the publication (Guenther et al., 2009a) and the purification was supervised by 
the group of Prof. Dr. Utz Fischer at the Institute of Biochemistry of the Julius-Maximilians-
University Würzburg. 
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Figure 8 – Purification of IGHMBP2 protein with the help of Ni-NTA beads. (A) Schematic diagram of 
experimental design: the first step of recombinant GST-IGHMBP2-6xHis protein purification using Ni-NTA beads. 
Ni-NTA=nickel nitrilotriacetic acid; recomb.=recombinant. (B) Sample examination of the different experimental 
sections using SDS-PAGE and Coomassie blue staining. (C) Verification of the IGHMBP2 protein expression in 
all 10 eluted fractions using SDS-PAGE and Coomassie blue staining. 
First, the pGEX-6P-1-GST-IGHMBP2-6xHis plasmid was overexpressed in competent 
E. coli Rosetta cells. Significantly increased protein was observed after induction compared 
to before (Fig. 8B, before and after induction). The protein lysate was produced by 
centrifugation followed by lysis. After centrifugation, most of the proteins were detectable in 
the pellet and only a small amount remained in the supernatant (Fig. 8B, pellet and 
supernatant). 
In the first purification step, the protein lysate was eluted into 10 fractions using Ni-
NTA beads (Fig. 8A). The lysate was incubated with Ni-NTA beads so that the GST-
IGHMBP2-6xHis protein could be bound to the beads and removed from the supernatant of 
the lysate. The successful elution of the purified GST-IGHMBP2-6xHis protein was confirmed 
by a beads sample after the elution in which the IGHMBP2 protein was only weakly 
detectable compared to a beads sample before elution (Fig. 8B, supernatant after binding 
and beads before elution). The IGHMBP2 level of the 10 eluted fractions was also checked 
(Fig. 8C). The varied fractions contained a different amount of GST-IGHMBP2-6xHis protein. 
In the fractions 2 to 5 the largest amount of protein could be determined (Fig. 8C). Since 
each fraction contained protein, all fractions were pooled for the second purification step. 
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Figure 9 - Purification of IGHMBP2 protein with the help of GST beads followed by antibody purification. 
(A) Schematic diagram of experimental design: the second step of recombinant GST-IGHMBP2-6xHis IGHMBP2 
protein purification using GST beads. GST=glutathione sepharose transferase; recomb.=recombinant. (B) Sample 
examination of the different experimental sections using SDS-PAGE and Coomassie blue staining. (C) 
Verification of the Ighmbp2 antibody concentration in all 10 eluted fractions using SDS-PAGE and Coomassie 
blue staining. AB means antibody and DMP means Dimethyl-pimelimidate. 
In the second purification step, the pooled fractions were incubated with GST beads 
and the bound GST-IGHMBP2-6xHis proteins were covalently bound to the beads using 
Dimethyl-pimelimidate (DMP). This created a specific matrix to purify the antiserum into 10 
fractions by immunoaffinity chromatography (Fig. 9A). This second purification step was 
performed to increase the purity of recombinant IGHMBP2 protein to produce a specific 
antibody. 
The IGHMBP2 level of all pooled fractions was checked (Fig. 9B, pooled fractions), 
the lysate was incubated with GST beads for the GST-IGHMBP2-6xHis protein to bind 
(Fig. 9B, beads before crosslink). The bound proteins were covalently linked to the beads by 
DMP (Fig. 9B, beads after crosslink). After crosslinking, the active coupling groups of the 
crosslinker were saturated (Fig. 9B, beads after saturation). The specific matrix for 
immunoaffinity chromatography was prepared and used to purify the antiserum. 
These beads were finally incubated with the antiserum in order to purify the specific 
antibodies against IGHMBP2 using the produced matrix. The successful binding of the 
antibody to the matrix was demonstrated by a small detected amount of protein (Fig. 9B, 
beads after antiserum). The successful elution of the 10 fractions was confirmed by the 
detection of GST-IGHMBP2-6xHis protein of the beads (Fig. 9B, beads after AB Elu). The 
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Ighmbp2 antibody level of all eluted fractions was checked (Fig. 9C). The varied fractions 
contained a different amount of antibody. In fractions 6 to 10, both the heavy chain and the 
light chain of the eluted Ighmbp2 antibody could be detected (Fig. 9C), so that only these 
fractions were pooled and concentrated using Centricon. 
In order to test the specificity of this antibody, a number of different validation tests 
was carried out. As already described in (Grohmann et al., 2004), Ighmbp2 is predominantly 
localized in the cytoplasm. Therefore, cytoplasmic and nuclear fraction lysates of HEK293 
cells were prepared to confirm the localization of IGHMBP2. 
 
Figure 10 - Validation of Ighmbp2 Antibody. (A) Representative Western Blot for the cytoplasmic and nuclear 
fraction of lysate from HEK293 cells. IGHMBP2 protein is predominantly localized in the cytoplasmic fraction. α-
Tubulin and Histone H3 are used to check the purity of the two fractions as a marker for the cytosolic and nuclear 
fraction. (B) Representative Western Blot for immunoprecipitated IGHMBP2 protein. Successful pulldown (PD) of 
IGHMBP2 and the PD with rabbit IgG control antibody is free of the target protein. The flow-through of IGHMBP2 
PD shows decreased IGHMBP2 protein compared to the flow-through of rbIgG PD. (C) Intracellular distribution of 
Ighmbp2 protein in primary wildtype motoneurons. It is observed predominantly in the cytoplasm of the cell body 
and the axon, but only weakly expressed in the growth cone. (D) Representative Western Blot of Ighmbp2-
deficient (Ighmbp2-def.) and Ighmbp2+/+ motoneuron lysate (left panel). Quantification of the Ighmbp2 protein 
level in Ighmbp2-def. and Ighmbp2+/+ motoneurons (right panel). Ighmbp2-def. motoneurons show a significant 
Ighmbp2 protein reduction of 73%. In D, data are shown as mean±SD. N defines the number of embryos; n 
indicates the number of experiments. Each experiment was repeated at least 3 times, if not mentioned otherwise. 
Modified according to (Surrey and Jablonka, 2018) and (Surrey et al., 2018). 
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The detection of IGHMBP2 protein in the respective fractions clearly showed that 
IGHMBP2 is predominantly localized in the cytoplasm and only a small amount can be found 
in the nucleus (Fig. 10A). Immunoprecipitation of HEK293 lysates using the Ighmbp2 
antibody showed a successful pulldown of IGHMBP2 protein (Fig. 10B). Subsequently, the 
purified antibody was tested in an immunocytochemical staining. The intracellular distribution 
of Ighmbp2 protein in primary motoneurons also showed a predominant localization in the 
cytoplasm of cell bodies and axons, but it was only weakly represented in the growth cones 
(Fig. 10C). To perform further detailed morphological and functional analyses of Ighmbp2-
deficient (Ighmbp2-def.) motoneurons, the protein level of Ighmbp2 was quantified in primary 
motoneurons. Ighmbp2-deficient motoneurons showed a significant Ighmbp2 reduction of 
73% compared to Ighmbp2+/+ (Fig. 10D). Based on these results, the purified Ighmbp2 
antibody could be used in the following experiments. 
 
4.2 Morphological and Functional Analyses of isolated Motoneurons from the 
Neuromuscular Disorder Mice (Nmd2J) and wildtype Mice 
Most of the results from section 4.2 are published in (Surrey et al., 2018).  
To address the question whether the SMARD1 phenotype results from de-regulation of 
protein biosynthesis, we performed morphological and functional analyses of isolated 
Ighmbp2-defcient motoneurons from the neuromuscular disorder mouse (Nmd2J) (Surrey et 
al., 2018). 
4.2.1 Ighmbp2 deficiency causes reduced β-actin protein levels in growth cones of 
isolated motoneurons 
Since the number of generated motoneurons per Nmd2J embryo is limited and 
genotype-dependent, it was first tested whether a lentiviral knockdown (KD) of Ighmbp2 in 
primary embryonic motoneurons isolated from wildtype (CD1) mice could circumvent these 
barriers. 
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Lentiviral KD of Ighmbp2 gene (shIghmb2) in primary cultured wildtype (CD1) 
motoneurons showed a significant reduction of 72% Ighmbp2 mRNA (Fig. 11B) but no 
alteration at the protein level was observed after 7 days in vitro (DIV7) (Fig. 11A, left and 
right panel). In addition, we performed morphological analyses of the axonal outgrowth and 
the branching behavior of isolated motoneurons under Ighmbp2 KD at DIV7. In this case, no 
significant alteration of axonal elongation (Fig. 11C, left panel) or branching capacity 
(Fig. 11C, right panel) was observed between wildtype, lentiviral KD of Ighmbp2 gene 
(shIghmbp2) and lentiviral control KD of GFP gene (shGFP) in primary motoneurons 
(Fig. 11C). 
For these reasons, all following experiments were executed with Ighmbp2-defcient 
motoneurons of the Nmd2J mouse model cultured on either a Schwann cell-specific laminin 
isoform (laminin-111) or synapse-specific laminin isoform (laminin-211/221) for three (DIV3), 
five (DIV5) and/or seven (DIV7) days according to the scientific issue. 
Figure 11 - Protein and mRNA level in primary cultured wildtype (CD1) motoneurons under Ighmbp2 KD. 
(A) Representative Western Blot of wildtype, shIghmbp2 and shGFP motoneuron lysates (left panel). 
Quantification of the Ighmbp2 protein level in all motoneuron lysates (right panel). Motoneurons with lentiviral 
gene transfer for shIghmbp2 (shIghmbp2) exhibit no reduced amount of Ighmbp2 protein compared to both 
control conditions (wildtype and lentiviral gene transfer for control shGFP). (B) However, a significant reduction of 
72% Ighmbp2 mRNA is observed in motoneurons with lentiviral gene transfer of shIghmbp2 compared to the 
wildtype. (C) Neither the shIghmbp2, nor shGFP motoneurons show altered axonal outgrowth (in each case left 
panels) or affected axon branching behavior (in each case right panels) in comparison to the wildtype. In A (right 
panel), B and C (right panel), data are shown as mean±SD. In C (left panel), data are shown as mean±SEM. N 
defines number of embryos (A, B) or number of analyzed cells (C); n indicates the number of experiments. % 
means percentage. Modified according to (Surrey et al., 2018). 
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The functional study started with the analysis of spontaneous Calcium (Ca2+) 
transients at the distal axon. This is an important parameter for the correct cellular 
differentiation and function of primary motoneurons. 
 
 
Analysis of spontaneous Ca2+ transients at the distal axon showed no changes in the 
frequency of spontaneous spike-like Ca2+ transients in Ighmbp2-deficient motoneurons 
compared to Ighmbp2+/+ at DIV5 (Fig. 12). This observation corresponded to the axonal 
outgrowth of Ighmbp2-deficient motoneurons at DIV3, DIV5, and DIV7. 
Figure 12 - Spontaneous Ca2+
transients in Ighmbp2-def. 
motoneurons. Representative 
live-cell recordings of spontaneous 
spike-like Calcium (Ca2+) transients 
of Ighmbp2-def. and Ighmbp2+/+
motoneurons at DIV5 (left panel). 
Ighmbp2-def. motoneurons show 
no affected frequency of 
spontaneous Ca2+ spikes, 
indicated by red dots, in their 
corresponding growth cones (right 
panel). Data are shown as 
mean±SD. N defines number of 
analyzed cells; n indicates the 
number of experiments. Modified 
according to (Surrey et al., 2018). 
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Figure 13 - Analyses of axonal outgrowth and branching behavior at DIV3, DIV5, and DIV7. (A, B) Neither at 
DIV3 (A) nor at DIV5 (B), Ighmbp2-def. motoneurons show altered axonal outgrowth (in each case left panels) or 
affected axon branching behavior (in each case right panels). In (C) representative images of Ighmbp2+/+ and 
Ighmbp2-def. motoneurons at DIV7 are depicted. (D) Ighmbp2-def. motoneurons display no altered axonal 
elongation (left panel), however an increased branching capacity of Ighmbp2-def. motoneurons can be observed 
at DIV7. In A, B, and D, axon elongation data are shown as mean±SEM and axon branching data are shown as 
mean±SD. N defines the number of analyzed cells; n indicates the number of experiments. % means percentage. 
Modified according to (Surrey et al., 2018). 
No alteration in axonal elongation was observed at all three differentiation stages 
(Fig. 13A-D). Indeed, Ighmbp2-deficient motoneurons exhibited slight but significantly 
enhanced formation of axon collaterals only observed at DIV7 (Fig. 13C-D), stated by axons 
with more than three axonal collateral branches and a decreased number of axons without 
collateral primary branches (Fig. 13C, white arrows and D). At DIV3 and DIV5, no difference 
of branching behavior was determined (Fig. 13A-B). 
As a next step, we focused on the growth cone compartment of Ighmbp2-deficient 
motoneurons. At DIV5, growth cones of Ighmbp2+/+ and Ighmbp2-deficient motoneurons 
were quantified in size and signal intensity of β-actin protein cultured on laminin-111 
(Fig. 14A-C). 
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Growth cone size of Ighmbp2-deficient motoneurons showed no alteration 
(Fig. 14A, B), but the signal intensity exhibited a significant reduction of β-actin protein 
(Fig. 14A, C) compared to the Ighmbp2+/+. Nonetheless, the total β-actin protein amount in 
whole cell lysates of Ighmbp2-deficient motoneurons was not changed in comparison to the 
Ighmbp2+/+ (Fig. 14D). 
Furthermore, growth cones of Ighmbp2+/+ and Ighmbp2-deficient motoneurons were 
quantified in size and signal intensity of α-actin protein at DIV5 (Fig. 15A-C). 
Figure 14 – Growth cones of Ighmbp2-def. motoneurons display reduced β-actin protein intensity cultured 
on laminin-111 at DIV5. (A) Representative images of β-actin protein in Ighmbp2-def. and Ighmbp2+/+ growth 
cones at DIV5. Quantification of (B) growth cone size and (C) β-actin signal intensity. Ighmbp2-def. motoneurons 
show no alteration in growth cone size but display a significant reduced β-actin protein signal intensity compared 
to Ighmbp2+/+. (D) Representative Western Blot of β-actin protein in Ighmbp2-def. and Ighmbp2+/+ motoneuron 
lysates (left panel). Quantification of β-actin protein level (right panel). The total amount of β-actin protein of 
Ighmbp2-def. motoneurons is not affected compared to Ighmbp2+/+. In B and C, data are shown as mean±SEM. In 
D, data are shown as mean±SD. N defines number of analyzed cells (B and C) or number of embryos (D); n 
indicates the number of experiments. Modified according to (Surrey et al., 2018). 
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Figure 15 - Growth cones of Ighmbp2-def. motoneurons display reduced α-actin protein intensity cultured 
on laminin-111 at DIV5. (A) Representative images of α-actin protein in Ighmbp2-def. and Ighmbp2+/+ growth 
cones at DIV5. Quantification of (B) growth cone size and (C) α-actin signal intensity. Ighmbp2-def. motoneurons 
show no alteration in growth cone size but display a significant reduced α-actin protein signal intensity compared 
to Ighmbp2+/+. (D) Representative Western Blot of α-actin protein in Ighmbp2-def. and Ighmbp2+/+ motoneuron 
lysates (left panel). Quantification of α-actin protein level (right panel). The total amount of α-actin protein of 
Ighmbp2-def. motoneurons is not affected compared to Ighmbp2+/+. In B and C, data are shown as mean±SEM. In 
D, data are shown as mean±SD. N defines the number of analyzed cells (B and C) or the number of embryos (D); 
n indicated the number of experiments. 
In accordance with β-actin protein quantifications, growth cone size of Ighmbp2-
deficient motoneurons showed no alteration (Fig. 15A-B), but the signal intensity exhibited a 
significant reduction of α-actin protein (Fig. 15A, C) compared to the Ighmbp2+/+. Likewise, 
the total α-actin protein amount in whole cell lysates of Ighmbp2-deficient motoneurons was 
not changed in comparison to the Ighmbp2+/+ (Fig. 15D). 
Finally, we performed morphological analyses of the cell body compartment of 
isolated motoneurons at DIV7 regarding the cell body size, the number of dendrites per cell 
body, mean dendrite length and total dendrite length (Fig. 16A-E). 
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In this case, no significant alteration was observed between Ighmbp2-deficient and 
Ighmbp2+/+ cell bodies (Fig. 16A-E). 
4.2.2 α-/β-actin and Ighmbp2 protein in wildtype (CD1) motoneurons 
Studies have already shown that the growth cones in Ighmbp2-deficient motoneurons 
are smaller and the β-actin protein is underrepresented in this cell compartment (Krieger et 
al., 2014b). This might have an effect on the biosynthesis of cytoskeletal proteins, such as α- 
and β-actin, influencing neurite growth and maturation. Therefore, the distribution pattern of 
α- and β-actin proteins compared to Ighmbp2 protein localization was investigated using 
immunocytochemical staining. The Co-staining of Ighmbp2 proteins and one of both actin 
isoforms may give possible hints for physical interaction (Fig. 17). 
Figure 16 – Morphological analyses of the cell body compartment cultured on laminin-111 at DIV7.
(A) Representative images of Ighmbp2-def. and Ighmbp2+/+ cell bodies. (B) Cell body size of Ighmbp2-def. and 
Ighmbp2+/+ motoneurons displays no alteration at DIV7. (C) Neither the dendrite number nor (D) the mean 
dendrite length nor (E) the total dendritic length shows significant differences in Ighmbp2-def. motoneurons 
compared to Ighmbp2+/+. In B-E, data are shown as mean±SEM. N defines number of analyzed cells; n indicates
the number of experiments. Modified according to (Surrey et al., 2018). 
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Figure 17 - Localization of α-/β-actin and Ighmbp2 in wildtype motoneurons. Representative images of (A) 
α-actin and (B) β-actin distribution pattern compared to Ighmbp2 protein localization. (A) α-Actin is evenly 
distributed, whereas (B) β-actin is predominantly localized in protrusions. Images are made by my former M.Sc. 
student Caren Zöller. Each experiment was repeated at least 3 times, if not mentioned otherwise. 
α-Actin protein was more evenly distributed throughout the cytoplasm of the cell body 
and localized in the neurites, alongside the axon and axonal branches of motoneurons, but it 
was higher concentrated in the axon and branch points than in the cell body and growth 
cones (Fig. 17A). β-Actin protein was predominantly expressed in the protrusions, including 
the growth cones and axonal branches. It was highly concentrated in the dendritic 
protrusions. A faint expression of β-actin was found alongside the neurites and in the soma 
of motoneurons (Fig. 17B). As previously described, Ighmbp2 was predominantly localized in 
the cytoplasm and in the axons of motoneurons, whereas its expression in the growth cone 
66 
 
was omitted (Fig. 17A). α-Actin and Ighmbp2 proteins were very similar distributed and 
suggest a co-localization, especially in the distal axon and axonal branches (Fig. 17A). 
4.2.3 β-actin mRNA level and distribution are not modified in soma and growth cones 
of Ighmbp2-deficient motoneurons 
Because of reduced α- and β-actin protein levels in Ighmbp2-deficient growth cones, 
we wanted to figure out how Ighmbp2 deficiency impacts the RNA level. For this purpose, we 
first performed RNA-Sequencing (RNA-Seq) analysis of Ighmbp2-deficient and Ighmbp2+/+ 
motoneurons at DIV7 (Fig. 18A). 
 
Figure 18 – Ighmbp2-def. motoneurons show significant upregulation of Fgfr1 but wildtype amount and 
distribution of α- and β-actin mRNA. (A) Transcriptome-wide detection of differentially expressed transcripts in 
Ighmbp2-def. compared to Ighmbp2+/+ motoneurons using RNA-Sequencing. The volcano plot displays the 
significance of change [-log10(pvalue)] vs. the magnitude of change [log2(fold_change)] for each. For better 
illustration, data points of transcripts with log2(fold_change)<-5 or >5 (all of which were not significantly altered) 
were left out. FPKM values for (B) Ighmbp2, (C) Fgfr1, (D) α- and (E) β-actin mRNA in the Ighmbp2-def. and 
Ighmbp2+/+ datasets. (B) Ighmbp2-def. motoneurons show significant reduction of 41% of Ighmbp2 mRNA, 
whereas the Fgfr1 mRNA is significantly upregulated by 106%. Neither (D) α-, nor (D) β-actin display an altered 
mRNA level in Ighmbp2-def. motoneurons compared to Ighmbp2+/+ using RNA-Sequencing. RNA-Seq transcript 
levels are measured as FPKM values (fragments per kilobase transcript per million mapped reads) which are 
calculated for each given gene by normalizing the number of gene-specific reads to the length of the gene and to 
the total number of reads mapped. (F) Representative images of α- and β-actin mRNA in Ighmbp2-def. and 
Ighmbp2+/+ cell bodies cultured on laminin-111 at DIV7 using FISH. Neither (G) α-, nor (H) β-actin show an altered 
mRNA level in Ighmbp2-def. motoneurons compared to Ighmbp2+/+ using qRT-PCR. In B, C, D, E, G and H, data 
are shown as mean±SD. N defines the number of embryos; n indicates the number of experiments. Each 
experiment was repeated at least 3 times, if not mentioned otherwise. Modified according to (Surrey et al., 2018). 
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No transcripts with a q-value<0.05, but only 123 transcripts with p-value<0,05 were 
found (Fig. 18A, dark spots). RNA-Seq dataset displayed a significant reduction of 41% 
Ighmbp2 mRNA, whereas Fgfr1 transcripts showed significant upregulation of 106% 
(Fig. 18C). In addition, α1- and β-actin transcripts exhibited no alteration in Ighmbp2-deficient 
motoneurons compared to Ighmbp2+/+ (Fig. 18D-E). 
FISH also confirmed that α- and β-actin mRNA in Ighmbp2-deficient motoneurons 
demonstrated no alterations in distribution pattern or amount (Fig. 18F). On top of that, α- 
and β-actin mRNA showed no changes in Ighmbp2-deficient motoneurons compared to the 
Ighmbp2+/+ using qRT PCR quantifications (Fig. 18G, H). 
 
Figure 19 - Ighmbp2-def. motoneurons show wildtype distribution and signal intensity of β-actin mRNA. 
(A) Representative images of β-actin mRNA in Ighmbp2-def. and Ighmbp2+/+ growth cones cultured on laminin-
111 at DIV5 using FISH. (B) Quantification of β-actin mRNA signal intensity in growth cones cultured on laminin-
111. Ighmbp2-def. motoneurons show no alteration in β-actin mRNA signal intensity compared to Ighmbp2+/+. (C) 
Representative images of β-actin mRNA in Ighmbp2-def. and Ighmbp2+/+ growth cones cultured on laminin-
211/221 at DIV5 using FISH. (D) Quantification of β-actin mRNA signal intensity in growth cones cultured on 
laminin-211/221. Ighmbp2-def. motoneurons display no changed β-actin mRNA signal intensity compared to 
Ighmbp2+/+. In B and D, data are shown as mean±SEM. N defines the number of analyzed cells; n indicates the 
number of experiments. Modified according to (Surrey et al., 2018). 
In addition, we analyzed the signal intensity of β-actin mRNA in growth cones of 
Ighmbp2-deficient motoneurons cultured on laminin-111 and laminin-211/221 using 
fluorescence in situ hybridization (FISH) at DIV5. Neither on laminin-111 (Fig. 19A-B) nor on 
laminin-211/221 (Fig. 19C-D), Ighmbp2-deficient motoneurons exhibited differences in  
β-actin mRNA level compared to Ighmbp2+/+ (Fig. 19B, D). Thus, no strong global effect at 
mRNA level in Ighmbp2-deficient motoneurons was detectable. 
4.2.4 Local translation of eGFPmyr-β-actin 3’UTR reporter is delayed in Ighmbp2-
deficient motoneurons 
Despite β-actin mRNA not being affected, we wanted to figure out whether the local 
translation of β-actin is changed upon Ighmbp2 deficiency. For this purpose, we performed 
Fluorescence Recovery after Photobleaching (FRAP) experiments to analyze the local 
translation of β-actin in growth cones (Fig. 20A-D) and cell bodies (Fig. 21A-B) of Ighmbp2-
deficient and Ighmbp2+/+ motoneurons at DIV5. 
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Figure 20 - Delayed synthesis of β-actin reporter in the growth cones of Ighmbp2-def. motoneurons 
cultured on laminin-111, but no effect in synthesis cultured on laminin-211/221. (A) Scheme of eGFPmyr-β-
actin 3’UTR. (B) Representative time-lapse images from fluorescence recovery after photobleaching (FRAP) in 
growth cones of eGFPmyr-β-actin 3’UTR-expressing Ighmbp2+/+ and Ighmbp2-def. motoneurons at DIV5. eGFPmyr 
was bleached and fluorescence recovery was recorded in a specific region of interest (indicated with white circles) 
within the growth cones. (C) Quantification of FRAP shows a significant reduction in growth cones cultured on 
laminin-111 (n=6 Ighmbp2+/+ and n=7 Ighmbp2-def. motoneurons) but shows no effect in the translation of 
eGFPmyr-β-actin 3’UTR reporter of Ighmbp2-def. motoneurons cultured on laminin-211/221 (n=4 Ighmbp2+/+ and 
n=3 Ighmbp2-def. motoneurons). (B-C) In control experiments, translation of eGFPmyr-β-actin 3’UTR reporter is 
inhibited using anisomycin indicating that the recovery is due to the de novo synthesized proteins. In B and C, 
data are shown as mean±SEM. % means percentage. Modified according to (Surrey et al., 2018). 
After 5 days in vitro, eGFPmyr lentiviral reporter construct (Fig. 20A) transfected 
Ighmbp2-deficient and Ighmbp2+/+ motoneurons were bleached and increasing eGFPmyr 
fluorescence recovery was monitored in growth cones for 1h after photobleaching (Fig. 20B). 
69 
 
Quantifications of FRAP analyses in defined regions of interest (ROI; indicated with white 
circles) exhibited a significant reduction in fluorescence recovery in growth cones 
(Fig. 20B, C) of Ighmbp2-deficient motoneurons compared to the Ighmbp2+/+ cultured on 
laminin-111, whereas the translation of eGFPmyr- β-actin 3’UTR reporter in Ighmbp2-deficient 
motoneurons cultured on laminin-211/221 was not affected (Fig. 20D). Essentially, it was 
observed that the local translation in the growth cones cultured on Laminin-211/221 was 
reduced compared to Laminin-111 (Fig. 20C-D). As a control experiment, eGFPmyr lentiviral 
reporter construct (Fig. 20A) transfected motoneurons were pre-treated with the translation 
blocker anisomycin which induced blocked recovery of eGFPmyr- β-actin 3’UTR reporter and 
proved increasing fluorescence recovery is due to the synthesis of newly synthesized protein 
and not caused by its diffusion (Fig. 20B-C). 
Figure 21 - Delayed synthesis of β-actin reporter in the cell body of Ighmbp2-def. motoneurons cultured 
on laminin-111. (A) Representative time-lapse images from fluorescence recovery after photobleaching (FRAP) 
in cell body of eGFPmyr-β-actin 3’UTR-expressing Ighmbp2+/+ and Ighmbp2-def. motoneurons at DIV5. eGFPmyr 
was bleached and fluorescence recovery was recorded in a specific region of interest (indicated with white circles) 
within the cell bodies. (C) Quantification of FRAP shows significant reduction of the translated eGFPmyr-β-
actin 3’UTR reporter in cell body cultured on laminin-111 (n=4 Ighmbp2+/+ and n=7 Ighmbp2-def. motoneurons). In 
control experiments, translation of eGFPmyr-β-actin 3’UTR reporter is inhibited using anisomycin indicating that the 
recovery is due to the de novo synthesized proteins. In B, data are shown as mean±SEM. % means percentage. 
Modified according to (Surrey et al., 2018). 
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In addition, Ighmbp2-deficient and Ighmbp2+/+ cell bodies were bleached and 
increasing eGFPmyr fluorescence recovery was monitored for 1h after photobleaching 
(Fig. 21A). Likewise, quantifications of FRAP analyses in defined regions of interest (ROI; 
indicated by white circles) showed a significant reduction in fluorescence recovery in cell 
bodies of Ighmbp2-deficient motoneurons compared to the Ighmbp2+/+ cultured on laminin-
111 (Fig. 21B). 
4.2.5 Minor quantitative differences of de novo synthesized proteins in Ighmbp2-
deficient motoneurons 
Time-lapse imaging study via fluorescence recovery after photobleaching (FRAP) 
visualized a local translation delay of an eGFPmyr- β-actin 3’UTR mRNA in growth cones and 
cell bodies from Ighmbp2-deficient motoneurons cultured on laminin-111. This observation 
raised the question whether Ighmbp2 deficiency leads to a general alteration of de novo 
synthesized proteins. To investigate newly synthesized proteins, we established a pSILAC 
protocol in Ighmbp2-deficient motoneurons compared to Ighmbp2+/+. Since the generated 
amount of motoneurons per embryo is deeply limited and the mortality rate is significantly 
increased during cultivation, the pSILAC analysis was performed at DIV3. Incorporated 
heavy and medium-heavy amino acids in de novo translated proteins of Ighmbp2-deficient 
and Ighmbp2+/+ motoneurons were analyzed by mass spectrometry of resulting mass 
differences.  
71 
 
 
Figure 22 – Minor quantitative differences of de novo synthesized proteins in Ighmbp2-def. motoneurons 
using pSILAC. (A) Quantification of de novo translated proteins of Ighmbp2-def. motoneurons compared to 
Ighmbp2+/+. Ighmbp2 deficiency causes only few up- or down-regulated proteins in comparison with Ighmbp2+/+ at 
DIV3 (highlighted in red and blue). (B) Representative Western Blot of Top1 and Sars2 in Ighmbp2-def. and 
Ighmbp2+/+ motoneuron lysates (left panel). Quantifications of Top1 (middle panel) and Sars2 (right panel) protein 
level. The total amount of both proteins in Ighmbp2-def. motoneurons is not altered compared to Ighmbp2+/+. (C) 
List of up- or down-regulated labeled pSILAC proteins in Ighmbp2-def. motoneurons compared to Ighmbp2+/+ (in 
A, highlighted in red). De novo synthesized proteins display no significant up- or down-regulation (p>0.05) in two 
out of three independent experiments (2/-2). In A, data are shown as median±horizontal error bars. In B, data are 
shown as mean±SD. N defines the number of embryos; n indicates the number of experiments. Each experiment 
was repeated at least 3 times, if not mentioned otherwise. MN means motoneurons and FC means fold change. 
Modified according to (Surrey et al., 2018). 
Quantification of pSILAC approach displayed only slight alteration by up- and down-
regulation of newly synthesized proteins in Ighmbp2-deficient motoneurons (MN) (Fig. 22A, 
highlighted in blue and red dots). Verification of two down-regulated proteins was performed 
using Western blot analysis at DIV7. No alterations of DNA topoisomerase 1 (Top1) and 
mitochondrial Serine-tRNA ligase (Sars2) in Ighmbp2-deficient motoneurons were detectable 
(Fig. 22B). Up- and down-regulated proteins in two out of three independent experiments 
were listed in Fig. 22C and highlighted in Fig. 22A in red. 
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For further investigation regarding protein synthesis, we performed two translation 
technologies, AHA-Labeling (Fig. 23A-C) and SUnSET (Fig. 23D). 
 
Figure 23 – No alteration of newly translated protein in Ighmbp2-def. motoneurons using AHA labeling 
and SUnSET analysis. (A) Representative images of de novo synthesized proteins 20h labeled with L-
azidohomoalanine (AHA) in Ighmbp2-def. and Ighmbp2+/+ cell bodies and distal axons. Quantifications of AHA 
signal intensity in (B) cell bodies and (C) distal axons of Ighmbp2-def. and Ighmbp2+/+ motoneurons. (B) Neither 
the cell body nor (C) the distal axon shows significant differences in de novo synthesized AHA-labelled proteins of 
Ighmbp2-def. motoneurons compared to Ighmbp2+/+. (D) Representative Western Blot of surface sensing of 
translation technology (SUnSET) in Ighmbp2-def. and Ighmbp2+/+ motoneurons at DIV7. Puromycin incorporation 
during 1h of incubation shows no alteration in both conditions. In B-C, data are shown as mean±SEM. In D, data 
are shown as mean±SD. N defines the number of analyzed cells (B-C) or the number of embryos (D); n indicates 
the number of experiments. Ctrl means control. Modified according to (Surrey et al., 2018). 
After 20h of AHA-labeling, the distribution and amount of newly synthesized proteins 
in the cell bodies and distal axons were quantified in Ighmbp2-deficient and Ighmbp2+/+. In 
both cell compartments, no alterations in protein synthesis and distribution pattern were 
detectable (Fig. 23A-C). SUnSET analysis was performed to measure the efficiency of 
protein synthesis in whole cell lysates. Neither Ighmbp2-deficient nor Ighmbp2+/+ 
motoneurons showed reduced puromycin incorporation during 1h incubation (Fig. 23D). 
Ighmbp2 deficiency showed no global changes in protein synthesis using both approaches 
(Fig. 23A-D) and caused only marginal impairment of de novo synthesis in primary cultured 
motoneurons. 
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4.3 RNA binding Capacity of Ighmbp2 Protein 
Most of the results from section 4.3 are published in (Surrey et al., 2018).  
As previously described, Ighmbp2 is an RNA/DNA helicase which can unwind RNA duplices 
(Guenther et al., 2009a). Based on sequence homology, IGHMBP2 has been classified as a 
member of the UPF1-like group within the helicase superfamily 1. Ighmbp2 seems to be 
functionally linked to pre-mRNA splicing/translation, DNA replication and tRNA processing 
(Jankowsky, 2011). 
4.3.1 Ighmbp2 binds only few RNAs 
To test whether Ighmbp2 influences translation caused by RNA binding, we 
performed a radioactive labeling of cross-linked protein-RNA complexes in HEK293 cells. 
With the help of this approach, we were able to visualize the general binding of Ighmbp2 to 
RNAs. 
 
Figure 24 – IGHMBP2 binds only few RNAs. (A) Representative Western Blot of IGHMBP2 immunoprecipitation 
(IP) to verify the successful pulldown (PD) of IGHMBP2. Rabbit IgG antibody IP is free of target protein, only the 
heavy chain of rabbit IgG antibodies are detectable. Pulldown efficiency is almost 100%, flow-through (FT) shows 
no IGHMBP2 protein (fourth panel/FT IGHMBP2). (B) Radioactive labeling of cross-linked IGHMBP2- and 
hnRNPR-RNA complexes. As a positive control, hnRNPR was used. hnRNPR complex is detectable at 65 and 
80kDa (first panel) and RNA binding is observed above (second panel). Ighmbp2 complex is weakly expressed at 
110kDa (third panel) followed by a faint RNA binding capacity (fourth panel). Each experiment was repeated at 
least 3 times, if not mentioned otherwise. FT means flow-through. 
IGHMBP2 pulldown (PD) validation was done by Western blot analysis (Fig. 24A). 
The positive control hnRNPR was used to confirm the radioactive labeling. With a high 
concentration of RNase enzyme, the hnRNPR complex was visible at 80 and 65kDa 
(Fig. 24B, first panel). Above these bands and at low RNase concentration, the smear 
confirmed RNA binding to the hnRNPR protein (Fig. 24B, second panel). In contrast to the 
positive control, IGHMBP2 complex with high RNase concentration was only weakly visible 
at 110kDa (Fig. 24B, third panel). RNA binding to IGHMBP2 was found very faintly because 
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the smear was only poorly detectable (Fig. 24B, fourth panel). These data suggested that 
IGHMBP2 binds only few RNAs. 
4.3.2 Ighmbp2 does not directly bind to β-actin mRNA 
To verify whether the delay of local translation of β-actin protein in Ighmbp2-deficient 
cell bodies and growth cones is caused by a direct interaction of β-actin mRNA to Ighmbp2 
protein, we performed immunoprecipitation (IP) of mRNA-protein complexes (RIP) analyses. 
It is already known that Insulin-like growth factor-2 mRNA- binding protein 1 (IMP1) is directly 
associated with β-actin mRNA (Farina et al., 2003; Huttelmaier et al., 2005). On this account, 
RIP analysis was performed with IMP1 as a positive pulldown (PD) control in comparison to 
IgG as a negative PD control in HEK293 cells. 
 
Figure 25 – IGHMBP2 does not directly bind to β-actin mRNA but IMP1 interacts with its own mRNA.  
(A) Representative Western Blot of IMP1- and IGHMBP2-immunoprecipitation (IP) of RIP to verify the successful 
pulldown (PD) of IMP1 and IGHMBP2. Rabbit IgG antibody IP is free of both target proteins, only the heavy chain 
of rabbit IgG antibodies is detectable. No protein is visible when antibodies are omitted (w/o AB). Co-IP of 
IGHMBP2 and IMP1 (lower panel) shows no direct protein-protein interaction of both proteins. qRT-PCR for (B) β-
actin, and (C) IMP1 mRNA of immunoprecipitated IMP1 and IGHMBP2 were performed. (B) Relative β-actin 
mRNA expression of IGHMBP2 in comparison to IMP1 shows that IGHMBP2 does not directly bind to β-actin 
mRNA. (C) Relative IMP1 mRNA expression of IGHMBP2 in comparison to IMP1 shows that IGHMBP2 does not 
directly bind to IMP1 mRNA, whereas IMP1 protein binds its own mRNA. Absolute copy numbers of target mRNA 
of IMP1 and β-actin are normalized to absolute copy numbers of target mRNA of input and IgG control condition. 
In B and C, IMP1 as positive control is normalized to 1. In B-C, data are shown as mean±SD. n indicates the 
number of experiments. w/o AB means without antibody. Modified according to (Surrey et al., 2018). 
IGHMBP2 and IMP1 PD validation of RIP was done by Western blot analyses 
(Fig. 25A, upper and middle panel). In addition, a Co-IP of IGHMBP2 and IMP1 showed that 
both proteins did not directly interact with each other (Fig. 25A, lower panel). Possible β-actin 
mRNA interaction with immunoprecipitated IMP1 and IGHMBP2 was quantified by 
quantitative Realtime-PCR (qRT-PCR) (Fig. 25B). These data showed no direct binding of β-
actin mRNA to IGHMBP2 protein, whereas IMP1 protein has bound to β-actin mRNA 
(Fig. 25B). 
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Furthermore, a possible interaction of IMP1 mRNA with the immunoprecipitated IMP1 
and IGHMBP2 was conducted by qRT-PCR (Fig. 25C). A direct interaction between IMP1 
mRNA and its protein was observed whereas Ighmbp2 protein showed no direct binding to 
IMP1 mRNA (Fig. 25C).  
 
4.4 Imp1 and Fgfr1 as affected Target Proteins in Ighmbp2-deficient Motoneurons 
Some of the results from section 4.4 are published in (Surrey et al., 2018).  
Based on previously described results, two affected target proteins, Insulin-like growth factor-
2 mRNA- binding protein 1 (Imp1) and fibroblast growth factor receptor 1 (Fgfr1) could be 
discovered in Ighmbp2-deficient motoneurons and are investigated below. 
4.4.1 Ighmbp2 deficiency causes reduced Insulin-like growth factor-2 mRNA- binding 
protein 1 (Imp1) level in isolated motoneurons 
To determine whether β-actin mRNA transport is disturbed by its primary RNA-
binding partner Imp1, we quantified Imp1 mRNA and protein level in Ighmp2-deficient 
motoneurons (Fig. 26). 
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Figure 26 - Amount and distribution of Imp1 mRNA and protein in Ighmbp2-def. motoneurons cultured on 
laminin-111. (A) Representative images of Imp1 protein distribution in Ighmbp2-def. and Ighmbp2+/+ cell bodies 
and distal axons. Quantification of the (B) cell body and the (C) distal axon in Ighmbp2-def. motoneurons 
compared to Ighmbp2+/+. In both cell compartments, Imp1 signal intensity is significantly reduced in Ighmbp2-def. 
motoneurons in comparison to Ighmbp2+/+. (D) Imp1 mRNA is not altered in Ighmbp2-def. motoneurons compared 
to Ighmbp2+/+ using qRT-PCR. (E) Representative Western Blot of Imp1 protein in Ighmbp2-def. and Ighmbp2+/+ 
motoneuron lysates (left panel). Quantification of Imp1 protein level (right panel). The total amount of Imp1 protein 
of Ighmbp2-def. motoneurons is significantly reduced compared to Ighmbp2+/+. In B-C, data are shown as 
mean±SEM. In D-E, data are shown as mean±SD. N defines the number of analyzed cells (B-C) or the number of 
embryos (D-E); n indicates the number of experiments. Modified according to (Surrey et al., 2018). 
First, the distribution and signal intensity of IMP1 protein in Ighmbp2-deficient and 
Ighmbp2+/+ cell bodies and distal axons were investigated. In both cell compartments, a 
significant reduced Imp1 signal intensity was observed in Ighmbp2-deficient motoneurons in 
comparison to the Ighmbp2+/+ (Fig. 26A-C). Imp1 mRNA showed no changes using qRT-PCR 
quantification (Fig. 26C). However, the protein level of Imp1 was significantly reduced in 
whole cell lysates of Ighmbp2-deficient motoneurons compared to the Ighmbp2+/+ (Fig. 26D). 
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Thus, we detected reduced β-actin protein level at the growth cone of Ighmbp2-deficient 
motoneurons which was accompanied by reduced levels of Imp1, an interactor of β-actin 
mRNA. 
To verify whether Imp1 protein (Fig. 26E) influences Fgfr1 transcript level (Fig. 18C) 
caused by Ighmbp2 deficiency, we performed RIP analyses regarding FGFR1 mRNA and 
IMP1/IGHMBP2 protein. 
Figure 27 – IMP1 protein binds to FGFR1 
mRNA. (A) Representative Western Blot of 
IMP1- and IGHMBP2-immunoprecipitation (IP) 
of RIP for validation of the pulldown (PD). (B) 
qRT-PCR for FGFR1 mRNA of 
immunoprecipitated IMP1 and IGHMBP2 were 
quantified. Relative FGR1 mRNA expression of 
IGHMBP2 in comparison to IMP1 shows that 
IGHMBP2 does not directly bind to FGFR1 
mRNA, whereas IMP1 shows a direct 
interaction with FGFR1 mRNA. In B, data are 
shown as mean±SD. n indicated the number of 
experiments. w/o AB means without antibody. 
 
 
 
Possible FGFR1 mRNA interaction with immunoprecipitated IMP1 and IGHMBP2 
protein was quantified by qRT-PCR (Fig. 27B). These data showed no direct binding of 
FGFR1 mRNA to IGHMBP2 protein, whereas IMP1 protein bound to FGFR1 mRNA 
(Fig. 27B). IGHMBP2 and IMP1 PD validation of RIP was done by Western blot analyses 
(Fig. 27A). 
4.4.2 Ighmbp2 deficiency causes reduced fibroblast growth factor receptor 1 (Fgfr1) 
level in isolated motoneurons 
RNA-Sequencing data have shown that Fgfr1 is significantly upregulated in Ighmbp2-
deficient motoneurons compared to Ighmbp2+/+ (Fig. 18A, C). This observation was also 
confirmed by an increased expression in Fgfr1 mRNA using qRT-PCR (Fig. 28A). In order to 
analyze whether the changed mRNA level of Fgfr1 in Ighmbp2-deficient motoneurons is also 
detectable on the protein level, quantification of Fgfr1 protein amount was performed using 
Western blot analysis. 
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Figure 28 – Ighmbp2-def. 
motoneurons show an increased 
expression of Fgfr1 mRNA, 
whereas Fgfr1 protein level is 
reduced. (A) Quantification of Fgfr1 
mRNA using qRT-PCR of Ighmbp2-
def. and Ighmbp2+/+ motoneurons 
cultured on laminin-111 at DIV7. 
Ighmbp2-def. motoneurons display a 
significantly increased expression of 
Fgfr1 mRNA compared to 
Ighmbp2+/+. (B) Western Blot 
analysis of Fgfr1 in untreated and 
bFGF long-term treated Ighmbp2-
def. and Ighmbp2+/+ motoneurons 
cultured on laminin-111 at DIV7. 
Untreated Ighmbp2-def. 
motoneurons show reduced Fgfr1 
protein amount about -31% in 
comparison to untreated Ighmbp2+/+ 
which significantly increases after 
bFGF long-term treatment in both 
conditions. Fgfr1 protein amount 
after bFGF treatment in Ighmbp2-
def. motoneurons is 27% lower 
compared to long-term treated 
Ighmbp2+/+. Data are shown as mean±SD. N defines the number of embryos; n indicates the number of 
experiments. 
In contrast to the increased Fgfr1 mRNA level, Fgfr1 protein in untreated Ighmbp2-
deficient motoneurons displayed a tendential protein reduction of 31% compared to 
untreated Ighmbp2+/+ (Fig. 28B). A long-term treatment of basic fibroblast growth factor 
(bFGF) increased the protein amount of Fgfr1 in both conditions, Ighmbp2-deficient and 
Ighmbp2+/+, whereas Fgfr1 protein level is 27% lower after bFGF treatment compared to the 
long-term treated Ighmbp2+/+. Treatment of bFGF rescued the protein amount in Ighmbp2-
deficient motoneurons more than to an untreated Ighmbp2+/+ level (Fig. 28B). 
 As Fgfr1 mRNA in Ighmbp2-deficient motoneurons is significantly upregulated 
whereas the protein amount is reduced but can be rescued by long-term bFGF treatment 
(Fig. 28A-B), the question arises whether bFGF treatment can also rescue the branching 
behavior of Ighmbp2-deficient motoneurons. To investigate the potential role of bFGF 
treatment in Ighmbp2 deficiency, we performed morphological analysis regarding axon 
branching capacity, growth cone size and signal intensity of β-actin protein. For this purpose, 
axonal branching capacity was quantified in Ighmbp2-deficient motoneurons and Ighmbp2+/+ 
with long-term bFGF treatment to analyze the effect of this growth factor on motoneuron 
differentiation behavior. 
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Figure 29 - bFGF treatment does not influence branching behavior of Ighmbp2-def. motoneurons.  
(A) Representative images of untreated or long-term treated Ighmbp2-def. and Ighmbp2+/+ motoneurons cultured 
on laminin-111 at DIV7. (B) bFGF treatment does not affect axon branching behavior of long-term treated 
Ighmbp2-def. motoneurons in comparison to untreated Ighmbp2+/+ motoneurons. In general, untreated and long-
term treated motoneurons of both conditions show no alteration of branching capacity related to the bFGF 
treatment. In B, data are shown as mean±SD. N defines the number of analyzed cells (C); n indicates the number 
of experiments. % means percentage. 
 Affected branching behavior of untreated Ighmbp2-deficient motoneurons compared 
to untreated Ighmbp2+/+ described above in Fig. 13C-D has been confirmed. The long-term 
treatment with bFGF displayed no significant effect on axonal outgrowth in both conditions. 
Neither long-term treated Ighmbp2-deficient nor long-term treated Ighmbp2+/+ motoneurons 
showed an altered branching behavior (Fig. 29A-B). 
Previous studies have shown that Ighmbp2-deficient motoneurons display reduced 
growth cone size and a decreased amount of β-actin protein cultured on laminin-211/221 
(Krieger et al., 2014b), whereas Ighmbp2-deficient motoneurons show exclusively reduced β-
actin protein level in the growth cones without reduced size when cultured on laminin-111 
(Surrey et al., 2018). This raises the question whether bFGF treatment influences the growth 
cone phenotype regarding β-actin protein. Therefore, Ighmbp2-deficient and Ighmbp2+/+ 
motoneurons were cultured with bFGF for 5 days on either laminin-111 or laminin-211/221 
and were immuno-stained against β-actin. Then, the effect of long-term bFGF treatment was 
analyzed by quantifications of the growth cone size and the signal intensity of β-actin 
(Fig. 30A-C and Fig. 31A-C). 
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Figure 30 - bFGF long-term treatment increases β-actin protein amount in Ighmbp2-def. growth cones 
cultured on laminin-111 at DIV5 but has no influence on the size. (A) Representative images of bFGF 
untreated and long-term treated Ighmbp2-def. and Ighmbp2+/+ growth cones cultured on laminin-111 at DIV5. 
Quantifications of the (B) growth cone size and (C) β-actin signal intensity of bFGF untreated and long-term 
treated Ighmbp2-def. and Ighmbp2+/+ growth cones. (B) bFGF treatment has no effect on the growth cone size. 
(C) Untreated Ighmbp2-def. motoneurons show a reduced signal intensity of β-actin protein compared to 
untreated Ighmbp2+/+, whereas bFGF long-term treatment increases the β-actin signal intensity to the normal 
untreated Ighmbp2+/+ level. Untreated and bFGF long-term treated Ighmbp2+/+ motoneurons display no 
statistically significant changed β-actin signal intensity. N defines the number of analyzes cells; n indicates the 
number of experiments. 
 bFGF treatment of Ighmbp2-deficient and Ighmbp2+/+ motoneurons cultured on 
laminin-111 showed no alteration in growth cone size (Fig. 30A-B). Long-term treated 
Ighmbp2-deficient growth cones displayed significantly increased β-actin signal intensity 
which was comparable to the untreated and long-term treated Ighmbp2+/+ β-actin signal 
intensity (Fig. A and C). Treatment of bFGF rescued the β-actin protein amount in Ighmbp2-
deficient growth cones to the untreated Ighmbp2+/+ level. 
 In addition, bFGF treatment of Ighmbp2-deficient and Ighmbp2+/+ growth cones 
cultured on laminin-211/221 was quantified regarding size and β-actin signal intensity 
(Fig. 31A-C). 
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Figure 31 - bFGF long-term treatment increases β-actin protein level and the size of Ighmbp2-def. growth 
cones cultured on laminin-211/221 at DIV5. (A) Representative images of bFGF untreated and long-term 
treated Ighmbp2-def. and Ighmbp2+/+ growth cones cultured on laminin-211/221 at DIV5. Quantifications of the (B) 
growth cone size and (C) β-actin signal intensity of bFGF untreated and long-term treated Ighmbp2-def. and 
Ighmbp2+/+ growth cones. (B) bFGF treatment compensated the reduced growth cone size in Ighmbp2-def. 
motoneurons to normal untreated Ighmbp2+/+ growth cone size. Untreated and bFGF long-term treated 
Ighmbp2+/+ growth cones show no alteration. (C) Untreated Ighmbp2-def. motoneurons show a reduced signal 
intensity of β-actin protein compared to untreated Ighmbp2+/+, whereas bFGF long-term treatment increases the 
β-actin signal intensity to the normal untreated Ighmbp2+/+ level. Untreated and bFGF long-term treated 
Ighmbp2+/+ motoneurons display no statistically significant changed β-actin signal intensity. N defines the number 
of analyzed cells; n indicates the number of experiments. 
In accordance with previous publications (Krieger et al., 2014b), untreated Ighmbp2-
deficient and Ighmbp2+/+ motoneurons cultured on laminin-211/221 showed a reduced growth 
cone size which was rescued by bFGF treatment to untreated Ighmbp2+/+ size level 
(Fig. 31A-B). Long-term treated Ighmbp2-deficient growth cones displayed significantly 
increased β-actin signal intensity compared to untreated and long-term treated Ighmbp2+/+ β-
actin signal intensity levels (Fig. 31A and C). Treatment of bFGF rescued the size and the β-
actin protein amount in Ighmbp2-deficient growth cones to the untreated Ighmbp2+/+ level. 
 As already described, bFGF is inter alia a ligand of FGFR1b, and 1c, FGFR2c, 
FGFR3c, FGFR and FGFR4Δ and can activate those receptors (Ornitz and Itoh, 2015). To 
determine whether the abundance of bFGF in the blood serum of Nmd2J mice causes the 
decreased amount of Fgfr1, we performed a C2 mouse factor antibody array with blood 
serum of P28 Nmd2J and Nmd+/+ mice. 
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Figure 32 - Regulated growth factors in the blood serum of P28 Nmd2J mice compared to Nmd+/+ using C2 
Mouse Growth Factor Antibody Array. Epidermal growth factor (Egf), insulin-like growth factor binding protein-
2/-3/-5 and -6 (Igfbp-2/-3/-5 and -6), insulin growth factor-I and II (Igf-I/-II) and macrophage colony stimulating 
factor (M-Csf) are significantly reduced whereas vascular endothelial growth factor receptor-1 (Vegf-R1) is 
increased in Nmd2J mice compared to Nmd+/+. Quantifications are normalized to Nmd+/+ equal to 1. Data are 
shown as mean±SD. n indicates the number of experiments per Nmd2J and Nmd+/+. 
 Quantification of C2 mouse growth factor antibody array displayed that bFGF is not 
significantly changed in Nmd2J mice compared to Nmd+/+. Nevertheless, several growth 
factors were altered in Nmd2J mice compared to Nmd+/+. Previous studies have shown that 
the level of insulin growth factor-I (Igf-I) in the blood serum at P14 and P42 Nmd2J mice is 
significantly reduced by 50% compared to Nmd+/+ but PEG-IGF-I application rescued the Igf-I 
level in the blood serum and improved the motor deficits seen in Nmd2J mice (Krieger et al., 
2014a). This treatment did not prevent motoneuron loss, which elucidated that additional 
mechanisms are involved leading to motoneuron loss in the Nmd2J mice. Significant 
reduction of approximately 41% of Igf-I confirmed the validity of our C2 mouse growth factor 
antibody array (Fig. 32, Igf-I). Strikingly, all IGF binding proteins of this array (Igfbp-2/ -3/ -
5 and -6) as well as Igf-II displayed a significant reduction in Nmd2J mice (Fig. 32, Igfbp-
2/ -3/ -5/ -6 and Igf-II). A reduction of immune modulator macrophage colony stimulating 
factor (M-Csf) could also be observed, whereas vascular endothelial growth factor 
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receptor-1 (Vegf-r1) was significantly upregulated in Nmd2J mice compared to Nmd+/+ 
(Fig. 32, M-Csf and Vegf-r1). 
 
4.5 Protein-protein Interactions of Ighmbp2 using ICC and Co-IPs 
To clarify the function of Ighmbp2, it is also necessary to identify interaction partners. 
Therefore, in the following section, possible protein interaction partners of Ighmbp2 were 
investigated using ICC and Co-IP. 
4.5.1 Glutamylated / tyrosinated tubulin and Ighmbp2 protein in wildtype (CD1) 
motoneurons 
 As already described by (de Planell-Saguer et al., 2009), Ighmbp2 is co-localized with 
tubulin. Microtubules are very important in the development and formation of the nervous 
system, as they are responsible for the formation and stability of elongated axons and 
dendrites. Thus, they are also crucial factors when it comes to the development of 
neurodegenerative diseases and form directional railways for organelle transport and create 
a structural backbone for axons and dendrites, which is responsible for the maintenance and 
formation of morphology. 
To determine a possible reason for increased branching behavior of Ighmbp2-
deficient motoneurons, we performed immunocytochemical staining of wildtype motoneurons 
against Ighmbp2 and two types of tubulin – stable, glutamylated and labile, tyrosinated 
tubulin. 
Glutamylated tubulin was evenly distributed throughout the cytoplasm of the cell 
body, alongside the axon but faintly expressed in the neurites and growth cones (Fig. 33A, 
upper and lower panel). Directional railways starting from the middle of the soma regarding 
and along the axons can be clearly observed (Fig. 33A, upper panel).  
Tyrosinated tubulin was predominantly expressed in the protrusions, including the 
growth cones and axonal branches. It was highly concentrated in the dendritic protrusions, 
but less expressed in the soma. The tyrosinated tubulin also formed railway structures 
(Fig. 33B).  
As previously described, Ighmbp2 localization is predominantly in the cytoplasm and 
in the axons of motoneurons, whereas its expression in the growth cone is omitted (Fig. 33A-
B). Both types of tubulin were very similar distributed to Ighmbp2 (Fig. 33). 
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Figure 33 – Localization of glutamylated / tyrosinated tubulin and Ighmbp2 in wildtype motoneurons. 
Representative images of (A) glutamylated and (B) tyrosinated distribution pattern compared to Ighmbp2 protein 
localization. (A) Glutamylated tubulin is evenly distributed except the neurites (upper panel) and the growth cones 
(lower panel), whereas (B) tyrosinated tubulin is predominantly localized in distal parts of motoneurons, like 
neurites and axons. Ighmbp2 is similarly distributed to both types of tubulins. Each experiment was repeated at 
least 3 times, if not mentioned otherwise. 
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4.5.2 Co-IP with tyrosinated tubulin and IGHMBP2 in HEK293 cells 
To examine a possible protein-protein interaction of tyrosinated tubulin and 
IGHMBP2, we performed a pulldown of IGHMBP2 in HEK293 cells following by a Co-
immunoprecipitation (IP) of tyrosinated tubulin protein. 
Figure 34 – Tyrosinated tubulin interacts 
with IGHMBP2 in HEK293 cells using 
Co-IP. Representative Western blot of 
immunoprecipitated IGHMBP2 and co-
immunoprecipitated tyrosinated tubulin 
(tyr. Tubulin). Validation of successful 
pulldown (PD) of IGHMBP2 (lower panel). 
Tyr. tubulin protein is detectable in 
immuno-precipitated PD IGHMBP2 and 
therefore associated with IGHMBP2 
protein. PD IgG, as a negative control, is 
free of IGHMBP2 and tyr. Tubulin. FT 
means flow-through. 
 
 
 Pulldown (PD) of IGHMBP2 was performed in HEK293 cells and validated using 
Western blot analysis against IGHMBP2 protein (Fig. 34, lower panel). Negative control 
condition with rabbit IgG antibody (PD IgG) was free of immunoprecipitated IGHMBP2, 
whereas IGHMBP2 protein was visible in PD of IGHMBP2 (PD Ighmbp2). Reduced amount 
of IGHMBP2 in the flow-through of immunoprecipitated IGHMBP2 (FT IGHMBP2) compared 
to the amount in FT IgG confirmed successful PD of IGHMBP2 protein (Fig. 34, lower panel). 
Co-IP of tyrosinated tubulin (tyr. tubulin) in immunoprecipitated IGHMBP2 protein lysate was 
performed to test whether both proteins interact with each other. In the PD of IGHMBP2, tyr. 
tubulin was detected, but no protein was visible in the negative control, PD IgG (Fig. 34, 
upper panel). Thus, IGHMBP2 protein interacts with tyrosinated tubulin in HEK293 cell. 
4.5.3 Protein-protein interaction of IGHMBP2 using Co-IP 
To analyze whether IGHMBP2 interacts with other proteins, we performed further Co-
IP related to common and known protein interactors in Ighmbp2-deficient motoneurons and 
in other motoneuron diseases. 
 IGHMBP2 belongs to the UPF1-like group within the helicase superfamily 1, which 
can unwind DNA and RNA duplices (Guenther et al., 2009a; Jankowsky, 2011). Two other 
members of the UPF1-like group are UPF1 and MOV10, which bind to the 3’UTR of co-target 
mRNAs. It is known that MOV10 forms a complex with UPF1 at 3'UTR (Gregersen et al., 
2014; Taylor et al., 2013). As both helicases belong to the same group as IGHMBP2, it 
should be tested whether IGHMBP2 is also a part of this complex. But neither UPF1 
(Fig. 35A, upper panel), nor MOV10 (Fig. 35A, lower panel) show a direct interaction with 
IGHMBP2 (Fig. 35A). IGHMBP2 shows no direct interaction with MOV10, but it is known that 
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inter alia argonaute 2 (AGO2) is co-located with MOV10 in P-bodies. Based on this, the 
question arises whether P-bodies interact with Ighmbp2. For this purpose, we performed Co-
IPs of U6 snRNA-associated Sm-like protein 4 (LSM4), AGO2 and trinucleotide repeat-
containing gene 6B protein (TNRC6B), which is associated with Ago proteins, with 
immunoprecipitated IGHMBP2 protein in HEK293 cells. However, LSM4 (Fig. 35B, upper 
panel), AGO2 (Fig. 35B, lower panel) or TNRC6B (data not shown) were not co-located with 
immunoprecipitated IGHMPB2. A regulatory role of miRNAs which is already shown for the 
SMN protein (Kye et al., 2014) also needs to be questioned for IGHMBP2 and requires 
further investigation. In order to exclude an interaction of SMN and IGHMBP2, a Co-IP was 
performed between the two proteins. It is known that UPF1 affects FUS- and TDP43-
associated toxicity in ALS (Barmada et al., 2015). IGHMBP2 shows a very high structural 
similarity to UPF1. Therefore, it was tested if SMN (Fig. 35D, upper panel), TDP43 (Fig. 35D, 
lower panel) or FUS (data not shown) interact with IGHMBP2. Finally, Co-IPs of the three 
proteins with IGHMBP2 showed that they were not associated with IGHMBP2. Pulldown (PD) 
of IGHMBP2 was performed in HEK293 cells and confirmed using Western blot analysis 
against IGHMBP2 protein (Fig. 35E). 
 
Figure 35 – Co-IPs of 
potential target proteins with 
IGHMBP2 in HEK293 cells. 
(A-D) Representative Western 
blot of immunoprecipitated 
Ighmbp2 and co-
immunoprecipitated possible 
target proteins. (A) Two 
members of the UPF1-like 
group within the helicase 
superfamily 1, UPF1 and 
Mov10, show no direct 
interaction with IGHMBP2. (B) 
Known P-bodies, LSM4 and 
Ago2, do not interact with 
IGHMBP2. (C) The two 
affected proteins, SMN and 
TDP43, in known 
neurodegenerative diseases 
are not associated with 
IGHMBP2. (D) Validation of 
successful pulldown (PD) of 
IGHMBP2. 
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5. Discussion 
Most parts of this discussion are published in (Surrey et al., 2018). 
The cellular role of Ighmbp2 in the PNS is still unclear, but previous studies suggest 
that Ighmbp2 has an influence on DNA and / or RNA metabolism (de Planell-Saguer et al., 
2009; Guenther et al., 2009a; Jankowsky, 2011). Defects in cytoplasmatic assembly of 
spliceosomal small nuclear ribonucleoproteins, pre-mRNA processing and activation of 
transcripts have already been shown in the pathomechanism of classical SMA (Campbell et 
al., 2000; Charroux et al., 1999; Fischer et al., 1997; Jablonka et al., 2001; Lefebvre et al., 
1998; Meister et al., 2000; Pellizzoni et al., 2001; Strasswimmer et al., 1999). This raises the 
question whether functional differences at RNA and protein level can also be detected under 
Ighmbp2 deficiency in addition to morphological anomalies of motoneurons. Functional 
studies on the Ighmbp2 protein can only be carried out if it is possible to tag or label the 
protein of interest, especially using an antibody. This self-produced antibody first had to be 
verified in order to determine its specificity and to prove the credibility of functional studies 
(see Fig. 8 and Fig. 9). The purified Ighmbp2 antibody was validated by fractionation assay, 
immunoprecipitation, immunocytochemical staining (ICC) of primary motoneurons and 
Western blot investigations (see Fig. 10). As previously described, studies have shown that 
Ighmbp2 is predominantly localized in the cytoplasm (Grohmann et al., 2004). The 
fractionation assay and immunocytochemical staining confirmed the localization with the help 
of this antibody (see Fig. 10A, C). Ighmbp2 is reduced about 73% in primary cultured 
motoneurons from Nmd2J mouse embryos (see Fig. 10D). The reduced protein amount of 20-
30% remaining level of functional Ighmbp2 under Ighmbp2 deficiency is comparable to what 
has already been described for embryonic (Grohmann et al., 2004) and postnatal spinal cord 
tissue (Krieger et al., 2014a), although neither of these studies provided quantification. 
Besides the distribution pattern by ICC and the general protein amounts 
determination of Ighmbp2 by Western blot quantification, it was also feasible to perform 
protein-protein interaction examinations between Ighmbp2 and postulated target proteins 
because immunoprecipitation was possible and specific (see Fig. 10B). An acute knockdown 
(KD) of Ighmbp2 in wildtype motoneurons results in approximately 72% reduction of Ighmbp2 
transcript levels (see Fig. 11B), whereas the Ighmbp2 protein level is not reduced during the 
weeklong culture period (see Fig. 11A). Likewise, no effect on axonal outgrowth or branching 
capacity under acute KD of Ighmbp2 could be determined (see Fig. 11C). Thus, only 
motoneurons from Nmd2J mouse models show Ighmbp2 deficiency / reduction, all further 
experiments with motoneurons had to be carried out with Nmd2J mice. 
In general, axon length measurements are performed at DIV7 to include additional 
morphological changes at later time points. Functional and morphological analyses at growth 
cones (growth cone sizes, distribution of β-actin protein and mRNA, FRAP, AHA labeling and 
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calcium imaging studies) are carried out at DIV5, the latest time point at which growth cones 
are properly shaped and less collapsed. RNA-Seq, Western blot, and SUnSET data are 
collected at DIV7 to include the latest time point at which the cells are viable and less 
affected by apoptotic changes. pSILAC experiments are carried out at DIV3 due to the 
amount of cells needed for the experiment. 
 
5.1 Ighmbp2 Deficiency in primary Motoneurons causes only minor morphological 
and functional Alterations 
The primary cultured Ighmbp2-deficient motoneurons cultured on Laminin-111 
showed no altered excitability at distal axons (see Fig. 12) or an affected axon elongation 
(see Fig. 13), but an increase of the axonal branches at DIV7 (see Fig. 13C, D). This slight 
morphological abnormality differs from primary motoneurons of SMA type I mouse models 
(Smn-deficient motoneurons) (Jablonka et al., 2007; Rossoll et al., 2003). In contrast to 
Ighmbp2-deficient motoneurons, Smn-deficient motoneurons show severe morphological and 
functional anomalies including the affected axonal outgrowth and growth cone size (Jablonka 
et al., 2007; Rossoll et al., 2003), as well as reduced spontaneous Ca2+ transients (Jablonka 
et al., 2007). Ighmbp2-deficient motoneurons show no alterations in spontaneous Ca2+ influx 
cultured on Laminin-111 (see Fig. 12) and only moderate changes cultured on Laminin-221 
(Krieger et al., 2014b). A similar effect can also be observed with the growth cone size. The 
reduced growth cone size of Ighmbp2-deficient motoneurons on laminin-221 (Krieger et al., 
2014b) is not visible on laminin-111 (see Fig. 14A, B and Fig. 15 A, B). A possible reason 
could be a failure of the F-actin assembly. Previous studies have shown that F-actin 
assembly in the growth cone of primary motoneurons is more prominent on β-chain laminin 
isoforms such as laminin-211/221 (Dombert et al., 2017). 
Based on these data, the disease mechanism in Ighmbp2-deficient motoneurons 
does not correspond to the defective Ca2+ homeostasis as described for Smn-deficient 
motoneurons (Jablonka et al., 2007; Ruiz et al., 2010). This assumption is supported by 
further studies describing an unaffected neurotransmission at the neuromuscular endplates 
of Nmd2J mice (Krieger et al., 2013). The late appearance of increased axonal branching of 
Ighmbp2-deficient motoneurons at DIV7 is consistent with observations in the Nmd2J mouse 
in which increased axonal sprouting of NMJ was observed at the gastrocnemius muscle 
(Krieger et al., 2013). 
However, defective collateral re-innervation was observed in some infantile SMARD1 
patients (Diers et al., 2005). This induced compensatory mechanisms of axonal re-growth 
and the formation of new NMJs is a positive feature regarding compensation of motoneuron 
loss in the early stages of the disease (Krieger et al., 2013). Neither severe forms of SMA 
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patients (Korinthenberg et al., 1997) nor related SMA mouse models (Murray et al., 2013) 
showed this kind of motoneuron behavior. These findings suggest that pre-symptomatic 
motoneuron loss in Nmd2J mice does not follow a “dying back” mechanism but could be 
induced by external effects. Previous studies have already shown that motoneurons prolong 
survival by inducing trophic factors using neuronal stem cells (Simone et al., 2014). If defects 
in the neurotrophic factor release exist, e.g. by Schwann cells, post-synapse, astrocytes, and 
other cells, this can lead to motoneuron loss. It has already been shown that Nmd2J mice 
suffer from Igf-1 deficiency (Krieger et al., 2014a) and that the external application of PEG-
IGF-1 to two-week-old mice compensates this deficiency. The increase of Igf-1 in the blood 
prevents muscle fiber degeneration in the gastrocnemius muscle and diaphragm but has no 
effect on the survival of motoneurons (Krieger et al., 2014a). As already described above, the 
differentiation and functionality of primary motoneurons cultured on a synapse-specific 
laminin isoform are mainly caused by BDNF and not GDNF or CNTF (Dombert et al., 2017). 
Based on these findings, the question arises whether Ighmbp2-deficient motoneurons cannot 
correctly recognize trophic factors and thus induce motoneuron death. In the pmn mouse and 
in the SOD1 mouse model for fALS, an external application of CNTF was able to extend the 
lifespan by counteracting the loss of motoneurons with the increase of CNTF (Giess et al., 
2002; Sendtner et al., 1992). Furthermore, previous studies of the pmn mouse have already 
shown that increased Igf-1 causes an extended lifespan associated with mitigated 
motoneuron cell body and axon loss in the phrenic nerve (Jablonka et al., 2011). 
It is therefore very obvious to consider and speculate about the affected trophic 
support, deficits in motoneurons to recognize these factors or other non-neuronal cells 
regarding the Nmd2J mouse. 
 
5.2 Ighmbp2 Deficiency in primary Motoneurons causes only minor Differences in 
Protein Biosynthesis 
As already described, Ighmbp2 seems to be a ribosome-associated helicase 
belonging to the superfamily 1 (SF1) of helicases (Jankowsky, 2011), and is able to unwind 
RNA (Guenther et al., 2009a). Members of these SF1 helicases are UPF1, MOV10, and 
Senataxin. In general, they are functionally linked to various processes of RNA metabolism 
such as transcription, splicing, translation and RNA decay (Fairman-Williams et al., 2010; 
Guenther et al., 2009a; Jankowsky, 2011). Reduced growth cone size cultured on laminin-
211/221 (Krieger et al., 2014b) and the decreased amount of α-/β-actin protein cultured on 
both laminin isoforms (see Fig. 14A, B and Fig. 15A, B) in combination with an increased 
axonal branching at DIV7 cultured on laminin-111 (see Fig. 13C, D) gives an indication of 
dysregulation of cytoskeletal proteins in Nmd2J motoneurons. Therefore, the question arises 
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whether Ighmbp2 deficiency also affects cellular mechanisms that lead to altered protein 
biosynthesis. Due to the high incidence and crucial function of α- and β-actin in the 
cytoskeleton, our study is focused on these proteins. Immunocytochemical co-staining of 
both actin isotypes with Ighmbp2 showed a similar distribution pattern (see Fig. 17A, B). In 
addition, RNA-Sequencing (see Fig. 18A, D and E), FISH (see Fig. 18F and see Fig. 19), 
and qRT-PCR quantification (see Fig. 18 G and H) showed no changes in the amount and 
distribution of both isotypes in Ighmbp2-deficient motoneurons compared to Ighmbp2+/+. 
Examination of α- and β-actin protein in Ighmbp2-deficient growth cones cultivated on 
laminin-111 displayed a compartment-specific reduced protein amount of both isotypes 
(see Fig. 14A, C and see Fig. 15A, C). This reduced amount can be considered as a 
consequence of a generally delayed protein biosynthesis (see Fig. 20 and see Fig. 21). 
FRAP analysis showed that the local translation of eGFPmyr-β-actin 3'UTR reporter in growth 
cones and cell body was significantly reduced in Ighmbp2-deficient motoneurons. However, it 
should be noted that this delayed translation effect was observed exclusively on Laminin-111 
and was not visible on Laminin-211/221. It has already been shown that the local translation 
of the eGFPmyr-β-actin 3'UTR reporter is regulated depending on the laminin isoforms, 
laminin-111 and laminin-211/221 (Rathod et al., 2012). The local translation in growth cones 
of motoneurons cultured on laminin-211/221 shows a lower efficiency compared to 
motoneurons cultured on laminin-111 (Rathod et al., 2012). These data and the results of 
this FRAP analysis suggest that the local translation is influenced by the substrate and the 
protein biosynthesis in motoneurons cultured on Laminin-211/221 is impoverished compared 
to Laminin-111. The invisible effect on the local translation of the eGFPmyr-β-actin 3'UTR 
reporter in Ighmbp2-deficient motoneurons cultured on Laminin-211/221 can be explained 
hereby. 
A comparable study of the local translation of α-actin is still pending, however, it is 
likely that a delayed compartment-independent protein biosynthesis is also present here. 
At the beginning of this study, the FRAP data should be visualized with the help of a 
time course Western blotting analysis. However, this was not feasible as the GFP protein 
itself is not eliminated by the laser power. The high-intensity illumination only causes the 
fluorescence lifetime to quickly elapse, while the GFP protein is structurally unaffected. Thus, 
a time course of newly synthesized GFP-expressed 3’UTR β-actin reporter via Western blot 
is not possible. In connection with the delayed local translation of the eGFPmyr-β-actin 3'UTR 
reporter no change in the total amount of β-actin protein in whole cell lysates was detected 
(see Fig. 14D). This observation was found for the total amount of α-actin protein 
(see Fig. 15D). Based on these results, dysregulation of the initiation or early elongation 
during translation could provide a possible clarification. It could be speculated that Ighmbp2 
modulates the entrance of specific mRNAs into the t
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a translational delay of specific proteins without showing a global effect on newly synthesized 
proteins. This hypothesis is supported by the pulsed SILAC (see Fig. 22), AHA-labeling 
(see Fig. 23A-C) and SUnSET studies (see Fig. 23D) which we performed. 
Furthermore, the slight effect on the two candidates, Top1 and Sars2, in the pSILAC 
approach of Ighmbp2-deficient motoneurons at DIV3 (see Fig. 22A, C) and the undetectable 
alteration by western blot verification at DIV7 (see Fig. 22B) implies a critical role of Ighmbp2 
at the initial steps of the translation. These slight effects on protein biosynthesis also indicate 
a cell compartment-specific role of Ighmbp2 on the translation mechanisms in primary 
cultured Nmd2J motoneurons. The delayed local translation of the eGFPmyr-β-actin 3'UTR 
reporter could not be explained by a direct interaction of Ighmbp2 protein with the β-actin 
mRNA by RIP analysis (see Fig. 25A, B). Therefore, Ighmbp2 as a factor for mRNP 
clearance or mRNA degradation, as described for MOV10 or Upf1, is rather unlikely. As 
already described, these two helicases form a complex at 3'UTR (Gregersen et al., 2014; 
Taylor et al., 2013). Supporting results for this hypothesis can be found in the protein-protein 
interaction analysis between Ighmbp2 with Mov10 or UPF1. It was found that Ighmbp2 is 
neither associated with Mov10 nor with UPF1 (see Fig. 35A). The short residence time of 
IGHMB2 onto nucleic acids gives additional hints regarding the function of this helicase 
(Kanaan et al., 2018). Despite the high similarity to UPF1, IGHMBP2 does not guarantee the 
required time window to accomplish several successive steps such as translation-dependent 
recognition of a premature termination codon, ribosome dissociation, mRNP remodeling, and 
recruitment of RNA decay factors (Kanaan et al., 2018). This also suggests that IGHMBP2 is 
not involved in NMD. 
In the case that Ighmbp2 has a regulatory role of miRNAs, as described for the SMN 
protein (Kye et al., 2014), it should still be questioned and it needs further investigation. 
 
5.3 Affected Targets in Ighmbp2-deficient Motoneurons 
5.3.1 Reduced Imp1 protein amount in Ighmbp2-deficient motoneurons 
In order to get a more direct link to β-actin, further results on Imp1 protein level were 
achieved. Quantifications of Imp1 protein level via Western blot analysis were done.  
In whole cell lysates of Ighmbp2-deficient motoneurons a reduced protein amount of 
insulin-like growth factor-2 mRNA binding protein 1 (Imp1) was found (see Fig. 26E) but the 
mRNA level was not affected (see Fig. 26D). Imp1 is described as β-actin mRNA interacting 
protein (Deshler et al., 1998; Ross et al., 1997) and in combination with a delayed local 
translation of the eGFPmyr-β-actin 3'UTR reporter in Ighmbp2-deficient motoneurons 
(see Fig. 20 and 21), it can be assumed that Imp1 may have an influence on this delayed 
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synthesis. The protein-mRNA interaction between IMP1 and β-actin is well described and is 
mediated by a sequence element in the 3' UTR of β-actin ("zipcode") mRNA and the mRNA-
binding KH domain of IMP1 (Chao et al., 2010; Farina et al., 2003; Patel et al., 2012). As 
already described, RNA looping is mediated by protein-mRNA interaction, which is regulated 
by the IMP1 concentration (Nicastro et al., 2017). IMP1 is found as ribonucleoprotein 
granules within the cell (Jonson et al., 2007) and it releases β-actin mRNA after 
phosphorylation (Ceci et al., 2012; Huttelmaier et al., 2005; Sasaki et al., 2010; Urbanska et 
al., 2017). 
To understand the role of Imp1 in delayed eGFPmyr-β-actin 3'UTR synthesis of 
Ighmbp2-deficient motoneurons, an extended morphological study on the specific distribution 
of Imp1-positive granules in different cell compartments is necessary. The 
immunocytochemical staining of Imp1 in Ighmbp2-def motoneurons also showed a reduced 
protein amount by signal intensity measurements of the soma and the distal axon 
(see Fig. 26A-C). These data are not reliable, as Imp1 is localized in granule-like structures 
(Degrauwe et al., 2016; Jonson et al., 2007; Niewidok et al., 2018) unevenly distributed 
throughout the whole cell. An exact quantification of Imp1 in different cell compartments 
requires high-resolution microscopy such as SIM, dSTORM or STED as well as Imp1 
knockdown or knockout in primary cultured motoneurons as a control. Quantification of Imp1 
positive granules would include size and shape of the granules besides signal intensities. 
Confocal microscopy with a resolution limit of 200nm would not yield reliable / reasonable 
data. However, additional experiments with high-resolution microscopy in combination with in 
situ hybridization of β-actin mRNA are required as well. In addition, validation of the used 
Imp1 antibody with a KD of Imp1 in motoneurons has to be completed to prove specificity. 
Studies in SMA motoneurons have already described in detail the crucial role of Imp1 in 
intracellular localization and local translation (Donlin-Asp et al., 2017a; Fallini et al., 2014). 
Furthermore, another study has already shown the crucial importance of Imp1 in 
neurodegenerative diseases (Donlin-Asp et al., 2017b). Nmd2J motoneurons show only a 
small morphological and functional alteration, although Imp1 cannot be excluded as an 
important regulator of cellular mechanisms in Ighmbp2-deficient motoneurons by a 
compartment-specific β-actin reduction in combination with Imp1. A possible reason why the 
protein amount of Imp1 in the pSILAC experiment is not detectable could be due to the short 
pulse-duration of 20h. Only newly synthesized proteins are labeled. Unfortunately, the 
number of motoneurons from a single mouse embryo is limited. Therefore, extended 
biochemical approaches such as ribosomal profiling and whole proteome analysis are not 
feasible. 
To investigate the connection between Ighmbp2 deficiency and Imp1 reduction, 
additional cellular and functional experiments have to be performed. The clarification of 
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further mRNA or protein interaction molecules with Imp1 could give us hints that influence 
the differentiation and survival of motoneurons. 
The reduced Imp1 protein amount could have an effect on the transport (Chao et al., 
2010; Farina et al., 2003; Patel et al., 2012) as well as on the translation of its bound mRNAs 
(Leung et al., 2006). A novel mRNA interaction with IMP1 protein was discovered by RIP 
analysis (see Fig. 27A, B). It should be emphasized that the Fgfr1 mRNA and the protein in 
Ighmbp2-deficient motoneurons are altered (see Fig. 28). In correlation with a reduced Imp1 
protein level, disturbed mRNA transport of Fgfr1 could be responsible for this effect. 
Therefore, the increased Fgfr1 mRNA (see Fig. 28A) and its reduced protein level 
(see Fig. 28B) could be explained by a predominantly local translation. To further investigate 
this hypothesis, in situ hybridization of Fgfr1 mRNA in combination with immunocytochemical 
staining of the Imp1 protein should be performed. This allows the quantification of the 
amount and distribution of mRNA and protein. Furthermore, the increased mRNA levels and 
the reduced protein amount of Fgfr1 under Ighmbp2 deficiency suggest impaired translation. 
As described above, the IMP1 protein also influences the translation of its bound mRNAs 
(Leung et al., 2006). The impaired translation of Fgfr1 can therefore also be explained by the 
reduced amount of Imp1 protein as its interaction partner. In addition, an impairment of the 
transport of the Fgfr1 to the membrane can be discussed. Further experiments regarding the 
Fgfr1 protein distribution in Ighmbp2-deficient motoneurons could provide hints for this and 
influence Fgfr1 signaling. 
 
5.3.2 Altered mRNA and protein amount of FGFR1 in Ighmbp2-deficient motoneurons 
As previously described, the RNA sequencing data identified a significantly increased 
Fgfr1 mRNA in Ighmbp2-def motoneurons cultured on laminin-111 on DIV7 (see Fig. 18C). 
qRT-PCR quantification confirmed this up-regulation (see Fig. 28A) so that Fgfr1 considers 
as a possible target under Ighmbp2 deficiency. 
The paracrine growth factor bFGF binds to FGFR1 (Ibrahimi et al., 2004), which is 
dimerized and activated by that (Chen et al., 2008; Furdui et al., 2006). The binding of bFGF 
depends on co-factors such as heparin, heparan sulfate proteoglycans and klotho 
(Schlessinger et al., 2000; Suzuki et al., 2008) and activates the MAPK signaling pathway as 
well as the PI3K/Akt, PLCγ and STAT signaling pathways (Ornitz and Itoh, 2015). These 
bFGF/FGFR1 mediated signaling pathways play a crucial role in neurogenesis and have 
been considered as a treatment approach for neurodegenerative diseases (Woodbury and 
Ikezu, 2014). Further investigations are needed to show whether the increase in Fgfr1 
protein by stimulation of bFGF leads to a rescue of the functional receptor. The functionality 
of the bFGF/FGFR1 mediated activation under Ighmbp2 deficiency can be performed with 
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the help of further Western Blot quantifications in which the phosphorylated Fgfr1 is 
investigated. Moreover, the distribution and localization of the receptor after bFGF long-term 
treatment in the growth cones as well as in soma should be analyzed to obtain details of 
impaired distribution patterns in Ighmbp2-deficient motoneurons. 
To investigate the influence of Fgfr1 in Ighmbp2-deficient motoneurons, further 
morphological and functional studies were performed under long-term treatment with bFGF. 
The Fgfr1 protein level under bFGF stimulation using Western Blot and the effect on the 
branching capacity as well as on the growth cone size and therein impaired β-actin protein 
amount was investigated. In addition, the content of different growth factors, especially 
bFGF, in the blood serum of P28 Nmd2J mice was tested. 
In contrast to the increased RNA level, a reduction of 31% Fgfr1 protein in untreated 
Ighmbp2-deficient motoneurons compared to untreated Ighmbp2+/+ was detected 
(see Fig. 28B). This observation suggests a translational defect so that the up-regulated 
mRNA could be a compensatory mechanism of the motoneuron. In a seven days long-term 
treatment with bFGF an upregulation of Fgfr1 in Ighmbp2-deficient and Ighmbp2+/+ 
motoneurons was observed, whereby treated motoneurons under Ighmbp2 deficiency 
showed a reduced amount of 27% Fgfr1 compared to treated Ighmbp2+/+ (see Fig. 28B). 
Nevertheless, the protein level of Fgfr1 in treated Ighmbp2-deficient motoneurons increased 
higher compared to untreated Ighmbp2+/+ (see Fig. 28B). Thus, stimulation with bFGF of 
Ighmbp2-deficient motoneurons were able to compensate the reduced protein content. The 
activation of Fgfr1 and down signaling pathways mediated by bFGF could explain this effect. 
The function of MAPK and PI3K/act pathways is associated with cell proliferation, growth and 
mRNA translation activation (Roux and Topisirovic, 2012). The external activation of the 
afore-mentioned signal cascades using bFGF treatment could promote the translation of the 
significantly increased Fgfr1 mRNA in Ighmbp2-deficient motoneurons and thus compensate 
the missing protein amount. Therefore, a possible treatment strategy using bFGF stimulation 
under Ighmbp2 deficiency should be considered. Increased branching behavior of Ighmbp2-
deficient motoneurons at DIV7 (see Fig. 13C, D) was already described in chapter 5.1. 
Therefore, the effect of long-term bFGF stimulation should be investigated on the axonal 
behavior of Ighmbp2-deficient motoneurons. The long-term treatment of bFGF showed no 
influence on axonal branching in Ighmbp2-deficient or Ighmbp2+/+ motoneurons (see Fig. 29). 
Increased branching behavior of Ighmbp2-deficient motoneurons compared to Ighmbp2+/+ 
displayed no alteration under bFGF stimulation (see Fig. 29). As already discussed in 
chapter 5.1, the ability to form additional axonal branches is to be regarded as a 
compensatory mechanism in the early stage of the disease and thus rather as a good 
feature. Consequently, this behavior is not mediated by the activation of the Fgfr1 and its 
95 
 
Furthermore, analyses of the growth cone size and signal intensity of β-actin in 
Ighmbp2-deficient growth cones after long-term treatment with bFGF cultured on Laminin-
111 (see Fig. 30) and Laminin-211/221 (see Fig. 31) were performed. In accordance with the 
results discussed in chapter 5.1, neither untreated nor treated Ighmbp2-deficient 
motoneurons cultured on Laminin-111 showed an altered growth cone size compared to 
untreated or treated Ighmbp2+/+ (see Fig. 30A, B). However, the bFGF stimulation of 
Ighmbp2-deficient motoneurons compensated the reduced β-actin signal intensity up to the 
Ighmbp2+/+ level, whereas untreated and long-term bFGF-treated Ighmbp2+/+ motoneurons 
showed no change in β-actin signal intensity (see Fig. 30A, C). 
bFGF long-term treatment of Ighmbp2-deficient motoneurons cultured on Laminin-
211/221 exhibits not only a compensation of the β-actin signal intensity (see Fig. 31A, C), but 
also an increase of the growth cone size (see Fig. 31A, B). Independent of the substrate, the 
bFGF stimulation mediates FGFR activation, which can compensate and rescue the reduced 
growth cone size on laminin-211/221 and the reduced β-actin signal intensity on laminin-111 
and laminin-211/221 in vitro. 
The phenotypical symptoms of P28 Nmd2J mice are already pronounced at this 
developmental stage. Severe atrophy of the gastrocnemius muscle, a reduced height, and 
body weight can be observed (Cox et al., 1998; Grohmann et al., 2004; Krieger et al., 
2014a). The examination of several growth factors in the blood serum of P28 Nmd2J 
compared to Nmd+/+ mice showed clear dysregulation, but bFGF was not significantly altered 
in the blood serum (see Fig. 32). However, this result does not exclude that activation of 
Fgfr1 is impaired. Therefore, further investigations should be performed regarding Fgfr1 
activation. It should be noted that all Igfbps and both Igf-I and -II were significantly reduced in 
the Nmd2J mice compared to Nmd+/+. As previous studies have shown, Igf-1 is significantly 
reduced to about 50%, but P14 Nmd2J mice showed a significant upregulation of Igfbp-2 and 
Igfbp-3 in the blood serum (Krieger et al., 2014a). However, P42 Nmd2J mice exhibited no 
significant differences of Igfbp-2 and Igfbp-3 in the blood serum compared to Nmd+/+  (Krieger 
et al., 2014a). These published results contrast with the observed Igfbp-2 and Igfbp-3 levels 
in the blood serum of P28 Nmd2J mice, as a clear downregulation can be observed here 
(see Fig. 32). A possible reason could be the heterogeneity of the developmental stages of 
P14, P28, and P42. Nevertheless, the involvement of Igfs and their binding proteins in 
SMARD1 is evident. For this reason, further investigations should be conducted. 
Interestingly, an upregulation of Vegf-r1 protein was detected in the blood serum of P28 
Nmd2J mice. Previous publications have shown that Vegf-r1 can be stimulated autocrine by 
Fgfr1 activation via the MAPK signaling pathway (Golfmann et al., 2018). Thus, the regulated 
Vegf-r1 protein is also related to the affected Fgfr1, which should be investigated later. 
 
96 
 
5.3.3 Imp1 and Fgfr1 as affected proteins in SMARD1 disease 
Additional and detailed investigation of the newly identified Imp1 and Fgfr1 targets in 
the Nmd2J mouse model could reveal the influenced cellular and functional mechanisms that 
occur under Ighmbp2 deficiency. Compensation of the altered protein levels of Imp1 and 
Fgfr1 by the external application could possibly inhibit or even stop the progression of 
SMARD1 disease. In order to carry out an all-encompassing analysis, further experiments 
with patient material are indispensable. This makes it possible to determine whether IMP1 
and FGFR1 also have an influence on the pathogenesis of SMARD1 in humans. The 
identification of Imp1 and Fgfr1 as affected targets in Nmd2J mice seems to be very 
promising, but it does not explain the exact function of Ighmbp2 but only opens secondary 
effects. Motoneurons under Ighmbp2 deficiency display only a minor regulation on RNA 
level, which show an upregulation of Fgfr1 mRNA (see Fig. 18A, C). At the protein level, the 
Fgfr1 (see Fig. 28B) and the Imp1 protein (see Fig. 26E) are downregulated. This 
observation is again more likely to suggest a translational defect rather than an affected RNA 
level. Previous studies can also confirm this assumption, as most mutations in SMARD1 
patients are located in the helicase domain of IGHMPB2 (Guenther et al., 2009a; Guenther 
et al., 2009b). A missing ribosome arrangement or an impairment in the tRNA pathway can 
be discussed as possible translational defects. Some studies have also hypothesized that 
translation cannot be correctly initiated due to bound miRNAs or proteins that cannot be 
properly removed caused by Ighmbp2 deficiency (de Planell-Saguer et al., 2009; Guenther et 
al., 2009a). The clarification of affected translational deficits under Ighmbp2 deficiency, which 
among others lead to reduced Imp1 and Fgfr1 protein levels, could provide an indication of 
the Ighmbp2 function. This could furnish an explanation for motoneuron death and thus yield 
an overview of the affected cellular mechanisms present in SMARD1 disease. 
 
5.4 Protein-protein Interaction of IGHMBP2 and possible Protein Targets 
The identification of protein interaction partners of IGHMBP2 could give an additional 
impression of its function. Immunocytochemical staining and Co-IP were performed to detect 
protein-protein interactions between IGHMBP2 and possible targets. Based on published 
results that IGHMBP2 was associated with tubulin (de Planell-Saguer et al., 2009) 
immunocytochemical staining of wildtype motoneurons against Ighmbp2 and two types of 
tubulin - stable, glutamylated and labile, tyrosinated tubulin- were performed (see Fig. 33). 
Tubulin is a heterodimer consisting of an α-tubulin and a β-tubulin subunit. These two 
subunits have a very high affinity to each other and form a heterodimer, which creates an 
intrinsic polarity - the dynamic plus end consisting of β-tubulins and the stable minus end 
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consisting of the α-tubulins. This polarity, in turn, is used by motor proteins such as dynein 
and kinesin to migrate on the surface of the microtubule to the plus and minus end with the 
help of ATP hydrolysis (Baas et al., 1988; Baas et al., 1989; Baas and Lin, 2011; Baas et al., 
2016). Therefore, a neuron consists of balanced stable (glutamylated) microtubule fractions 
and balanced, unstable (tyrosinated) microtubule fractions. In the axon, the microtubules are 
mainly uniformly oriented with their plus end toward to the distal end, whereas in the 
dendrites the microtubules exhibit a non-uniform, rather mixed polar distribution (Baas et al., 
1988; Baas et al., 1989; Baas and Lin, 2011; Baas et al., 2016). As already mentioned, 
microtubules have an important function during the development and formation of the 
nervous system, as they are responsible for the formation and stability of elongated axons 
and dendrites. Both types of tubulin show a very similar distribution to Ighmbp2 and this 
suggests a co-localization, especially in the axons and axonal branches (see Fig. 33). IP 
using anti-Ighmbp2 antibody from HEK293 cells was performed and probed against 
tyrosinated tubulin to analyze the interaction between immunoprecipitated IGHMBP2 and 
tyrosinated tubulin. It was possible to detect a faint signal (see Fig. 34, upper panel). Thus, 
IGHMBP2 protein interacts with tyrosinated tubulin in HEK293 cell. This observation is 
consistent with the results of Planell-Saguer et al. 2009, which also showed only a faint 
interaction of α-tubulin with IGHMBP2 (de Planell-Saguer et al., 2009). Co-IP of 
immunoprecipitated IGHMBP2 of HEK293 cells with glutamylated tubulin is still outstanding. 
The crucial role of microtubules in axonal outgrowth or stabilization and the protein-protein 
interaction with Ighmbp2 provides a possible explanation for the increased branching 
capacity of Ighmbp2-deficient motoneurons. Further studies should be carried out based on 
these results. 
IGHMBP2 belongs to the UPF1-like group within the helicase superfamily 1 and is 
able to unwind DNA and RNA duplices (Guenther et al., 2009a; Jankowsky, 2011). Two 
other known members of this group are UPF1 and MOV10, which bind to the 3'UTR of co-
target mRNAs. Mov10, which is a messenger ribonucleoprotein (mRNP) clearance factor, 
remodels local secondary structures of mRNAs and displaces proteins from mRNAs targeted 
for UPF1-mediated degradation (Gregersen et al., 2014). UPF1 is one key factor in 
nonsense-mediated decay (NMD) (Kervestin and Jacobson, 2012). It is known that MOV10 
forms a complex with UPF1 at 3'UTR (Gregersen et al., 2014; Taylor et al., 2013). Since 
IGHMBP2 belongs to the same group as MOV10 and UPF1, it should be determined if it 
belongs to this complex as well. However, it was demonstrated that neither UPF1 
(see Fig. 35A, upper panel) nor MOV10 (see Fig. 35A, lower panel) interact with IGHMBP2. 
In summary, IGHMBP2 is not part of the complex of MOV10 and UPF1 at 3'UTR, but it is 
known that among others argonaute 2 (Ago2) is co-localized with Mov10 in P-bodies. 
Processing bodies (P-bodies) are located in the cytoplasm of eukaryotic cells. They consist 
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of several enzymes involved in mRNA turnover. Previous studies have already described 
that P-bodies play a crucial role in general mRNA decay, nonsense-mediated mRNA decay, 
adenylate-uridylate-rich element-mediated mRNA decay, and microRNA induced mRNA 
silencing (Kulkarni et al., 2010). Thus, the question arises whether Ighmbp2 interacts with P-
bodies. Co-IPs were performed with LSM4 (a decapping co-activator as part of the 
multimeric protein complex with P-bodies) AGO2, and TNRC6B, which is associated with 
Ago proteins, with immunoprecipitated IGHMBP2 in HEK293 cells (Eulalio et al., 2007). Even 
so, IGHMBP2 did not interact with LSM4 (Fig. 35B, upper panel), AGO2 (Fig. 35B, lower 
panel) and TNRC6B (data not shown). The similarity to UPF1 caused additional 
investigations. It is already described that UPF1 reduces FUS- and TDP43-associated 
toxicity by a NMD mechanism in ALS (Barmada et al., 2015). In addition, a regulatory role of 
miRNAs for the SMN protein was demonstrated (Kye et al., 2014), which could also be 
questionable for IGHMBP2 protein. Based on this, protein interaction between IGHMBP2 
with FUS, TDP43, and SMN was determined. No interaction between the proteins could be 
found, which makes the role of Ighmbp2 as a factor for mRNP clearance or mRNA 
degradation unlikely. This was already discussed in chapter 5.2. 
 
5.5 SMARD1 compared to SMA and CMT2 
Previous studies have shown that the SMN protein and its role in spinal muscular 
atrophy (SMA) has been described as a master regulator in ribosome biology (Bernabo et al., 
2017), mRNA localization and local translation (Akten et al., 2011; Donlin-Asp et al., 2016; 
Fallini et al., 2011; Fallini et al., 2014; Fallini et al., 2016; Hubers et al., 2011; Rossoll et al., 
2003; Sanchez et al., 2013). In comparison to Smn-deficient motoneurons, Ighmbp2-deficient 
motoneurons show only minor changes at RNA and protein level. A possible conclusion is 
that a limited but highly specific number of target molecules under Ighmbp2 deficiency could 
be responsible for the differentiation and survival of motoneurons. However, another 
hypothesis could be that Ighmbp2 also has cellular functions in addition to its function as a 
translation modulator. External studies have identified two heterozygous mutations in 
IGHMBP2 associated with Charcot-Marie-Tooth type 2 (CMT2) which is the axonal form of 
CMT disease (Cottenie et al., 2014). The phenotypic appearance of CMT2 patients is slow 
progressive muscle weakness, sensory loss, and axonal neuropathy, but no respiratory 
impairment, which contrasts with SMARD1 patients (Cottenie et al., 2014). Patients with 
CMT2 show a higher IGHMBP2 protein level compared to SMARD1 patients (Cottenie et al., 
2014). Dominantly inherited mutations in five different genes of cytoplasmic tRNA synthetase 
(aaRS) could be described as the genetic cause for axonal and intermediate forms of CMT. 
In general, aaRSs are enzymes that catalyze “tRNA aminoacylation” by covalently binding 
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amino acids to their related tRNAs. With this knowledge in combination that Ighmbp2 is a 
ribosome-associated helicase, ribosomal stalling could be debated as another possible 
disease mechanism for SMARD1 (Surrey and Jablonka, 2018). 
It is questionable whether further cellular signaling pathways under Ighmbp2 
deficiency are impaired. If all previously mentioned facts regarding postmitotic motoneurons 
are placed in context, the new synthesis of proteins does not influence global cellular change 
at the protein level. In addition, no direct mRNA binding of affected target proteins such as β-
actin were detected (see Fig. 25A, B). In general, the interaction of IGHMBP2 protein with 
RNA molecules was moderate to weak (see Fig. 24). Therefore, there are many arguments 
in support of an indirect or modulating role of Ighmbp2 in translation. However, it should not 
be ruled out that even small alterations can lead to motoneuron loss. Nevertheless, further 
investigations should be carried out regarding non-cell autonomous mechanisms, as it is well 
known that this can also lead to the death of motoneurons. 
 
5.6 Non-cell-autonomous Disease Mechanisms 
It can be summarized that the fast and enormous loss of motoneurons only a few 
days after the birth of the Nmd2J mouse cannot be completely explained by small 
morphological and functional changes of the postmitotic primary cultured Ighmbp2-deficient 
motoneurons. In principle, many studies have been conducted on the Ighmbp2 function 
regarding RNA and translation processes in non-neuronal proliferating cells or neuron-like 
cell lines (de Planell-Saguer et al., 2009; Guenther et al., 2009a). This makes it possible to 
investigate an effect of cellular mechanisms in non-neuronal cells under Ighmbp2 deficiency, 
which in addition to motoneurons can lead to loss. Non-cell autonomous mechanisms have 
already been described for various forms of amyotrophic lateral sclerosis by mutations in 
SOD1 (Clement et al., 2003) and TDP-43 (Haidet-Phillips et al., 2011; Lee et al., 2016; 
Meyer et al., 2014) and spinal and bulbar muscular atrophy (SBMA) (Sambataro and 
Pennuto, 2012). This opens the view on non-cell autonomous mechanisms which might 
impact motoneuron differentiation and survival because of affected trophic support. 
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